Sapablursen once every 4 weeks increased hepcidin, reduced phlebotomy, and improved the quality of life in people with polycythemia vera. Sapablursen was generally safe and well tolerated. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20260…
Blood (journal)
Blood is a peer-reviewed medical journal published by the American Society of Hematology. It was established by William Dameshek in 1946. The journal changed from semimonthly (24 times annually) to weekly publication at the start of 2009. It covers clinical and basic research in all areas of hematology, including disorders of leukocytes, both benign and malignant, erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. More on Wikipedia
-
Blood Journals Portfolio
@BloodPortfolio
-
Blood Journals Portfolio
@BloodPortfolio
OGM and t-NGS classify 84% of adult BCR::ABL1-negative B-ALL into International Consensus Classification subtypes. This integrated workflow provides a detailed view of genetic alterations in each BCR::ABL1-negative B-ALL subtype. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/21/7299/5705…
-
Blood Journals Portfolio reposted
SETH Trombosis y Hemostasia @SETH__Oficial
Reframing hematologic and thrombovascular care for transgender and gender-diverse individuals: a scoping review ➡️ ashpublications.org/bloodadvances/article/10/21/7197/5698…, publicado en @BloodPortfolio
-
Blood Journals Portfolio reposted
Andrew Portuguese, MD @AJPortuguese
🧵 How should we choose reduced-intensity conditioning for older patients with AML/MDS undergoing allogeneic transplant?
Our new @BloodPortfolio study uses @CIBMTR data from >11,000 patients to compare 5 commonly used RIC/NMA regimens. | @fredhutch
🔗 doi.org/10.1182/blood.2026036096 -
Blood Journals Portfolio reposted
UChicago Leukemia Program
@UChicagoLeuk
new @BloodPortfolio article focusing on RIC in older adults with AML and MDS getting allo-HCT with @mariamtn89 as a co-author!
pubmed.ncbi.nlm.nih.gov/43023552/ -
Blood Journals Portfolio
@BloodPortfolio
New in Blood Global Hematology! The cell therapy gap in Latin America: barriers, solutions, and a Chilean road map ashpublications.org/bloodglobal/article/2/4/100174/571623…
-
Blood Journals Portfolio
@BloodPortfolio
Delayed erythroid recovery after 5-FU chemotherapy stems from HSC-intrinsic lineage bias. Suppressed erythropoiesis is driven by an interleukin-1β–independent mechanism involving caspase-1–mediated cleavage of ROCK1. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/21/7339/5705…
-
Blood Journals Portfolio
@BloodPortfolio
Liso-cel plus ibrutinib showed substantial efficacy with deep remissions, supporting use of the combination in patients with R/R CLL/SLL. Read the full article in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20260…
-
Blood Journals Portfolio
@BloodPortfolio
RBCs can be supercooled without oil-phase surface sealing in fluorinated ethylene propylene bags without ice nucleation for 42 days. Large-volume storage & ethanol supplementation reduce hemolysis in supercooled storage. Read in Blood RCI: ashpublications.org/bloodrci/article/2/4/100123/570507/Oi…
-
Blood Journals Portfolio
@BloodPortfolio
#mrd in #aml shows gene-specific clearance patterns, not just positive or negative status. Clonal position and mutation type shape persistence, informing more precise MRD interpretation and monitoring. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/4/100150/570266…
-
Blood Journals Portfolio
@BloodPortfolio
A retrospective life-years saved (LYS) analysis quantifies remarkable but imbalanced advances in treating blood cancers over time. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/21/7209/5698… #bloodcancer
-
Blood Journals Portfolio
@BloodPortfolio
Maternal Hb <8 g/dL predicts a fourfold increased preeclampsia risk, adverse fetal outcomes in pregnancies complicated by #scd. Prophylactic red blood cell transfusion in severe sickle cell genotype reduced pain, preeclampsia and improved fetal outcomes: ashpublications.org/bloodrci/article/2/4/100122/570530/Ma…
-
Blood Journals Portfolio
@BloodPortfolio
New in Blood Advances! Reframing hematologic and thrombovascular care for transgender and gender-diverse individuals: a scoping review. Read here ➡️ ashpublications.org/bloodadvances/article/10/21/7197/5698…
-
Blood Journals Portfolio
@BloodPortfolio
Celebrating 10 years of Blood Advances with its 10 most-cited articles! What factors shape CAR T-cell therapy outcomes? Learn in "Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma" ashpublications.org/bloodadvances/article/4/19/4898/46420…
-
Blood Journals Portfolio
@BloodPortfolio
New in Blood Global Hematology! Starting from scratch: establishing a cooperative group for adult #all treatment in #brazil through the Implementation Research Logic Model ashpublications.org/bloodglobal/article/2/4/100168/571258…
-
Blood Journals Portfolio reposted
Human Immunology News
@humanimmunenews
🔬 Researchers from @ZJU_China provide a comprehensive molecular characterization of lymphoproliferative disorder following CD7 CAR-T therapy and identify potential intervention strategies.
Read their article in @BloodPortfolio ➡️ ashpublications.org/blood/article-abstract/doi/10.1182/bl…. -
Blood Journals Portfolio reposted
Dr. Uma Borate: Professor
@beatalleukemia
Check out our commentary ( led by @pbandjamshidi ) on the fantastic paper by @ZhuoerXie @md_padron @MikkaelSekeres @AmyDeZern @nancykgillis @Ramikomrokji offspring in @BloodPortfolio A clone by any other name: convergence of CCUS and LR-MDS ashpublications.org/blood/article/148/20/2446/571911/A-cl…
-
Blood Journals Portfolio
@BloodPortfolio
New Blood Podcast episode! Blood editor Dr. Laura Michaelis interviews Drs. Sabine Eichinger of Medical University of Vienna and Jeanne Palmer of @MayoClinic on their latest articles highlighting emerging research and treatment strategies in hematology:
bloodpodcast.transistor.fm/episodes/148-20 -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Sapablursen for erythrocytosis control in patients with polycythemia vera, Paravertebral extramedullary chronic myelomonocytic leukemia mimicking myeloid sarcoma, and more. Explore here: ashpublications.org/blood/issue/148/20
-
Blood Journals Portfolio
@BloodPortfolio
The rs2887399-T allele in patients with MDS and CMML with specific mutations is associated with reduced #aml progression and improved AML PFS. Read the full article in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/4/100290/570…
-
Blood Journals Portfolio
@BloodPortfolio
NEW! American Society of Hematology 2026 guidelines for diagnosis of iron deficiency. Explore in Blood Advances: ashpublications.org/bloodadvances/article/10/21/7353/5705…
#bloodadvances #id #irondeficiency #clinicalguidelines -
Blood Journals Portfolio
@BloodPortfolio
Fetal outcomes were generally preserved in #cml pregnancy, but maternal disease control frequently deteriorated, with progression risk. Outcomes reflect gaps in monitoring and therapy access, highlighting the need for resource-adapted CML care. ashpublications.org/bloodglobal/article/2/4/100165/571129…
-
Blood Journals Portfolio
@BloodPortfolio
MEIS2 inhibits CRBN and sustains BCMA expression that predisposes myeloma to inferior progression-free survival during IMiD therapy. CDK4/6i restores CRBN activity and promotes BCMA loss to boost IMiD/CELMoD efficacy, supporting combination therapy. ashpublications.org/bloodneoplasia/article/3/4/100285/570…
-
Blood Journals Portfolio
@BloodPortfolio
As we wrap up celebrating Blood's 80th anniversary, we’re excited to highlight exemplars of highly influential papers from the last decade. Starting here: ashpublications.org/blood/article/133/1/7/6611/Venetoclax…
Post not available here, view on X
Blood Journals Portfolio
@BloodPortfolio
This was a landmark paper as it helped define a new treatment approach for a patient population with historically limited options and poor outcomes. It was presented at the annual meetings of @ASH_hematology in Atlanta, December 2017, and @EHA_Hematology in Stockholm, June 2018.
Blood Journals Portfolio
@BloodPortfolio
Today, venetoclax with decitabine or azacitidine has become standard-of-care, first-line treatment for many older patients with #aml, reflecting the lasting clinical impact of these findings.
-
Blood Journals Portfolio
@BloodPortfolio
MRD dynamics uncover new patient subgroups and its strong prognostic value may help guide individualized treatment approaches in MM. Immunotherapy interception of MRD prolonged survival compared to identical treatment given at relapse in human-like models. ashpublications.org/blood/article/doi/10.1182/blood.20260…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Advances out now featuring Hematologic care for transgender and gender-diverse people, Affordable cure within reach for thalassemia, Life-years saved by advances in blood cancer therapy: a retrospective analysis, and more. Explore ➡️ ashpublications.org/bloodadvances/issue/10/21
-
Blood Journals Portfolio
@BloodPortfolio
A modified MTX-rituximab-temozolomide regimen achieved a 77% complete response rate in patients with newly diagnosed PCNSL. The MTX-rituximab-temozolomide regimen was well tolerated and yielded a 72% 2-year PFS rate in patients aged ≥70 years. ashpublications.org/bloodneoplasia/article/3/4/100315/571…
-
Blood Journals Portfolio
@BloodPortfolio
Prime editing enables immunosuppression-resistant genetic, antigen-specific, and CAR T-cell therapies. Edited T cells are controllable in vivo using common immunosuppressants with minimal perturbation of T-cell biology. Read the full article in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20260…
-
Blood Journals Portfolio
@BloodPortfolio
Half of AYAs with ALL treated at non-SCCs live either equidistant or closer to an SCC. Health insurance coverage, rather than travel time, had consistent associations with treatment at an SCC. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/4/100314/571…
-
Blood Journals Portfolio reposted
Yu-Hung Wang
@yu_hung_wang
Integrating Functional Marrow Reserve and Molecular Risk Improves Prediction of Post-Transplant Outcomes in MDS
doi.org/10.1016/j.bneo.2026.100275
@Ramikomrokji @BloodPortfolio @Bloodneoplasia @TheEBMT_Trainee @aamdsif @MDSFoundation @ic_MDS @MDS_Hub #mdssm -
Blood Journals Portfolio reposted
Nina Cabezas-Wallscheid
@Nina_CabezasW
Extremely excited to share our lab's latest findings, now published in Blood 👏🏻🥳 @BloodPortfolio !
We show that young MPP6 is a long-term, lymphoid-biased population with HSC-like properties. Strikingly, upon aging.. 1/5
ashpublications.org/blood/article/doi/10.1182/blood.20260… -
Blood Journals Portfolio
@BloodPortfolio
In older patients with FLT3-mutated #aml, the addition of quizartinib to chemotherapy significantly reduced relapse risk and improved OS. Read the full article in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
Changes in muscle and fat distribution occur early in treatment highlighting the need for interventions to stabilize body composition. Patients with a higher volume of disease are more likely to experience certain side effects such as nerve pain. ashpublications.org/bloodneoplasia/article/3/4/100303/570…
-
Blood Journals Portfolio
@BloodPortfolio
Patient-reported geriatric impairments are common in older adults with MM, including transplant-eligible patients. Older age, comorbidities, patient-reported limitations, and anxiety are significantly associated with high-grade nonhematologic toxicity. ashpublications.org/bloodadvances/article/10/20/6957/5698…
-
Blood Journals Portfolio
@BloodPortfolio
A VigiBase analysis identified 19 antineoplastic therapies associated with #vte risk including a novel link with nintedanib. VTE typically occurs within 6 months of treatment emphasizing the need to include specific therapies in cancer VTE risk assessment. ashpublications.org/bloodvth/article/3/4/100212/570795/An…
-
Blood Journals Portfolio
@BloodPortfolio
An 8-gene–based (CHEK1, EXO1, MCM4, TK1, KIF14, SEPTIN11, PHF19 and HMGB3) proliferation score was derived for patients with MM. High proliferation score emerged as an independent prognostic marker. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/4/100288/570… #multiplemyeloma #bloodneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
Ig-derived mutated HLA peptides are directly measured in primary #mm for the first time, confirming a promising source of neoantigens in MM. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/20/7098/5698… #multiplemyeloma #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
CMV reactivation is common after CAR T-cell therapy for #lbcl, including in the 2L setting. Corticosteroid exposure is a major risk factor for CMV reactivation. Read in Blood ICT: ashpublications.org/bloodict/article/2/4/100089/571036/St…
-
Blood Journals Portfolio reposted
Stowers Institute
@ScienceStowers
From the lab to the cover of @BloodPortfolio! 🩸
We're excited to share that research from the Stowers Institute's Li Lab is featured on the cover of the November 5 issue of Blood, a journal of the @ASH_hematology.
The study tackles a longstanding challenge in stem cell research: how to expand blood-forming #stem cells in the lab without compromising their ability to rebuild the blood and immune systems.
Explore the #research behind the cover: www.stowers.org/news/stowers-scientists-overcome-key-barr… -
Blood Journals Portfolio
@BloodPortfolio
TAR iPSCs yield fewer MK with precocious maturation and enhanced apoptosis compared to TAR-corrected iPSCs. Gene expression differences involve apoptosis & cell cycle, and splicing differences involve splicing & platelet degranulation. Read in Blood VTH: ashpublications.org/bloodvth/article/3/4/100201/570163/An…
-
Blood Journals Portfolio
@BloodPortfolio
Big news for #stemcell and #cordblood research! Read the Blood article here: ashpublications.org/blood/article-abstract/doi/10.1182/bl…
Stowers Institute
@ScienceStowers
NEW research from the Li Lab 🩸
Stowers scientists developed a new system to expand blood-forming stem cells from human cord blood while preserving their long-term function, overcoming a longstanding challenge in stem cell research.
Published in @BloodPortfolio.
Read more:This media couldn't be displayed. See it on the original post. -
Blood Journals Portfolio
@BloodPortfolio
Cheers to 10 years of Blood Advances! Founded in December 2016, it's now in the 10 most cited journals in hematology, publishing more peer-reviewed hematology research than any other academic journal worldwide. Learn more and explore testimonials: ashpublications.org/bloodadvances/pages/10-years-ba
-
Blood Journals Portfolio
@BloodPortfolio
In hematopoietic cell transplants, infused donor Tregs prevent #gvhd without impairing #gvl effect, mediated by donor Tcons. Peripheral blood Tregs express CXCR4 at lower intensity than Tcons. Tregs do not home to the BM, leaving Tcons unleashed. ashpublications.org/bloodadvances/article/10/20/7023/5702… #hsct
-
Blood Journals Portfolio
@BloodPortfolio
New! Drs. Lindsey George of @ChildrensPhila, @MilesHorton9 & @thomaseliotlew of @PeterMacCC & @WEHI_research join to discuss characterization of prothrombotic mechanisms of recombinant FVIII Aurora and using immunosuppressants as tools for in vivo control: bloodpodcast.transistor.fm/episodes/prothrombotic-fviii-m…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Epigenetically activating T cells to attack AML, Ex vivo expansion of human long-term HSCs, and more. Explore here: ashpublications.org/blood/issue/148/19
-
Blood Journals Portfolio
@BloodPortfolio
Serum IgG levels declined after CAR-T infusion reaching a nadir at 9 months and remaining suppressed for >2 years after infusion. Older age, low preinfusion IgG levels, and a low CD4/CD8 ratio predisposed patients to post–CAR-T hypogammaglobulinemia. ashpublications.org/bloodict/article/2/4/100085/570600/In…
-
Blood Journals Portfolio
@BloodPortfolio
Ruxolitinib appears to be a tolerable, adjustable, and safe treatment option for second-line treatment of MF. Cytopenias can be managed effectively with close monitoring during ruxolitinib therapy, resulting in low rates of treatment discontinuation. ashpublications.org/bloodglobal/article/2/4/100162/571095…
-
Blood Journals Portfolio
@BloodPortfolio
Syk Y519,520F knockin mice were generated, and they produced homozygous pups that did not follow the Mendelian genetics. Syk Y519,520F mice had intestinal inflammation, which was similar to that observed in phospholipase Cγ2 or SLP76 null mice. ashpublications.org/bloodvth/article/3/4/100225/571272/Ph…
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
📢 The wait is over: Abstracts for the 68th ASH Annual Meeting and Exposition are live!
More than 6,300 abstracts have been accepted for oral and poster presentations at #ash26.
Browse now: www.hematology.org/meetings/annual-meeting/abstracts
#hematology #hemeonc -
Blood Journals Portfolio
@BloodPortfolio
The fetal HSC state is permissive, with mixed in vitro output, whereas adult HSCs exhibit chromatin-level and functional myeloid bias. Fetal lymphoid progenitors exhibit lymphomyeloid chromatin priming with reduced PAX5 motif and enhancer accessibility. ashpublications.org/bloodadvances/article/10/20/6873/5699…
-
Blood Journals Portfolio reposted
Hayder Saeed, MD
@HayderSaeed_MD
Longer PFS, more days of care: the CAR T vs bispecifics trade-off in R/R FL. Retrospective, 228 pts, 17 US centers: median PFS NR vs ~19 mo, OS similar, yr-1 care contact days 58-69 vs 44-49. @majorajay @BloodPortfolio #lymsm #follicularlymphoma doi.org/10.1182/bloodadvances.2026020899
-
Blood Journals Portfolio
@BloodPortfolio
Experts recommend several NPIs, such as massage and guided imagery, to manage adolescent #scpc. The BoriZafi framework provides a strong foundation for educational tools that promote effective pain management during pain crises. ashpublications.org/bloodglobal/article/2/4/100158/570785…
-
Blood Journals Portfolio
@BloodPortfolio
ELTS score stratified FFS in #cml across treatments, with superior discrimination over Sokal score in the 2G-TKI setting. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/20/7139/5701…
-
Blood Journals Portfolio
@BloodPortfolio
Peritransplant 2′-FL is safe and tolerable in pediatric HSCT recipients. 2′-FL reduces intestinal dysbiosis after #hsct. Read the full article in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20260…
-
Blood Journals Portfolio
@BloodPortfolio
Recognizing the importance of PRO data, 85% of Blood and Marrow Transplant Clinical Trials Network trials have included PROs since 2013. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/20/7058/5705…
-
Blood Journals Portfolio
@BloodPortfolio
TAG-AZA-VEN is a new therapeutic option for patients with BPDCN and may improve on outcomes observed with single-agent TAG. It's effective in both 1L and relapsed BPDCN, with a manageable safety profile, including in an elderly patient population. ashpublications.org/blood/article/doi/10.1182/blood.20260…
-
Blood Journals Portfolio
@BloodPortfolio
Subcutaneous denecimig administered Q2W was well tolerated, with no safety concerns in HA with/without inhibitors. Most patients with HA experienced zero treated bleeds during denecimig prophylaxis, indicating protection from bleeding. Read here: ashpublications.org/bloodadvances/article/10/20/6946/5697…
-
Blood Journals Portfolio
@BloodPortfolio
"Real-world thrombotic and survival outcomes with ESAs in cancer-related anemia" read the systematic review in Blood VTH: ashpublications.org/bloodvth/article/3/4/100207/570733/Re…
-
Blood Journals Portfolio
@BloodPortfolio
Prognostic value of measuring LSC frequency in AML: a systematic review and meta-analysis ashpublications.org/bloodadvances/article/10/20/6904/5701… #aml #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Pain-specific PROs are worse in young adulthood than the preadolescent period in individuals with SCD. Pain duration & frequency are worse in the preadolescent period highlighting the need for longitudinal studies and early intervention. Read in Blood RCI: ashpublications.org/bloodrci/article/2/4/100121/570253/Ea…
-
Blood Journals Portfolio
@BloodPortfolio
The SF3b complex in cancer: structural basis, molecular mechanisms, and therapeutic opportunities #bloodadvances ashpublications.org/bloodadvances/article/10/20/6915/5701…
-
Blood Journals Portfolio
@BloodPortfolio
Endothelial IDO1 drives venous thromboembolism via the Trp-Kyn axis in cancer-bearing mice. Read the full study in Blood VTH: ashpublications.org/bloodvth/article/3/4/100209/570596/En…
-
Blood Journals Portfolio
@BloodPortfolio
PACSIN2 facilitates clathrin-mediated transferrin receptor (CD71) internalization during terminal erythroid maturation. PACSIN2 deficiency results in mild hypochromic microcytic anemia, altered EBI macrophages, and splenic iron accumulation. ashpublications.org/bloodrci/article/2/4/100128/570589/PA…
-
Blood Journals Portfolio reposted
Andy Lane
@lane_andy
Very happy to have participated in this podcast with @BloodPortfolio about our new paper on the phase 2 trial of TAG-AZA-VEN for #bpdcn bloodpodcast.transistor.fm/episodes/xxx
-
Blood Journals Portfolio reposted
andi roy
@andiroy
Pleased to see this out @BloodPortfolio ashpublications.org/blood/article/148/17/2146/568798/LIN2…
-
Blood Journals Portfolio
@BloodPortfolio
New episode of the Blood Podcast out now discussing new drug combinations for #bpdcn and reduced intestinal dysbiosis after #hsct. Dr. Laurie Sehn interviews Drs. Andrew Lane of @DanaFarber and Pooja Khandelwal of @CincyChildrens on their latest research:
bloodpodcast.transistor.fm/episodes/xxx -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring A TAG team for achieving deep remissions in BPDCN, MEIS1 guardian USP22 fuels transcription in KMT2Ar leukemia, Securing HMO coverage for HSCT, and more. Explore here: ashpublications.org/blood/issue/148/18
-
Blood Journals Portfolio
@BloodPortfolio
Immediate implant reconstruction after mastectomy yielded 54% lower DVT and 33% lower hematoma rates. Procedural complexity alone does not determine clotting and bleeding risk after breast cancer surgery; patient selection matters. Read in Blood VTH: ashpublications.org/bloodvth/article/3/4/100208/570595/Th…
-
Blood Journals Portfolio reposted
Sussex Blood Cancer Research
@Sussex_BCR
@RhysMorganLab & @oknsvm in @BiochemBiomedUS, and David Palmer at @BSMSMedSchool feature in new research out this week in @ASH_hematology @BloodPortfolio
The study led by Profs @andiroy & @milnetom68 at @MRC_WIMM show LIN28B's role in infant B-ALL. 👊
ashpublications.org/blood/article/148/17/2146/568798/LIN2… -
Blood Journals Portfolio
@BloodPortfolio
"Platelets in sickle cell disease: biomarkers, mediators, and lessons from clinical trials" read the review article in Blood VTH: ashpublications.org/bloodvth/article/3/4/100214/570794/Pl…
-
Blood Journals Portfolio
@BloodPortfolio
An Hb and heme-binding ApoHb-Hp complex protects the heart and kidneys from injury caused by chronic hemolysis. Female mice show partial natural resilience to hemolysis, and both sexes benefit from ApoHb-Hp treatment. Read in Blood RCI: ashpublications.org/bloodrci/article/2/4/100120/570254/Se…
-
Blood Journals Portfolio
@BloodPortfolio
NEW in Blood Advances! American Society of Hematology 2026 guidelines for immune thrombocytopenia: initial and second-line therapy for adults with primary ITP ashpublications.org/bloodadvances/article/10/20/7076/5702… #clinicalguidelines #itp #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
There is an unmet need to overcome resistance to venetoclax in #aml, particularly in the context of TP53 mutations. Pitavastatin enhances venetoclax cytotoxicity in AML cell lines and primary samples, including those with common mechanisms of resistance. ashpublications.org/bloodneoplasia/article/3/4/100296/570…
-
Blood Journals Portfolio
@BloodPortfolio
The SickleFit virtual exercise intervention is feasible and highly enjoyable for adults aged ≥40 years with #scd. Participants demonstrated improvements in physical performance, with 65% showing increased endurance on 6-minute walk. Read in Blood RCI: ashpublications.org/bloodrci/article/2/4/100124/570508/Th…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Advances out now! Featuring A next-generation FVIIIa mimetic in the making, A comprehensive review of T-cell lymphoma following CAR T-cell immunotherapy, and more. Explore here: ashpublications.org/bloodadvances/issue/10/20
-
Blood Journals Portfolio
@BloodPortfolio
In comparison of DEC vs AZA, there was no difference in OS or LFS for patients with #mds. There were no major differences in transfusion dependence or QoL metrics for patients treated with DEC vs AZA. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/4/100293/570…
-
Blood Journals Portfolio reposted
Sussex Blood Cancer Research
@Sussex_BCR
📰 New network publication! 🗞️
Congrats to Prof @andrea_pepper2, Dr Emma Kennedy and team in @BSMSMedSchool for their publication in @ASH_hematology @BloodPortfolio.
Study identifies distinct CLL subgroups and assays for predicting BTKi sensitivity. 👊
ashpublications.org/blood/article/doi/10.1182/blood.20250… -
Blood Journals Portfolio
@BloodPortfolio
Plasma serotonin is cleared even after SERT inhibition, indicating compensatory, SERT-independent pathway(s) can maintain serotonin balance. Read the full article in Blood VTH: ashpublications.org/bloodvth/article/3/4/100203/570555/Se…
-
Blood Journals Portfolio
@BloodPortfolio
This is, to our knowledge, the first large-scale quantitative characterization of TET2 VAF as a continuous prognostic variable in #cmml. Read the full multicenter study in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/4/100286/570…
-
Blood Journals Portfolio reposted
Yu-Hung Wang
@yu_hung_wang
Officially out! Prognostic implications of #tet2 variant allele frequency in chronic myelomonocytic leukemia: a multicenter study
doi.org/10.1016/j.bneo.2026.100286
#mdssm #mpnsm #cmml
@Bloodneoplasia @BloodPortfolio @aamdsif @MDSFoundation @ic_MDS -
Blood Journals Portfolio reposted
Yu-Hung Wang
@yu_hung_wang
A comparison of overall survival and quality of life in patients with MDS treated with azacytidine vs decitabine
doi.org/10.1016/j.bneo.2026.100293
#mdssm @aamdsif @MDSFoundation @ic_MDS @BloodPortfolio @Bloodneoplasia -
Blood Journals Portfolio
@BloodPortfolio
asxl1 and IDH2R172K comutation epigenetically silences tet2 and activates the MAPK and AP-1 pathways in leukemia. Targeting DNA methylation, ROS, MAPK, and AP-1 mitigates leukemogenesis associated with asxl1 and IDH2R172K comutations in zebrafish. ashpublications.org/bloodadvances/article/10/19/6610/5698…
-
Blood Journals Portfolio
@BloodPortfolio
Anbal-cel achieved high CR rates and durable responses in relapsed or refractory large B-cell lymphoma. Anbal-cel demonstrated a favorable safety profile, with no increased risk of CAR T-cell–related adverse events. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
Mubiru, Menon et al demonstrate that the Ctrough was 96.5 μg/mL, with little variation between the 2 groups. Read the full article in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/4/100164/571096…
-
Blood Journals Portfolio
@BloodPortfolio
Hi-C sequencing for 159 patients with #dlbcl reveals genome-wide rearrangements and fusion genes, and shows high sensitivity and specificity. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/19/6828/5691…
-
Blood Journals Portfolio
@BloodPortfolio
Relative to their donors, allo-HCT recipients with #scd have 3.8-fold higher odds of #ch involving #ddr gene mutations. Read the plenary paper in Blood: ashpublications.org/blood/article/148/17/2099/569969/Char…
-
Blood Journals Portfolio
@BloodPortfolio
Multiyear hydroxyurea confers sustained neurocognitive benefits for children with SCA in overall cognition and attention. African clinical programs should prioritize early initiation and sustained, universal access to hydroxyurea for all children with SCA. ashpublications.org/bloodglobal/article/2/4/100163/571128…
-
Blood Journals Portfolio
@BloodPortfolio
HGBCL remains a challenging clinical entity in the era of modern therapies. MYC/BCL6-R disease demonstrated higher incidence of CNS relapse than MYC/BCL2-R cases. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/19/6538/5696…
-
Blood Journals Portfolio
@BloodPortfolio
"GATA-3 identifies a distinct subset of T-PLL associated with skin involvement and CCR4 expression" read the research letter in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/4/100299/570…
-
Blood Journals Portfolio
@BloodPortfolio
A scoping review of genetic modifiers in sickle cell disease: pathways driving leg ulcer development and progression ashpublications.org/bloodglobal/article/2/4/100151/570451… #scd #sicklecelldisease
-
Blood Journals Portfolio
@BloodPortfolio
IRF4-R in CAYA and adult #lbcl are mediated by the same activation-induced deaminase mechanism but differ in breakpoint location. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/19/6524/5697…
-
Blood Journals Portfolio
@BloodPortfolio
Press play on the new Blood Podcast episode: Restoring Stem Cell Function After Iron Overload! Blood Editor Dr. Laurie Sehn interviews Dr. Annamaria Aprile of the San Raffaele Telethon Institute for Gene Therapy on her latest Blood paper ➡️ bloodpodcast.transistor.fm/episodes/restoring-stem-cell-f…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring BCMA and GPRC5D CAR T cells for MM, PF4 is necessary for thrombosis in triple-positive APS, How I Treat autoimmune neutropenia in adults, and more. Explore here: ashpublications.org/blood/issue/148/17
-
Blood Journals Portfolio
@BloodPortfolio
rFVIIa prophylaxis was associated with reduced treated bleeds, hospitalization, and platelet transfusion use in severe GT. Reduced acute care costs partially offset increased rFVIIa costs, resulting in approximate cost neutrality. Read in Blood VTH: ashpublications.org/bloodvth/article/3/4/100219/570974/Cl…
-
Blood Journals Portfolio
@BloodPortfolio
Approximately 1/3 of patients with R/R CLL treated with continuous venetoclax experience a “long-term” response of >5 years. Long-term responders remain at risk of relapse, infections, hematological toxicity, and emergence of BCL2 mutations. Read here: ashpublications.org/bloodadvances/article/10/19/6459/5698…
-
Blood Journals Portfolio
@BloodPortfolio
Black patients had 20-34% higher odds of longer TTI across aggressive NHL subtypes, persisting after multivariable adjustment. TTI increased over time with 18-31% higher odds of longer TTI in 2016-2022 vs 2004-2009 despite improved survival outcomes. ashpublications.org/bloodneoplasia/article/3/4/100294/570…
-
Blood Journals Portfolio
@BloodPortfolio
CD3×CD20 bispecific T-cell engager depletes precursor B cells in primary lymphoid organs. Depletion of EBV susceptible B-cell precursors is associated with prevention of lymphomagenesis, surpassing the efficacy of rituximab. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/19/6585/5697…
-
Blood Journals Portfolio
@BloodPortfolio
Iron regulation varies across the vascular endothelium, with resistance arteries having the lowest iron stores. Arterial iron deficiency and the subsequent loss of α-globin is required for increased NO signaling in IDA. Read in Blood: ashpublications.org/blood/article/148/16/2072/569428/Arte…
-
Blood Journals Portfolio reposted
Yazan Abou-Ismail, MD - د. يزن أبواسماعيل
@DoctorYazanA
Pleased to share our latest peer-reviewed article just published with #bloodadvances. The story of this publication is very unique: lasting 6 years, encompassing 4 studies, and 15 US institutions. We analyzed 3 different models (2 of which we developed with the @USTMAConsortium including a #machinelearning model) to predict death from TTP. We concluded that none are reliable in predicting TTP mortality, and that mortality prediction should not guide clinical decision making in TTP. Every #ttp patient should be considered high risk.
I do believe negative studies are equally important to positive ones to publish and avoid publication bias, as this can have important clinical implications. Beyond grateful to all collaborators and collaborating institutions! #hematology #artificialintelligence 🩸 @BloodPortfolio @ASH_hematology
ashpublications.org/bloodadvances/article/10/20/6900/5700… -
Blood Journals Portfolio
@BloodPortfolio
Mosun demonstrated high efficacy and low toxicity in a real-world population containing high-risk patients with indolent lymphomas. Read the full consortium analysis in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/4/100280/569…
-
Blood Journals Portfolio
@BloodPortfolio
Adjusting for baseline disease burden, inferior event-free survival and overall survival were observed in those with each HLH-like syndrome. Inferior outcomes in HLH-like syndromes were driven primarily by CD19− relapse events and nonrelapse mortality. ashpublications.org/bloodadvances/article/10/19/6422/5697…
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
Final Reminder! Join ASH Journal Club Monday to learn how stress erythropoiesis functions as part of immune/inflammation response, and how defects in resolving inflammation can lead to inflammatory anemia.
🔗 academy.hematology.org/course/info.php?id=1786
#hematology #hemetwitter @BloodPortfolio -
Blood Journals Portfolio
@BloodPortfolio
IL-6R inhibition during HSCT promotes type I interferon signaling in blood monocytes and CD4+ T cells. IL-6R inhibition during cellular immunotherapy promotes the expansion of cytolytic CD4+ T cells, including the Eomes+ fraction. Read in Blood: ashpublications.org/blood/article/148/16/2059/569756/IL-6…
-
Blood Journals Portfolio
@BloodPortfolio
Minor design choices can reshape protein interactions recruited to the CAR and produce clinically meaningful differences. CAR-recruited protein interactions should be assessed, they may reveal critical differences that standard preclinical assays miss. ashpublications.org/bloodict/article/2/4/100079/569993/CD…
-
Blood Journals Portfolio
@BloodPortfolio
"Burkitt lymphoma: current understanding, unmet needs, and research directions" read the full review article in Blood Advances: ashpublications.org/bloodadvances/article/10/19/6796/5697…
-
Blood Journals Portfolio
@BloodPortfolio
Addition of NAV to RUX did not change symptom severity; TSS at week 24 was not significantly different between the 2 treatment arms. Read the full article in Blood: ashpublications.org/blood/article/148/16/2029/569436/TRAN…
-
Blood Journals Portfolio reposted
CU Anschutz Lymphoma Program
@CULymphoma
Our @CUHematology lymphoma faculty Drs. @majorajay & @StevenBairMD contribute to the national CUBIC Consortium, with their latest publication on real-world outcomes of mosunetuzumab in indolent lymphomas now published @BloodPortfolio. #lymsm ashpublications.org/bloodneoplasia/article/3/4/100280/569…
-
Blood Journals Portfolio
@BloodPortfolio
BCMA-targeted therapies achieved an 83% overall hematologic response rate in patients with heavily pretreated AL amyloidosis. Deep hematologic responses (≥very good partial response) were achieved in ∼70% of CAR-T and BsAb recipients. ashpublications.org/bloodadvances/article/10/19/6435/5697…
-
Blood Journals Portfolio
@BloodPortfolio
Hepcidin is the principal regulator of systemic iron metabolism and a biomarker of iron status, inflammation, and erythroid activity. Read the full article in Blood RCI: ashpublications.org/bloodrci/article/2/4/100108/569942/He…
-
Blood Journals Portfolio
@BloodPortfolio
Combined with proven clinical benefits, these results support the wider adoption of VWF prophylaxis for type 3 VWD in the United States. Read the article in Blood Advances: ashpublications.org/bloodadvances/article/10/19/6719/5696…
-
Blood Journals Portfolio
@BloodPortfolio
Motivating patients to do IS is difficult, time consuming, and often unsuccessful according to medical providers. This study identified barriers and facilitators in the implementation of IS in pediatric patients with #scd. Read in Blood RCI: ashpublications.org/bloodrci/article/2/4/100109/569981/Im…
-
Blood Journals Portfolio
@BloodPortfolio
The combination of CPX-351 and GO led to an overall response rate of 30% in patients with R/R AML and high-risk MDS after HMA. Among patients with R/R AML who achieved a cCR, the 1-year OS rate was 56%, and no events of hepatic SOS were observed. ashpublications.org/bloodneoplasia/article/3/4/100292/570…
-
Blood Journals Portfolio
@BloodPortfolio
Hemolysis is increased during an ADAMTS13 relapse in patients with iTTP. Threshold for the initiation of rituximab might need to be reconsidered to prevent recurring events of elevated hemolysis. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/19/6513/5696…
-
Blood Journals Portfolio
@BloodPortfolio
Quechua males living at 5000m show iron-restricted erythropoiesis despite strong erythropoietin-ERFE signaling, suppressed hepcidin. NFKB1 genotype is linked to altered hepcidin and ferritin regulation showing genetic influence on high-altitude adaptation. ashpublications.org/bloodrci/article/2/4/100114/570106/A-…
-
Blood Journals Portfolio
@BloodPortfolio
"Combination therapy with nelarabine, pegaspargase, and venetoclax for adult patients with R/R T-cell ALL/LBL" explore the research letter in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/4/100300/570…
-
Blood Journals Portfolio
@BloodPortfolio
Check out this month's CME-accredited article in Blood: Rapid peak cilta-cel expansion is associated with delayed neurotoxicity in multiple myeloma ashpublications.org/blood/article/148/16/1961/569598/Rapi…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now! Featuring The enigma of rapid response vs safety in AL amyloidosis, Myelofibrosis end points and self-evident truths, Ironing out vascular control in anemia, and more. Explore here: ashpublications.org/blood/issue/148/16
-
Blood Journals Portfolio
@BloodPortfolio
Your weekly dose of hematology research has arrived! Today's episode features Drs. Dr. Moritz Fürstenau of University Hospital Cologne and Dr. William Dunn of @Cambridge_Uni discussing their latest papers on CLL and clonal monocytosis. Listen here: bloodpodcast.transistor.fm/episodes/venetoclax-combinatio…
-
Blood Journals Portfolio
@BloodPortfolio
Treatment with EPO-based therapy achieved hemoglobin recovery in 74% of patients with anemia who declined transfusions. Recovery by EPA-based therapy is slower than transfusion in patients with anemia. Read the full study in Blood RCI: ashpublications.org/bloodrci/article/2/4/100113/570006/Er…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Advances out now! Featuring New views on VUSs in RUNX1-FPD, Democratizing cancer risk testing in children before alloHCT, CATCHing chronic GVHD, and more. Explore here: ashpublications.org/bloodadvances/issue/10/19
-
Blood Journals Portfolio
@BloodPortfolio
They model hemophilia pain in FVIIIKO mice showing altered movement, weight-bearing, hyperalgesia and nocifensive behaviors. Underlying mechanisms of neuroinflammation with neutrophil and mast cell activation show treatable targets for hemophilia pain. ashpublications.org/bloodadvances/article/10/19/6366/5691…
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
New evidence-based recommendations on #myelofibrosis address routine clinical questions and identify where stronger evidence is needed to improve care.
Learn more about the guidelines, published today in @BloodPortfolio www.hematology.org/news-and-media/press-releases/2026/ash…
#mpnsm #hematology -
Blood Journals Portfolio reposted
Jorge Cortes MD
@jorgecortesmd
We are recruiting for a motivated and accomplished lymphoma expert who wants to build a career at @ONealCancerUAB @uabmedicine, a great place to work, with great potential to grow and expand our clinical research. @ASH_hematology @BloodPortfolio Apply at: uab.peopleadmin.com/postings/28125
-
Blood Journals Portfolio reposted
Open Medicine Insights
@OpenMedInsights
🗞️ American Society of Hematology 2026 Guidelines for the Management of Myelofibrosis in Adults
@BloodPortfolio
ashpublications.org/bloodadvances/article/doi/10.1182/blo… -
Blood Journals Portfolio
@BloodPortfolio
Distinct metabolically active leukemic cells are enriched in aggressive #cll subsets and exhibit a BcR-mTOR-MYC-OXPHOS signature. Most CLL cases exhibit intraclonal immunogenetic diversification suggestive of ongoing somatic hypermutation. ashpublications.org/bloodneoplasia/article/3/4/100282/570…
-
Blood Journals Portfolio
@BloodPortfolio
High-throughput 3-dimensional HC serves as a tool for clinical monitoring of #scd. Hydroxyurea-induced fetal Hb level variation affects RBC response to voxelotor. Read the full article in Blood RCI: ashpublications.org/bloodrci/article/2/4/100116/570156/Ho… #sicklecelldisease #bloodrci
-
Blood Journals Portfolio reposted
Nico Gagelmann
@NicoGagelmann
Really excited to share the first comprehensive study of germline DDX41 in MDS undergoing transplantation in @BloodPortfolio .
Grateful to Coleman Lindsley, germline brain Chris Reilly @DanaFarber and whole team from @CIBMTR 🙏❤️
ashpublications.org/blood/article/doi/10.1182/blood.20260… -
Blood Journals Portfolio reposted
Hematology Advisor
@HematologyAdv
Frontline therapy with ibrutinib and venetoclax demonstrates a manageable safety profile and produces high overall response rates in older patients with #mcl
According to @BloodPortfolio, this strategy yields high complete response rates and durable remission rates!
Read more here: www.hematologyadvisor.com/news/mantle-cell-lymphoma-ibrut… -
Blood Journals Portfolio
@BloodPortfolio
Human myeloma cell line models of acquired IMiD/CELMoD resistance show alterations in lipid metabolism. A genome-wide CRISPR screen performed in a model of acquired resistance identified dependencies in two lipid pathway genes. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/4/100281/570…
-
Blood Journals Portfolio
@BloodPortfolio
Assessment based on AA alone is insufficient to study aspirin efficacy. A multiagonist approach improves detection of residual reactivity and identifies thromboxane A2-dependent and -independent HARPR. Read in Blood VTH: ashpublications.org/bloodvth/article/3/4/100204/570553/In…
-
Blood Journals Portfolio
@BloodPortfolio
The partnership delivered regular education, standard operating procedure development, and strengthened laboratory–clinical integration. Consistent remote engagement and multidisciplinary collaboration supported sustainable hematology service development. ashpublications.org/bloodglobal/article/2/4/100157/570784…
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
Explore the role of itaconate in stress erythropoiesis during the new ASH Journal Club, including how this anti-inflammatory metabolite may influence the differentiation of stress erythroid progenitor cells.
Save your spot! academy.hematology.org/course/info.php?id=1786
#hematology @BloodPortfolio -
Blood Journals Portfolio
@BloodPortfolio
The B domain of FVIII stabilizes it by shielding crucial domains, preventing early activation and inhibitor binding. B-domain glycosylation and cleavage are key to FVIII conformational stability, aiding in proper folding and secretion. Read in Blood VTH: ashpublications.org/bloodvth/article/3/4/100194/569911/De…
-
Blood Journals Portfolio
@BloodPortfolio
Overweight/obesity at diagnosis is associated with inferior EFS in male, but not female, patients aged ≥10 years with #all. Male patients aged ≥10 years with overweight/obesity represent a vulnerable patient group at increased risk of relapse or death. ashpublications.org/bloodneoplasia/article/3/4/100273/569…
-
Blood Journals Portfolio
@BloodPortfolio
Public treatment funding is associated with a higher risk of death in #dlbcl than private funding. Lower educational level is associated with higher risk of death in DLBCL. Read the study in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/4/100159/570787…
-
Blood Journals Portfolio
@BloodPortfolio
HSC-derived MLCs engraft throughout several brain regions in NHPs after gene-modified autologous HSCT. MLCs adopt a similar transcriptome and morphology to endogenous microglia, yet retain some features associated with peripheral macrophages. Read here: ashpublications.org/bloodadvances/article/10/19/6359/5692…
-
Blood Journals Portfolio
@BloodPortfolio
The pGen-SHM plot visually captures the dynamics of immune reconstitution after allo-HSCT. After BMT, the plot distinguished graft-derived mature B cells from newly generated, maturing B cells. Read the full article in Blood ICT: ashpublications.org/bloodict/article/2/4/100080/570000/B-…
-
Blood Journals Portfolio
@BloodPortfolio
A panel of expert hematologists developed recommendations to address global disparities and resource constraints in #cll management. Recommendations address molecular risk, targeted therapy selection, and strategies for relapsed/refractory CLL. Read here: ashpublications.org/bloodglobal/article/2/4/100148/570268…
-
Blood Journals Portfolio
@BloodPortfolio
AIHA is associated with significant morbidity in children, with a high rate of secondary diagnoses and chronic/relapsing course. Expanded testing, monitoring, and treatment approaches are needed in the pediatric AIHA population. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/19/6346/5695…
-
Blood Journals Portfolio
@BloodPortfolio
Functional antibody and CD8 T-cell responses to mRNA vaccination are attenuated in HSCT recipients. Reduced TCF-1high mature naïve T cells may underlie impaired T-cell memory response. Read the full article in Blood ICT: ashpublications.org/bloodict/article/2/4/100083/570100/Re…
-
Blood Journals Portfolio
@BloodPortfolio
CML in Colombia shows rising prevalence and 86.3% 5-year survival in real-world practice. Despite high survival, 38% required treatment change because of resistance or intolerance. Read the full article in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/4/100155/570786… #cml #colombia
-
Blood Journals Portfolio
@BloodPortfolio
Immunosequencing (clonoSEQ) characterizes B-cell recovery in patients with B-cell acute lymphoblastic leukemia after CAR T-cell therapy. Immunosequencing metrics define the developmental stage of B-cell repertoire recovery. Read in Blood ICT: ashpublications.org/bloodict/article/2/4/100081/570014/Tr…
-
Blood Journals Portfolio
@BloodPortfolio
A 20-gene LymphGen-like classifier resolves Indian #dlbcl subtypes and reclassifies genetic risk beyond COO in ∼20% of cases. VAF analysis reveals TP53 & MYD88 as early founding events with 72% of the patients harboring a therapeutically actionable target ashpublications.org/bloodglobal/article/2/4/100136/569899…
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
Happy #nationalhispanicheritagemonth from ASH! 🎉
ASH celebrates the remarkable contributions of Hispanic and Latino/a/x hematologists, researchers, and clinicians advancing research and care for people with blood disorders. 🩸
#hematology -
Blood Journals Portfolio reposted
Juan P. Alderuccio
@JuanAlderuccio
Honored to be part of this @DanaFarberNews @SylvesterCancer collaboration led by @JenCrombieMD, now out in @BloodPortfolio
Glofit + Pola-R-CHP in untreated DLBCL (IPI ≥2):
- 95% CR
- 24-mo PFS 95%
- CRS 10%, all grade 1
- No ICANS
ashpublications.org/blood/article-abstract/doi/10.1182/bl… -
Blood Journals Portfolio
@BloodPortfolio
A new hematology conversation is waiting for you! This week's #bloodpodcast episode features Drs. Chalothorn and Gutstein of @Regeneron and Dr. Thanabalasuriar of @mcgillu to discuss their latest papers published in Blood. Listen here:
bloodpodcast.transistor.fm/episodes/new-perspectives-on-a… -
Blood Journals Portfolio
@BloodPortfolio
We've launched a new editorial series in Blood titled
"Evolving Paradigms in Hematology". Read the inaugural editorial, by Deputy Editor Helen Heslop, "From specialized centers to community care: expanding the reach of CAR T-cell therapy" here ➡️ ashpublications.org/blood/article/148/15/1855/571316/From… -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Decoding factor XI inhibition, Seeing the myeloma bone marrow through an ecological lens, Human HSPC clones balance stochastic diversification with cytokine-induced differentiation, and more. Explore here: ashpublications.org/blood/issue/148/15
-
Blood Journals Portfolio reposted
Ohio State Hematology
@OSUHematology
Congrats Jonathan Brammer, MD, on publishing the first international consensus criteria for T-LGL leukemia in @BloodPortfolio! 🩸
This work, led by Dr. Brammer through the International LGLL Consortium, includes contributions from Drs. Braunstein & Ruiz.
doi.org/10.1182/blood.2025030252 -
Blood Journals Portfolio
@BloodPortfolio
G6PDd rewires splenic macrophage metabolism in hyperlipidemia by restricting NADPH-dependent redox and heme metabolism. NADPH limitation links RBC fragility to erythrophagocytosis-associated metabolic remodeling in splenic macrophages during hyperlipidemia ashpublications.org/bloodrci/article/2/4/100119/570174/Gl…
-
Blood Journals Portfolio
@BloodPortfolio
"Recurrent VTE in patients with thrombophilia after stopping anticoagulation: a systematic review and meta-analysis" read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/19/6331/5697…
-
Blood Journals Portfolio
@BloodPortfolio
The novel tandem BCMA-CAR reduced tonic signaling and attenuated off-tumor activity in vitro compared with previously published BCMA-CARs. The optimized CAR retained potent antimyeloma activity in vivo. Read the full article in Blood ICT: ashpublications.org/bloodict/article/2/4/100078/569891/Op…
-
Blood Journals Portfolio
@BloodPortfolio
Arabian Gulf national APL cohort (N = 75): 5-year OS and LFS both 90.4%; 95.5% achieved complete remission. All 7 deaths occurred within 30 days of diagnosis, and 5 preceded ATRA, underscoring the need for rapid APL recognition. Read here: ashpublications.org/bloodglobal/article/2/4/100154/570783… #apl #kuwait
-
Blood Journals Portfolio
@BloodPortfolio
Anemia was present in 52.6% of patients with MF in Argentina and was associated with increased mortality. Common treatments for patients with anemia included epoetin alfa (70.8%) and ruxolitinib (20.8%). Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/4/100146/570265…
-
Blood Journals Portfolio
@BloodPortfolio
AAV-FVIII-SQ has enhanced activation by thrombin, which is captured by the OSA. OSA FVIII activity predicts AAV-FVIII-SQ hemostatic function. Read the full article in Blood: ashpublications.org/blood/article/148/14/1848/569427/One-…
-
Blood Journals Portfolio
@BloodPortfolio
Optimized allogeneic stem cell apheresis overcame collection challenges: 100% male success, 5% female failure and 0% tertiary collections. Single-session collection maintained robust engraftment kinetics and 91% day-100 survival while minimizing donor risk ashpublications.org/bloodglobal/article/2/4/100106/568347…
-
Blood Journals Portfolio
@BloodPortfolio
Fibroblast-derived FGF18 binds to FGFR3 on #aml cells to drive leukemic progression and suppress CD8+ T-cell effector function. FGF18 neutralization disrupts stromal-leukemic cross talk and enhances anti–PD-1 immunotherapy efficacy in AML. ashpublications.org/blood/article/148/14/1800/569391/FGF1…
-
Blood Journals Portfolio
@BloodPortfolio
NX-5948 selectively removes platelet BTK and prevents thrombosis without affecting bleeding. BTK degradation could provide safer clot prevention for patients who cannot tolerate standard antiplatelet drugs. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/18/6090/5694…
-
Blood Journals Portfolio reposted
Juan P. Alderuccio
@JuanAlderuccio
Latest from our @SylvesterCancer lymphoma group in @BloodPortfolio, led by @MDStanch, showing how body composition and PET/CT metrics inform response and toxicity in advanced-stage Hodgkin lymphoma treated with BV-AVD
ashpublications.org/bloodneoplasia/article/doi/10.1016/j.… -
Blood Journals Portfolio reposted
Joseph Aslan
@JoePlatelet
Happy to share our #firstedition @BloodPortfolio paper from @yiiihengzhang and @OHSUCardio @OHSUChemBio @OHSU_BME team: mPTP inhibitors selectively suppress #platelet procoagulant activity and #thrombosis while preserving key platelet functions. doi.org/10.1182/blood.2025032930
-
Blood Journals Portfolio
@BloodPortfolio
After 41.5 months median follow-up liso-cel showed high rates of durable responses and sustained clinical benefit in patients with 3L+ FL. Liso-cel demonstrated a favorable long-term safety profile, including low rates of infection in patients with 3L+ FL. ashpublications.org/blood/article/148/14/1789/569473/Dura…
-
Blood Journals Portfolio
@BloodPortfolio
Children with #sca have similar post–measles vaccine seroprotection compared with the general population. #hydroxyurea at the time of vaccination does not diminish measles seroprotection, and earlier hydroxyurea initiation enhances protection. ashpublications.org/bloodadvances/article/10/18/6249/5697…
-
Blood Journals Portfolio
@BloodPortfolio
Ziftomenib 600mg once daily combined with venetoclax/azacitidine demonstrated deep and durable responses in R/R NPM1-m #aml. The combination was well tolerated, with low rates of differentiation syndrome and corrected QTc prolongation. Read here: ashpublications.org/blood/article/148/14/1775/568820/Zift…
-
Blood Journals Portfolio
@BloodPortfolio
The tumor immune microenvironment in extramedullary myeloma is dominated by macrophages with a suppressive phenotype. Bidirectional cellular interactions predict activation of canonical PC survival pathways and drive immunosuppressive macrophage phenotype. ashpublications.org/bloodadvances/article/10/18/6221/5694…
-
Blood Journals Portfolio
@BloodPortfolio
The impaired hematopoietic recovery in Plg-/- mice after 5-fluorouracil is reversed by genetic/pharmacological elimination of fibrinogen. Fibrin suppresses hematopoietic recovery via αMβ2-dependent myeloid interactions. Read here: ashpublications.org/bloodadvances/article/10/18/6079/5692…
-
Blood Journals Portfolio
@BloodPortfolio
MAST accurately guided iron therapy decisions in microcytic anemia, reducing inappropriate iron treatment. MAST performance was robust despite malaria and reliably excluded #thalassemia in a resource-limited setting. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/4/100153/570452…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Menin inhibitors unleash JUND-mediated resistance mechanisms, How I treat thrombotic microangiopathy in the setting of triggers, and more. Explore here: ashpublications.org/blood/issue/148/14
-
Blood Journals Portfolio
@BloodPortfolio
New Blood Podcast episode out now covering durable treatment strategies for relapsed and refractory hematologic malignancies! Dr. Laura Michaelis interviews Drs. Harry Erba of @DukeHealth and Sairah Ahmed of @UTMDAnderson on their latest Blood papers: bloodpodcast.transistor.fm/episodes/designing-durable-rem…
-
Blood Journals Portfolio
@BloodPortfolio
"Sickle cell disease, sickle cell trait, and hemoglobin C trait in Spanish-speaking Latin America" Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/4/100152/570335… #scd #latinamerica
-
Blood Journals Portfolio
@BloodPortfolio
Opportunistically phenotyping WBMRI is a scalable biomarker for exploring risk stratification and the effects of therapies on normal tissue. AI can be used for automated and opportunistic extraction of body composition metrics from routinely acquired WBMRI ashpublications.org/bloodadvances/article/10/18/6103/5695…
-
Blood Journals Portfolio
@BloodPortfolio
"Thromborepair: the tissue repair partner to thromboinflammation" read the full review article in Blood VTH: ashpublications.org/bloodvth/article/3/4/100198/570099/Th…
-
Blood Journals Portfolio
@BloodPortfolio
"Molecular diagnosis of myeloproliferative neoplasms in a resource-limited public health system in Brazil" Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/4/100140/570148…
-
Blood Journals Portfolio
@BloodPortfolio
This prospective trial of sirolimus in 78 adults with R/R wAIHA/ES shows high 6-month response rates (ORR, 80.7%; CRR 51.3%). Sirolimus is a safe, cost-effective option with low relapse, providing a durable, corticosteroid-sparing therapy. ashpublications.org/bloodadvances/article/10/18/6198/5690…
-
Blood Journals Portfolio
@BloodPortfolio
NSD2-LDD selectively degrades NSD2, reversing the oncogenic program of t(4;14) #mm and validating NSD2 as a therapeutic target. It also reduces supportive bone marrow microenvironment interactions in vivo, controlling disease and extending survival. ashpublications.org/blood/article/148/13/1694/569426/NSD2…
-
Blood Journals Portfolio
@BloodPortfolio
"Disease-specific safety and efficacy of DOACs vs LMWH for CAT in patients with brain metastases: a real-world analysis" read the full research letter in Blood VTH: ashpublications.org/bloodvth/article/3/4/100197/570082/Di…
-
Blood Journals Portfolio
@BloodPortfolio
Outpatient #aml induction was feasible and reduced time to treatment initiation, with low mortality rates in trial and real-world settings. This induction model may improve access to timely AML therapy in resource-limited settings. Read here: ashpublications.org/bloodglobal/article/2/4/100147/570269…
-
Blood Journals Portfolio
@BloodPortfolio
Late cytopenia is a complication after CD19 CAR T-cell therapy for R/R LBCL. High CAR-HEMATOTOX score, receipt of bridging therapy, and axicabtagene ciloleucel predict late cytopenia after CD19 CAR T-cell therapy. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/18/6188/5693…
-
Blood Journals Portfolio
@BloodPortfolio
DOT1L maintains GCB-DLBCL identity by supporting ncPRC1-associated H2AK119ub1 deposition at PRC1/2 targets enriched for PC differentiation. Read the full article in Blood: ashpublications.org/blood/article/148/13/1683/568800/DOT1…
-
Blood Journals Portfolio
@BloodPortfolio
LD-ITI+EMI accelerates tolerance by reducing bleeding without increasing direct costs. Bleeding during ITI is associated with delayed achievement of immune tolerance. Read the full study in Blood VTH: ashpublications.org/bloodvth/article/3/4/100200/570162/Em…
-
Blood Journals Portfolio
@BloodPortfolio
Across 59 centers in 30 countries major geographic and income gaps persist in hemoglobinopathy staffing, diagnostics, and therapies. SSA has the highest #scd burden, high patient-to-specialist ratio, limited diagnostic capacity, and limited access to care. ashpublications.org/bloodglobal/article/2/4/100145/570267…
-
Blood Journals Portfolio
@BloodPortfolio
Allogeneic HCT resulted in greater normalization of rheology compared to GT in patients with #scd. Rheology after HCT from HbAS donors normalized to HbAS control levels, whereas rheology after GT did not. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/18/6170/5697…
-
Blood Journals Portfolio
@BloodPortfolio
TAMI added to VEN/AZA was well tolerated but did not improve efficacy in RARA+ AML, and the study was stopped early for futility. RARA positivity alone may not predict benefit from RARα-targeted therapy in this setting. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/4/100279/569…
-
Blood Journals Portfolio
@BloodPortfolio
Expert recommendations addressed key #hemophilia management challenges to optimize patient care in the Gulf region. Read the full study in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/4/100133/569941…
-
Blood Journals Portfolio
@BloodPortfolio
Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring #bloodadvances ashpublications.org/bloodadvances/article/doi/10.1182/blo…
-
Blood Journals Portfolio
@BloodPortfolio
"Soluble B-cell maturation antigen as a biomarker of progression and treatment response in patients with myeloma precursors" read the research letter in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/4/100284/570…
-
Blood Journals Portfolio
@BloodPortfolio
Hematological cancers cause ∼10% of cancer deaths in North Africa and are projected to double by 2050 due to population growth and aging. Read the full study in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/4/100135/569898… #cancer #northafrica
-
Blood Journals Portfolio
@BloodPortfolio
Minor histocompatibility antigen TCR-T #bloodadvances ashpublications.org/bloodadvances/article/10/18/6064/5694…
-
Blood Journals Portfolio
@BloodPortfolio
Combined systemic chemoradiotherapy improves survival over either alone in stage I/II #mcl in a national database study. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/4/100283/570…
-
Blood Journals Portfolio reposted
Talha Badar
@TalhaBadarMD
Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia ashpublications.org/blood/article-abstract/doi/10.1182/bl…
Promising phase II data for frontline venetoclax + pediatric-inspired chemotherapy in 167 pts age 14–60 with newly diagnosed Ph-negative ALL: CR 91%, post-induction MFC-MRD negativity 73% among responders, 2-year OS 78.5% and DFS 76.7%. Toxicities were mainly hematologic/infectious. Encouraging depth of response, but single-arm design, historical comparator, and short follow-up mean randomized validation is still needed. #all #leusm. @BloodPortfolio -
Blood Journals Portfolio
@BloodPortfolio
Long-read (Oxford Nanopore) TP53 sequencing is feasible in the point-of-care setting in a resource-limited African setting. Pathogenic TP53 mutations were confirmed in 6.25% of treatment-naïve Tanzanian patients with #cll. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/4/100130/569884…
-
Blood Journals Portfolio
@BloodPortfolio
New from the Blood Podcast! Dose Makes the Cure: Venetoclax in Ph- ALL. Dr. James Griffin interviews Dr. Jianxiang Wang on his latest paper titled "Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia." bloodpodcast.transistor.fm/episodes/dose-makes-the-cure-v…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Expanded antigen-specific donor regulatory T cells for GVHD prevention, Degrading NSD2 rewires the myeloma niche, Fibrocytes take the wheel in myelofibrosis, and more. Explore here: ashpublications.org/blood/issue/148/13
-
Blood Journals Portfolio
@BloodPortfolio
"Why standard tests miss spike-induced clot alterations" read the letter to the editor in Blood Advances: ashpublications.org/bloodadvances/article/doi/10.1182/blo…
-
Blood Journals Portfolio
@BloodPortfolio
Detailed #apl characterization at tertiary centers includes clinical, morphological, immunophenotypic, molecular, and cytogenetic profiling. This study focuses on diagnostic accuracy and the identification of prognostic indicators. Read here: ashpublications.org/bloodglobal/article/2/4/100149/570264…
-
Blood Journals Portfolio
@BloodPortfolio
Quantitative flow provides better assessment of antigen density than conventional methods. Antigen density is affected by previous treatment and can impact target selection. Read in Blood ICT: ashpublications.org/bloodict/article/2/3/100067/568976/An…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood ICT out now! Featuring BCMA-targeted T-cell engager therapy induces sustained remission in immune thrombocytopenia,
Preleukapheresis risk factors for BCMA CAR-T product manufacturing failure, and more. Explore here: ashpublications.org/bloodict/issue/2/3 -
Blood Journals Portfolio
@BloodPortfolio
Automated NGS in #mexico reveals a distinct #aml profile with high Fms-like tyrosine kinase 3 mutations and few age-related variants. AML risk assessment improved via genomics but survival was limited by restricted access to targeted therapies and HCT. ashpublications.org/bloodglobal/article/2/4/100126/569741…
-
Blood Journals Portfolio
@BloodPortfolio
MEK and RAS inhibition resensitize resistant #aml cells, suggesting therapeutic potential for combined FLT3, BCL2, and RAS-pathway inhibition. Read in Blood: ashpublications.org/blood/article/148/12/1588/568816/Dyna…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Advances out now featuring Estrogen-associated thrombosis and the road not taken, Minor histocompatibility antigen TCR-T, A practical approach to risk stratification of incidental T-cell clonality, and more. Explore here: ashpublications.org/bloodadvances/issue/10/18
-
Blood Journals Portfolio
@BloodPortfolio
We're thanking Dr. Griffin for his 6 years of service, and welcoming two new editors to the Blood Podcast. Check out our full update: www.linkedin.com/feed/update/urn:li:activity:750825370886…
-
Blood Journals Portfolio
@BloodPortfolio
High MPV and neutrophils with low PNR are accessible hematological signatures for vaso-occlusive crisis and ischemic stroke in pediatric #scd. Read the full study in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/4/100124/569740…
-
Blood Journals Portfolio
@BloodPortfolio
PKMYT1 is highly expressed in del(17p) MM, and its inhibition represents a vulnerability. PKMYT1 inhibitor triggers DNA damage and mitotic catastrophe, leading to apoptosis in del(17p) MM cells. Read in Blood: ashpublications.org/blood/article/148/12/1559/568862/PKMY… #mm #multiplemyeloma
-
Blood Journals Portfolio
@BloodPortfolio
This article, published in 1958, presents one of the first cooperative multicenter comparative trials in modern clinical oncology. Read "A comparative study of two regimens of combination chemotherapy in acute leukemia" here: ashpublications.org/blood/article-abstract/13/12/1126/756…
Post not available here, view on X
Blood Journals Portfolio
@BloodPortfolio
In those days, AML and ALL could not be distinguished, and the same treatment was applied to both. Remarkably, survival was better for patients responding to chemotherapy.
Blood Journals Portfolio
@BloodPortfolio
Many of the authors continued their contributions to developmental cancer therapy. Donald Pinkel would pioneer the successful "total therapy" for pediatric ALL. *Our editors chose to highlight this study, in honor of Blood's 80th anniversary, as one of its most impactful articles
-
Blood Journals Portfolio
@BloodPortfolio
First-line ibrutinib plus venetoclax showed promising efficacy with a high CR rate and durable remissions in patients with nonblastoid #mcl. Check out this month's CME accredited article in Blood: ashpublications.org/blood/article/148/12/1547/569472/Firs…
-
Blood Journals Portfolio
@BloodPortfolio
CTX110 showed acceptable safety and promising preliminary efficacy at higher DLs in patients with R/R B-cell NHL. Allogeneic, off-the-shelf CTX110 is a more consistent product with decreased time to treatment compared with marketed CAR T-cell treatments. ashpublications.org/bloodadvances/article/10/17/5778/5681…
-
Blood Journals Portfolio
@BloodPortfolio
Two years after treatment, CAR-T recipients report long-term improvements in multiple HRQoL domains. PRO fatigue in the acute post–CAR-T period may be a novel prognostic marker for treatment response that warrants prospective validation. ashpublications.org/bloodneoplasia/article/3/4/100278/569…
-
Blood Journals Portfolio
@BloodPortfolio
TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma. Read the research letter in Blood Advances: ashpublications.org/bloodadvances/article/10/17/5934/5695… #mm #multiplemyeloma #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Highlighting Dr. Nina Cabezas-Wallscheid of @ETH to wrap up peer review week:
www.linkedin.com/feed/update/urn:li:activity:750682311951… #peerreview #peerreviewweek #prw2026 -
Blood Journals Portfolio reposted
Blood Cancers Today
@Blood_Cancers
A phase 2 trial published in @BloodPortfolio shows promising 3-year survival with azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated #aml.
💡 Learn more, with insight from @NicholasShortMD of @UTMDAnderson.
➡️ www.bloodcancerstoday.com/post/most-aml-relapses-during-a… -
Blood Journals Portfolio
@BloodPortfolio
Arterial thrombotic events occurred at a clinically meaningful frequency over 5 years in adult Japanese individuals with hemophilia. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/17/5789/5693… #hemophilia #japan #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
MDSm+ in favorable-risk NPM1-mutated #aml do not independently predict prognosis after adjusting for age. Patients with NPM1-mutated AML who are aged ≥65 years have inferior outcomes regardless of MDSm+. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/4/100272/569…
-
Blood Journals Portfolio
@BloodPortfolio
Your weekly Blood Podcast episode has arrived! Join Dr. Laurie Sehn to interview Drs. @mtfulciniti of @DanaFarber and @dalessandrolab of @CUMedicalSchool on their latest papers published in Blood:
bloodpodcast.transistor.fm/episodes/exploiting-vulnerabil… -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Decentralized clinical trials in hematology, How I treat chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists, and more. Explore here: ashpublications.org/blood/issue/148/12
-
Blood Journals Portfolio reposted
Anaïs Schavgoulidze
@ASchavgoulidze
Excited to share that our work from my time at @DanaFarber has been published in @BloodPortfolio : "PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk #multiplemyeloma".
Also very grateful that our work was chosen for the cover of the journal (credit Vanessa Favasuli) -
Blood Journals Portfolio reposted
Thor Halfdanarson
@OncoThor
You want to know more about how to treat chemotherapy induced thrombocytopenia with thrombopoietin receptor agonists?
@BloodPortfolio has you covered...
ashpublications.org/blood/article-abstract/doi/10.1182/bl… -
Blood Journals Portfolio
@BloodPortfolio
We're continuing the #peerreviewweek celebration! Check out this feature on Dr. Rami Khoriaty: www.linkedin.com/feed/update/urn:li:activity:750572570690… #prw2026
-
Blood Journals Portfolio
@BloodPortfolio
Extreme endurance exercise induces an inflammatory response with hepcidin-driven iron restriction. Upregulation of iron uptake and downregulation of iron export/storage genes in PBMC show a compensatory response to cellular iron deficiency. ashpublications.org/bloodadvances/article/10/17/5836/5681…
-
Blood Journals Portfolio
@BloodPortfolio
Although effective for #aha management, emicizumab remains underused in hospitals due to its high cost. Addition of up-front emicizumab to rFVIIa vs rFVIIa alone yielded lower total direct cost and improved health states. Read in Blood VTH: ashpublications.org/bloodvth/article/3/4/100195/569910/Co… #bloodvth
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood RCI out now! Featuring Glutathione reductase deficiency and episodic hemolysis, Reflections on the dual nature of iron in life, Pyruvate kinase activators in the context of erythropoiesis defects and more. Explore here: ashpublications.org/bloodrci/issue/2/3
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
New clinical guidelines for iron deficiency from ASH aim to help identify cases that may otherwise go undiagnosed. Updated ferritin thresholds support earlier, more accurate diagnosis. Learn more: www.hematology.org/news-and-media/press-releases/2026/ash… @BloodPortfolio
-
Blood Journals Portfolio
@BloodPortfolio
Abnormal serum immunofixation patterns are common after BCMA CAR-T in multiple myeloma and are preceded by immune events. Read the research letter in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/4/100267/569… #mm #multiplemyeloma #bloodneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
The GPVI- and polyphosphate-dependent procoagulant activity of highly reactive platelets mediates the thrombogenic potential of fibrin. Read the study in Blood VTH: ashpublications.org/bloodvth/article/3/4/100191/569685/Pl… #bloodvth
-
Blood Journals Portfolio
@BloodPortfolio
Low M1 infiltration is the main immune-related negative prognostic factor for progression-free survival in anti-CD20 + CHOP–treated patients. Pola-R-CHP activity appears largely independent of M1 macrophage enrichment or overall immune cell infiltration. ashpublications.org/bloodneoplasia/article/3/4/100264/569…
-
Blood Journals Portfolio
@BloodPortfolio
Cellular and bispecific therapies show promising activity for CNS myeloma, whereas IT therapy appears to have limited efficacy. CNS myeloma is rare, aggressive, and strongly associated with high-risk cytogenetics and multifocal EMD. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/17/5828/5693…
-
Blood Journals Portfolio
@BloodPortfolio
In a DCE including 1455 patients with WM from 5 countries, 6 treatment properties influenced patient preferences. Longer response durations and avoidance of severe toxicity were prioritized over oral or fixed-duration regimens, guiding clinical practice. ashpublications.org/bloodneoplasia/article/3/4/100271/569…
-
Blood Journals Portfolio
@BloodPortfolio
Happy Peer Review Week! #prw2026 We'll be featuring our amazing peer reviewers every day. Here is the first highlight for Blood Neoplasia on Karen Keeshan: www.linkedin.com/feed/update/urn:li:activity:750531204905…
-
Blood Journals Portfolio
@BloodPortfolio
HbF elevation has limited diagnostic and prognostic value in patients with BMFS. PNH clones favor AA, whereas very short (less than first percentile) lymphocyte telomere length favors IBMFS. Read in Blood RCI: ashpublications.org/bloodrci/article/2/3/100115/570157/Fe… #bloodrci
-
Blood Journals Portfolio
@BloodPortfolio
Find the Blood Advances paper here: ashpublications.org/bloodadvances/article/doi/10.1182/blo… #bloodcancerawarenessmonth
Blood Cancers Today
@Blood_Cancers
A new analysis published in @BloodPortfolio estimates blood cancer therapies have saved 25.8M life-years, revealing where innovation has transformed survival and where progress lags.
💡 Learn more, with insight from E. Anders Kolb, MD (@BloodCancerUtd) and Ann-Kathrin Eisfeld, MD (@OSUHematology).
➡️ www.bloodcancerstoday.com/post/blood-cancer-advances-save… -
Blood Journals Portfolio
@BloodPortfolio
Patients with SM-AHN and genetically unrelated MC and AHN cells have more indolent disease and better outcomes vs patients with shared alterations. Read the study in Blood Advances: ashpublications.org/bloodadvances/article/10/17/5916/5691…
-
Blood Journals Portfolio
@BloodPortfolio
WNK1 is identified as a promising therapeutic target in T-ALL and its inhibition induces mitotic defects. WNK1 is overexpressed in the TAL1-related T-ALL subgroup, suggesting a selective therapeutic window. Read in Blood: ashpublications.org/blood/article/148/11/1423/568516/Inhi…
-
Blood Journals Portfolio
@BloodPortfolio
MCL cells rely on ROR1-related signaling in overcoming resistance to Ibru and Ven. ROR1 small-molecule inhibitor KAN571C kills both sensitive and resistant #mcl cells by blocking ROR1 signaling and triggering apoptosis. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/4/100269/569…
-
Blood Journals Portfolio
@BloodPortfolio
GPRC5D-directed therapy demonstrated superior survival compared with B-cell maturation antigen–directed BsAbs in patients with active #pcl. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/17/5938/5695…
-
Blood Journals Portfolio
@BloodPortfolio
In HHAs the levels and origin of EVs reflect disease characteristics & mode of red blood cell clearance. In HHA sTfR reflects erythropoietic activity and can't be used to monitor deregulated iron metabolism or ineffective erythropoiesis. Read in Blood RCI: ashpublications.org/bloodrci/article/2/3/100102/569664/Er…
-
Blood Journals Portfolio
@BloodPortfolio
MR1T cells recognize and kill various #aml cell lines and primary leukemias. Pemetrexed treatment increases MR1 surface expression and synergizes with MR1T-cell therapeutic effects in vivo. Read in Blood ICT: ashpublications.org/bloodict/article/2/3/100073/569763/Ac…
-
Blood Journals Portfolio
@BloodPortfolio
Donor CMV serostatus strongly influences the timing, maturation, and function of CMV-specific T and adaptive NK cells after HSCT. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/17/5800/5693…
-
Blood Journals Portfolio
@BloodPortfolio
High response rate (ORR 56%, CR 42%) and durable CR (1‑year DoCR 75.7%). Primary refractory/early relapsed disease, ECOG PS of >1, and bulky disease of ≥7.5 cm predicted lower CR rates and shorter PFS. Read the article in Blood ICT: ashpublications.org/bloodict/article/2/3/100072/569544/Re…
-
Blood Journals Portfolio
@BloodPortfolio
The BBB is disrupted in adults with #scd and associated with brain microstructural injury. BBB permeability is associated with immune regulation, extracellular matrix degradation, lipid metabolism, and arginine-proline metabolism. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
The use of EHL hyperactive FIX-Padua increases the overall gene therapy efficacy in hemophilia B. This novel transgene may improve the outcome of future hemophilia B gene therapy clinical trials. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/17/5852/5694…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring An RNA splicing–translation circuit for hematopoietic fate, NF-κB as a compass for CAR-T fitness in multiple myeloma, Type-I interferon–activated NK cells control polycythemia vera in vivo and more. Explore here: ashpublications.org/blood/issue/148/11
-
Blood Journals Portfolio
@BloodPortfolio
New episode! Drs. @milnetom68 and Dominique Bonnet discuss their latest articles published in Blood on #all and #bonemarrow. Listen here:
bloodpodcast.transistor.fm/episodes/myb-driven-all-and-ve… -
Blood Journals Portfolio
@BloodPortfolio
Favezelimab plus pembrolizumab showed sustained antitumor activity in participants with anti–PD-1–refractory cHL. It also had a manageable safety profile with no new safety signals observed. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/4/100252/568…
-
Blood Journals Portfolio
@BloodPortfolio
AYA patients treated with pediatric-style and adult regimens demonstrate similar complete remission rates and depth of response in #aml. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/17/5899/5692…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Global Hematology out now featuring Inequities in clinical trial availability in Europe, The correlation between Hb and the clinical spectrum of SCA, Rethinking Hispanic/Latino as an ethnic category in leukemia research & more. Explore: ashpublications.org/bloodglobal/issue/2/3
-
Blood Journals Portfolio
@BloodPortfolio
GLUL restricts cytotoxic ammonia accumulation in MKs and is conducive to MK maturation and thrombocytopoiesis. Read in Blood: ashpublications.org/blood/article/148/10/1344/568858/GLUL…
-
Blood Journals Portfolio
@BloodPortfolio
New clinical guidelines: American Society of Hematology 2026 guidelines for the diagnosis and management of severe and very severe acquired aplastic anemia. Read in Blood Advances ➡️ ashpublications.org/bloodadvances/article/10/17/5962/5673…
-
Blood Journals Portfolio
@BloodPortfolio
Arlo-cel resulted in deep and durable responses in heavily pretreated RRMM. Safety and efficacy outcomes from this phase 1 clinical study support further development of arlo-cel in phase 2 and 3 clinical trials. Read in Blood: ashpublications.org/blood/article/148/10/1240/568830/Arlo…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Advances out now featuring When endurance running leads to functional iron deficiency, Myelodysplasia in VEXAS syndrome, and more. Explore here: ashpublications.org/bloodadvances/issue/10/17 #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Epitranscriptomic reader IMP1 is a novel regulator of fetal erythroid cell phenotype. Embryonic globin expression is directly regulated by IMP1 at the posttranscriptional level. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/16/5518/5690… #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Anti-CCRL2 ADC shows prominent antileukemic effect in high-risk MDS/AML, including TP53-mutated in vitro and in vivo models. Anti-CCRL2 ADC demonstrates no significant toxicity against healthy hematopoietic cells and systemic toxicity in mice. Read here: ashpublications.org/bloodadvances/article/10/16/5653/5685…
-
Blood Journals Portfolio
@BloodPortfolio
GSR is critical to glutathione homeostasis, and GSR deficiencies can mimic G6PD deficiency. In a patient with hemolysis and evidence of oxidative damage, one should have a strong suspicion for a defect in glutathione metabolism. Read in Blood RCI: ashpublications.org/bloodrci/article/2/3/100111/569980/He…
-
Blood Journals Portfolio
@BloodPortfolio
Low-dose vemurafenib plus rituximab produces deep responses with a favorable safety profile in patients with HCL. This approach represents a lower-toxicity alternative to conventional therapies and warrants validation in larger prospective studies. ashpublications.org/bloodadvances/article/10/16/5635/5691…
-
Blood Journals Portfolio
@BloodPortfolio
It's #bloodcancerawarenessmonth! Research is one of the most powerful tools we have. This research letter is a great place to start, just published in Blood Advances, "Life-years saved by advances in blood cancer therapy: a retrospective analysis" ashpublications.org/bloodadvances/article/doi/10.1182/blo…
-
Blood Journals Portfolio
@BloodPortfolio
In this week's #bloodpodcast episode, Dr. Laurie Sehn interviews Drs. Camille Laurent and Christine Bezombes on their latest Blood paper "Patient-derived lymphoma spheroids reveal predictive markers of glofitamab resistance in relapsed/refractory B-NHL." bloodpodcast.transistor.fm/episodes/predictive-markers-of…
-
Blood Journals Portfolio
@BloodPortfolio
VBAND produced a 100% overall response rate including 90% complete responses in a real-world #ptcl cohort. Median progression-free survival was 11.5 months in the frontline and 13.5 months in R/R setting with only 2 manageable adverse events. Read here: ashpublications.org/bloodglobal/article/2/3/100123/569739…
-
Blood Journals Portfolio
@BloodPortfolio
B-ALL creates a growth-permissive bone marrow microenvironment by secretion of specific large EVs. MSC conditioned by large EVs modulate the availability of B-ALL growth factor IGF1. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/16/5620/5690…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring The hidden role of neutrophils in steroid-resistant GVHD, IL-16 drives a novel pathway of BTK inhibitor resistance, Precision transfusion medicine in the omics era and more. Explore here: ashpublications.org/blood/issue/148/10
-
Blood Journals Portfolio reposted
Anastasia Tikhonova
@DrStass
What happens to the bone marrow after chemotherapy?
Very excited to share our new paper, featured on the cover of @BloodPortfolio, led by an incredibly talented student in my lab, Ximing Li! 🎉
ashpublications.org/blood/article-abstract/doi/10.1182/bl… -
Blood Journals Portfolio
@BloodPortfolio
PICC implementation is feasible and safe among patients with hematological malignancies in resource-constrained settings. PICCs lasted longer and were safe in patients with thrombocytopenia from resource-limited settings. Read here: ashpublications.org/bloodglobal/article/2/3/100129/569883…
-
Blood Journals Portfolio
@BloodPortfolio
ASO depletion of pathogenic MBD1 transcripts in vitro promotes erythroid differentiation, showing the utility of RNA therapies for MDS. Read the full article in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #mds #hspc #bloodjournal
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
Advances in the treatment of major blood cancers have saved more than 25 million years of life in the United States over the past 75 years. But gains have not reached everyone equally.
Read more from @BloodCancerUtd new in @BloodPortfolio www.hematology.org/news-and-media/press-releases/2026/inv… -
Blood Journals Portfolio
@BloodPortfolio
The study shows first in vivo proof of a novel concept: complement intervention based on regulation by the engineered fusion protein #trifu. Regulatory intervention is effective & comparable to C3/C5 depletion by cobra venom factor in xenotransfusion model ashpublications.org/bloodadvances/article/10/16/5722/5691…
-
Blood Journals Portfolio
@BloodPortfolio
Mezigdomide treatment activates T cells and reduces exhausted-like T-cell populations in patients with myeloma. Ikaros degradation by mezigdomide enhances anti–B-cell maturation antigen CAR-T and bispecific TCE therapy efficacy in vitro and in vivo. ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
September is National #sicklecellawareness Month. 🩸 Throughout the month, ASH is highlighting efforts to advance SCD research, care, and community. @ConquerSCD
-
Blood Journals Portfolio
@BloodPortfolio
This paper from 1953 established the importance of molecular diagnosis for hemoglobin disorders & genetic counseling. Read "Electrophoretic demonstration of type S (sickle cell) hemoglobin in erythrocytes incapable of showing the sickle cell phenomenon": ashpublications.org/blood/article/8/3/270/44730/Studies-o…
Post not available here, view on X
Blood Journals Portfolio
@BloodPortfolio
Gel electrophoresis of the family's hemoglobins revealed that the asymptomatic parent's red cells contained small quantities of hemoglobin S, indicating that this parent had sickle cell trait despite the negative sickling test.
Blood Journals Portfolio
@BloodPortfolio
In honor of Blood's 80th anniversary, we're looking back at the most impactful articles from its history. Our editors have selected to highlight this one as a milestone in #sicklecelldisease research.
-
Blood Journals Portfolio reposted
Ajay Major, MD, MBA
@majorajay
Proud to share our @ASH_hematology @BloodPortfolio manuscript, led by my trainee Dr. @vpizzuti44 @CUInternalMed.
Longitudinal PROs and QoL trajectories over 2 years after CAR T-cell therapy. #lymsm #mmsm🧵
doi.org/10.1016/j.bneo.2026.100278 -
Blood Journals Portfolio
@BloodPortfolio
TACI × CD3 bsAb potently suppresses MM cell growth. TACI × CD3 bsAb represents a promising strategy to overcome BCMA escape in relapsed/refractory MM. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/16/5669/5688… #mm #multiplemyeloma #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
In CEPHEUS, D-VRd led to higher sustained MRD-negative CR or better rates vs VRd in transplant-ineligible/-deferred patients with NDMM. Deeper MRD responses with D-VRd translated into significantly improved PFS vs VRd. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/16/5594/5688…
-
Blood Journals Portfolio
@BloodPortfolio
del(5q) drives progressive chromosome evolution in TP53-mutant preleukemic HSPCs. Aneuploid HSPCs exhibit a shared gene expression signature that confers distinct therapeutic vulnerabilities in AML-CK. Read the full article in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #bloodjournal
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Neoplasia is out featuring Co-option of lineage plasticity as a hallmark of multipotent acute leukemias, Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphoma and more. Explore here: ashpublications.org/bloodneoplasia/issue/3/3
-
Blood Journals Portfolio
@BloodPortfolio
An adapted FeCl3 model generates stable thrombi suitable for postonset therapeutic testing. The thrombi display a heterogeneous composition (platelets, fibrin, red blood cells) that resembles that of human thrombi after thrombectomy. Read in Blood VTH: ashpublications.org/bloodvth/article/3/3/100188/569701/A-…
-
Blood Journals Portfolio
@BloodPortfolio
HAPLO and MMUD transplants achieve post-transplant outcomes that are not different than MUD in a large, prospective study. UCB transplantation was associated with inferior survival and treatment-related mortality compared to MUD. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/16/5543/5688…
-
Blood Journals Portfolio
@BloodPortfolio
IKZF1 & IKZF3 promote T-cell exhaustion via epigenetic control leading to reduced cytokines and increased exhaustion genes. Mezigdomide-mediated degradation of IKZF1/IKZF3 restores function in Tex leading to enhanced B-cell maturation antigen TCE activity. ashpublications.org/blood/article/148/9/1115/568350/Mezig…
-
Blood Journals Portfolio
@BloodPortfolio
Increased VWF-to-ADAMTS13 ratio is associated with large WMH on brain magnetic resonance imaging. Disruption of the VWF-ADAMTS13 axis is implicated in vascular disease pathogenesis and may be a biomarker of cerebrovascular disease risk. Read in Blood VTH: ashpublications.org/bloodvth/article/3/3/100186/569493/In…
-
Blood Journals Portfolio
@BloodPortfolio
3-year OS rate (70.6%) for WT1 peptide–vaccinated patients was much higher than 30% for historical control patients. Maintenance cancer immunotherapy using WT1 peptide vaccines was suggested to be effective & safe for pediatric refractory acute leukemias. ashpublications.org/bloodadvances/article/10/16/5531/5691…
-
Blood Journals Portfolio
@BloodPortfolio
Patients with high-risk asymptomatic early-stage CLL (del(17p) or mutated TP53) do not derive an EFS benefit from early ibrutinib treatment. Read the full study in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #cll #bloodjournal
-
Blood Journals Portfolio
@BloodPortfolio
Platelets synthesize nascent ADAM17 during storage, aligning with progressive cleavage of GPIbα. Intact GPIbα surface concentration in resting and stimulated platelets is regulated by ADAM17 in a gene-dose–dependent manner. Read in Blood VTH: ashpublications.org/bloodvth/article/3/3/100183/569492/Na…
-
Blood Journals Portfolio
@BloodPortfolio
The intervention was feasible and was associated with dose-dependent modulation of the microbiome and an increase in fecal SCFA. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/16/5505/5690…
-
Blood Journals Portfolio
@BloodPortfolio
D-VCd resulted in deeper and more rapid hematologic responses and recovery of organ function, resulting in superior survival. The superior survival achieved with D-VCd supports and further solidifies this regimen as the standard of care for AL amyloidosis. ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
Platelet miR-144-5p regulates COX-1 expression and contributes to variability in response to low-dose aspirin. Reduced platelet miR-144-5p identifies patients with faster COX-1 recovery and residual thromboxane generation during aspirin treatment. ashpublications.org/bloodvth/article/3/3/100185/569494/Pl…
-
Blood Journals Portfolio reposted
Ohio State Hematology
@OSUHematology
Congratulations to @FrancescaCottin & Elvira Umyarova, MD, on their new publication in Blood Advances: “Maintenance Therapy and Improved Relapse-Free Survival in Patients with Monoclonal Gammopathy of Renal Significance.” 🩸
@BloodPortfolio
Read more: doi.org/10.1182/bloodadvances.2025018896 -
Blood Journals Portfolio reposted
ASH
@ASH_hematology
ASH has released 2026 guidelines on initial and second-line therapy for adults with primary immune thrombocytopenia (ITP).
Explore the guidelines:
www.hematology.org/resources/clinical-practice-guidelines…
#hematology -
Blood Journals Portfolio
@BloodPortfolio
New episode of the Blood Podcast is out now! Blood editor Laurie Sehn interviews Drs. Efstathios Kastritis of @uoaofficial and Lucia Chen of @TischCancer on their latest articles published in Blood:
bloodpodcast.transistor.fm/episodes/better-together-addin… -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Regulating thromboinflammation via the IL-4-GPVI axis, Ibrutinib monotherapy for CLL, T-cell exhaustion in MM mitigated by mezigdomide, and more. Explore here: ashpublications.org/blood/issue/148/9
-
Blood Journals Portfolio reposted
Ohio State Hematology
@OSUHematology
Congrats @ParvathiRangan2, @sumithira_vasu, Hannah Choe, MD, & @JiashengW1 on their publication, “Recipient Endothelial IRF1 Mediates IFNγ-Driven Tissue Tolerance in Mouse Models of Acute Graft-versus-Host Disease” published in @BloodPortfolio! 🩸
doi.org/10.1182/blood.2026033806 -
Blood Journals Portfolio
@BloodPortfolio
Exosomes delivering miR-26 prime erythroblasts to hyperstimulate mTORC1 with 10-fold less stimulant to improve anemia without cancer risk. Read the full study in Blood RCI: ashpublications.org/bloodrci/article/2/3/100104/569784/Ex…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood VTH out now! Featuring New insights into flavonoid binding to the thromboxane A2 receptor, Sirolimus outperforms alpelisib in models of NRASQ61R-driven vascular overgrowth, and more. Explore here: ashpublications.org/bloodvth/issue/3/3
-
Blood Journals Portfolio reposted
Fernando Martín Moro
@Fer_martinmoro
Real-world effectiveness and safety of Zanubrutinib in Spanish patients with relapsed/refractory marginal zone #lymphoma | @BloodAdvances @BloodPortfolio
Hot off the press! 🔥 @DrAMuntanola @ant_salar @geltamo
ashpublications.org/bloodadvances/article/doi/10.1182/blo… -
Blood Journals Portfolio
@BloodPortfolio
High-dose IV NAC is safe when administered as a continuous infusion in adults with #scd at disease baseline. NAC decreases VWF multimer size, drastically decreases dense cell numbers, and improves systemic redox balance. Read in Blood RCI: ashpublications.org/bloodrci/article/2/3/100101/569662/Sa…
-
Blood Journals Portfolio
@BloodPortfolio
NEW! Guideline on the emergency management of critical bleeding in patients with immune thrombocytopenia. Explore in Blood Advances: ashpublications.org/bloodadvances/article/10/16/5558/5664… #itp #bloodadvances #clinicalguidelines
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
Prepare, review, and stay current. 🩸📖 The HRS + ASH-SAP bundle combines expert instruction and trusted self-assessment resources for fellows preparing for boards and hematologists refreshing their knowledge. apps.hematology.org/store/products/category/ASH Self-Asse…
#abim #hematology @BloodPortfolio -
Blood Journals Portfolio
@BloodPortfolio
VBAND produced a 100% overall response rate, including 90% complete responses in a real-world PTCL cohort. Median progression-free survival was 11.5 months in the frontline and 13.5 months in the R/R setting, with only 2 manageable adverse events. ashpublications.org/bloodglobal/article/doi/10.1016/j.bgl…
-
Blood Journals Portfolio
@BloodPortfolio
Public healthcare patients with MDS had longer diagnostic delays and reduced access to molecular testing and therapies. Structural disparities influenced diagnostic access and contemporary MDS care within a tertiary center. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/3/100128/569768…
-
Blood Journals Portfolio
@BloodPortfolio
Blockade of FcγRIII abrogates anti–HPA-1a–mediated platelet clearance in vivo, demonstrating its potential as a therapeutic target in FNAIT. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/15/5400/5690…
-
Blood Journals Portfolio
@BloodPortfolio
Doxycycline reduces ESS and does not appear to be associated with genotype. It also may be an effective conservative option for the management of epistaxis in HHT. Read in Blood VTH: ashpublications.org/bloodvth/article/3/3/100193/569682/Do…
-
Blood Journals Portfolio
@BloodPortfolio
Elements within PROS1 intron 1 modulate PS expression across tissues. Rare intron 1 variants reduce reporter activity and may contribute to PS deficiency. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/15/5215/5682…
-
Blood Journals Portfolio
@BloodPortfolio
Treatment options for KLA remain limited, underscoring the need for new systemic therapies. Sirolimus outperformed alpelisib in suppressing abnormal vascular overgrowth in NRASQ61R-driven KLA models. Read in Blood VTH: ashpublications.org/bloodvth/article/3/3/100192/569683/Si…
-
Blood Journals Portfolio
@BloodPortfolio
Low and high concentration thrombin–released EVs from endothelial cells contain distinct miR cargo. miR-409-5p and miR-155-5p in EVs are responsible for concentration-dependent cytoprotective and cytopathic effects of thrombin, respectively. Read here: ashpublications.org/bloodadvances/article/10/15/5199/5671…
-
Blood Journals Portfolio
@BloodPortfolio
Genistein synergizes with aspirin to inhibit platelet aggregation and thrombus formation, suggesting benefit in aspirin resistance. Read in Blood VTH: ashpublications.org/bloodvth/article/3/3/100187/569758/Ne…
-
Blood Journals Portfolio
@BloodPortfolio
Older adults with #aml have different expectations compared to their oncologist regarding how their physical function will change. Future research is needed to understand the clinical impact of discordant expectations and how to support their communication ashpublications.org/bloodadvances/article/10/15/5389/5690…
-
Blood Journals Portfolio
@BloodPortfolio
New episode of the Blood Podcast out now! Listen to Dr. Laura Michaelis interview Drs. @JoshuaHillMD of @fredhutch and Jeffrey Weitz of @McMasterU on their latest papers released in Blood today:
bloodpodcast.transistor.fm/episodes/balancing-infection-a… -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring MRD and genetics for treatment in Ph− ALL, CAR-T targeting cathepsin-G in AML, HRG binds platelets and inhibits aggregation, and more. Explore here: ashpublications.org/blood/issue/148/8
-
Blood Journals Portfolio reposted
Federico Repetto, MD
@RepettoF_MD
Excited to share our case published in @BloodPortfolio! 🩸
We highlight an unusual intramuscular relapse of BPDCN without active skin disease and stepwise TP53 progression superimposed on canonical TET2 founder alterations.
🔗 ashpublications.org/blood/article/148/8/1066/570128/Blast… -
Blood Journals Portfolio
@BloodPortfolio
PRCA shows marked diagnostic heterogeneity, where molecular data can help identify challenging secondary forms, such as MDS-associated cases. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/15/5285/5687…
-
Blood Journals Portfolio reposted
Nathan Punwani
@npunwani
Based on the long-term 10 year follow-up data from CALGB 10403, up to half of young adults (ages 18-39) with Philadelphia negative acute lymphoblastic leukemia (T & B cell-ALL) are able to be cured with a pediatric inspired, asparaginase-containing chemo regimen
T-ALL patients are more likely to be cured with pediatric-based regimens. Relapses typically happen in the first 3 years. Late relapses are more likely to occur in B-ALL, and that too, mainly in "Philadelphia-like" B-ALL.
The long-term results of CALGB 10403 further cement the importance of early clearance of minimal residual disease (MRD). Patients who achieve "super-remission" as I like to call it have an 85% 10 year disease-free-survival! ashpublications.org/bloodadvances/article/10/16/5487/5682… -
Blood Journals Portfolio reposted
Yale Cancer Center
@YaleCancer
.@GeorgeGoshuaMD joined the Blood Podcast to discuss recent research in @BloodPortfolio: "Haploidentical transplant, gene therapy, and standard care in #sicklecelldisease: a cost-effectiveness analysis."
bloodpodcast.transistor.fm/episodes/148-7
@SmilowCancer @YaleHematology -
Blood Journals Portfolio
@BloodPortfolio
Treatment decisions should be guided by PNH clone size, hemolysis, hemoglobin level and thrombotic history, PNH-related symptoms, and BMF. Read in Blood RCI: ashpublications.org/bloodrci/article/2/3/100103/569663/Ex…
-
Blood Journals Portfolio
@BloodPortfolio
PLCG2 SSM or deletion led to exon-skipped variants with enhanced phospholipase activity and BTKi resistance. PLCG2 exon-skipped variant expressions were predominantly unaltered after ibrutinib-based regimen but decreased after venetoclax treatment. ashpublications.org/bloodadvances/article/10/15/5185/5688…
-
Blood Journals Portfolio
@BloodPortfolio
Free heme from chronic hemolysis drives septic AKI in #scd, linking exaggerated inflammation and oxidative stress to kidney dysfunction. Therapeutic HPX restoration buffers heme, preserves renal function, and improves survival in septic hemolytic SCD. ashpublications.org/bloodvth/article/3/3/100184/569491/Au…
-
Blood Journals Portfolio
@BloodPortfolio
Longitudinal ctDNA monitoring refines risk stratification, enables treatment individualization, and may improve clinical outcomes. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100250/568…
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
Join the ASH Journal Club on August 28 to discuss the discovery of hematopoietic progenitor cells in the adult human lung, including anatomic location, niche, and potential function compared to matched samples in the bone marrow.
Enroll today: academy.hematology.org/course/info.php?id=1769
#hematology -
Blood Journals Portfolio
@BloodPortfolio
This landmark paper, published in 1988, was the first to describe the use of all-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL). Read "Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia" here: ashpublications.org/blood/article/72/2/567/166655/Use-of-…
Post not available here, view on X
Blood Journals Portfolio
@BloodPortfolio
This remarkable clinical work was followed by the discovery of the unique t(15;17) translocation and the PML-RARa fusion gene, now used for the definitive diagnosis and monitoring of #apl.
Blood Journals Portfolio
@BloodPortfolio
We've selected to highlight this study as one of the most impactful from Blood's history, in honor of its 80th anniversary.
-
Blood Journals Portfolio
@BloodPortfolio
Outcomes after anakinra treatment for ICANS are suboptimal: 72-hour SNI rate of 43%, median resolution of 8 days, and 28-day TRM of 13%. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/15/5264/5688…
-
Blood Journals Portfolio
@BloodPortfolio
The authors report a novel THBD mutant (C256S) that causes bleeding, thrombosis, and atypical hemolytic uremic syndrome. THBD-C256S has a defect in the cellular trafficking/export pathway. Read in Blood VTH: ashpublications.org/bloodvth/article/3/3/100182/569266/Im…
-
Blood Journals Portfolio
@BloodPortfolio
A NMAC-HID transplant would be cost-effective for long-term SCD remission in adults. The maximum GT price vs standard care across Tanzania, Nigeria, and India ranges from $4200 to $22 000. Read the study in Blood: ashpublications.org/blood/article/148/7/896/568518/Haploi…
-
Blood Journals Portfolio
@BloodPortfolio
Reduced-intensity BMT with PTCy broadens donor availability and results in robust, durable donor chimerism and minimal GVHD. Haplo-BMT with PTCy achieves 96% survival in pediatric and young adult patients with R/R and TN SAA. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/15/5442/5690…
-
Blood Journals Portfolio
@BloodPortfolio
Differential phosphorylation of calcium and talin-1 regulators may promote high cytosolic calcium levels and integrin αIIbβ3 inactivation. Read the study in Blood VTH: ashpublications.org/bloodvth/article/3/3/100181/569270/Te…
-
Blood Journals Portfolio
@BloodPortfolio
Real-world patients died within 12 months of initiating 1L therapy, including many patients who died within 3 months. A minority of potentially eligible and fit patients received CAR Ts in the second or 3L setting, suggesting barriers to treatment. ashpublications.org/bloodadvances/article/10/15/5325/5688…
-
Blood Journals Portfolio
@BloodPortfolio
CXCL12-CXCR4, focal adhesion kinase, and platelet endothelial cell adhesion molecule 1 govern platelet extravasation; CXCR4 blockade reduces platelet infiltration and tumor burden. Read the study in Blood VTH: ashpublications.org/bloodvth/article/3/3/100180/569269/Mo…
-
Blood Journals Portfolio
@BloodPortfolio
Non-ICANS neurologic toxicity after BCMA CAR-T therapy: a systematic review and meta-analysis of 4630 patients with multiple myeloma. Read in Blood Advances - ashpublications.org/bloodadvances/article/10/15/5413/5674…
-
Blood Journals Portfolio
@BloodPortfolio
CD169-tdTomato-Cre mice enable the accurate identification of macrophages and selective gene manipulation in macrophages. SP and BM but not liver macrophages are involved in erythrophagocytosis at steady state. Read in Blood RCI: ashpublications.org/bloodrci/article/2/3/100100/569596/Ch… #bloodrci
-
Blood Journals Portfolio
@BloodPortfolio
Only a potent CARD11 mutation is an alternative oncogenic driver to autonomous BCR signaling in ABC-DLBCL. Prediction of responsiveness to BTK inhibition requires exact knowledge of molecular mechanisms of BCR pathway activation in ABC-DLBCL. Read here: ashpublications.org/bloodneoplasia/article/3/3/100261/569…
-
Blood Journals Portfolio
@BloodPortfolio
“Immunologic dream team”: BiTEs periallotransplant to redirect donor lymphocytes toward GVL. Read in Blood Advances - ashpublications.org/bloodadvances/article/10/15/5227/5685…
-
Blood Journals Portfolio
@BloodPortfolio
Echinocytosis triggered by PIEZO1 agonists is independent of Ca2+ entry, KCNN4 activity, or water loss but relates to cytoskeleton dynamics. Physiologically, Ca2+, but not KCNN4, is a key actor of RBC immediate deformability. Read in Blood RCI: ashpublications.org/bloodrci/article/2/3/100095/568857/PI…
-
Blood Journals Portfolio reposted
Anuja Java, MD (she/her)
@anuja_java
New in @BloodPortfolio 🩸
Our “How I Treat” on TMA with clinical triggers.
When pregnancy, severe HTN or kidney txp coexist with TMA, when is the trigger enough & when to suspect complement-mediated disease & how to treat? A practical framework.
doi.org/10.1182/blood.2026033525 -
Blood Journals Portfolio
@BloodPortfolio
Longer time from last alkylating agent exposure was significantly associated with lower odds of manufacturing failure in patients with MM. Read the study in Blood ICT: ashpublications.org/bloodict/article/2/3/100068/569106/Pr…
-
Blood Journals Portfolio
@BloodPortfolio
New episode! #blood editor Dr. James Griffin interviews Drs. George Goshua, Gerd Blobel, and Paul Kaminski on their latest papers. They cover cost-effectiveness of current #scd treatments and potential therapeutic targets for fetal hemoglobinopathies
bloodpodcast.transistor.fm/episodes/148-7 -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now! Featuring NOTCHing the MSC-endothelial interplay in the HSC niche, IKAROS descent and rise of lenalidomide-associated B-ALL, Granulopoiesis under attack by mutant IDH1 and more. Explore here: ashpublications.org/blood/issue/148/7
-
Blood Journals Portfolio reposted
Emma M. Groarke
@emmamgroarke
Excited to see our How-I-Treat now officially out in @BloodPortfolio! Free link below:
www.sciencedirect.com/science/article/pii/S00064971260108… -
Blood Journals Portfolio reposted
Hamza Hashmi
@hhashmi87
Grateful for this @BloodPortfolio opportunity to co-author this commentary with the greatest #shammailankody: Depth of response isn't the problem anymore-it's sustaining it!
🧵Bispecific BCMA/GPRC5D CAR T for extramedullary myeloma (Zhou et al.) hits striking early efficacy: 97% ORR, 43% stringent CR, 100% MRD-negativity in responders. But durability lags: median PFS just 5.8mo, with EMD-site relapse the main driver.
doi.org/10.1182/blood.2026034568
#mmsm #cartcell #myeloma #medtwitter -
Blood Journals Portfolio
@BloodPortfolio
High B7-H3 expression is associated with bone lesions, fractures, and worse progression-free survival in >200 patients with #mm. An NK cell engager induced NK cells to kill MM cells, OCs, fibroblasts, and MDSC. Read in Blood ICT: ashpublications.org/bloodict/article/2/3/100069/569385/B7… #multiplemyeloma #bloodict
-
Blood Journals Portfolio
@BloodPortfolio
"Barriers and facilitators to blood donation in the Global South, and Global North ethnic minorities: a scoping review" read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/3/100119/569370…
-
Blood Journals Portfolio
@BloodPortfolio
RAAS inhibition is associated with worsening anemia and may increase red blood cell transfusion requirements in SCD. Erythroid progenitor function is suppressed by losartan and can be rescued with erythropoietin. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20260… #scd
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Advances out now featuring Thrombin reprograms endothelial extracellular vesicles, Novel therapies for von Willebrand disease, Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma and more. Explore ashpublications.org/bloodadvances/issue/10/15
-
Blood Journals Portfolio
@BloodPortfolio
Rethinking "Hispanic/Latino" as an ethnic category in leukemia research. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/3/100120/569484… #all #aml
-
Blood Journals Portfolio
@BloodPortfolio
Loss of the Stag2 rheostat causes accessibility-driven Gata1 retargeting, providing a mechanistic framework for dyserythropoiesis in MDS. Read the study in Blood: ashpublications.org/blood/article/148/6/767/568191/Stag2-…
-
Blood Journals Portfolio
@BloodPortfolio
This study, published in 1960, from the Atomic Bomb Casualty Commission presents the calculated incidence of leukemia among individuals exposed to the nuclear bomb in Hiroshima. Read "Leukemia in Hiroshima atomic bomb survivors" in Blood: ashpublications.org/blood/article/15/3/313/37173/Leukemia…
Blood Journals Portfolio
@BloodPortfolio
The peak incidence was observed at 5 to 7 years following exposure, with the incidence growing to 1720 per million population per year. This paper is another we selected as one of the most impactful from Blood's history, in honor of its 80th anniversary.
-
Blood Journals Portfolio
@BloodPortfolio
A microfluidic platform simultaneously quantifies ADAMTS13 activity and detects ADAMTS13 antibodies in patients with TTP. The novel ADAMTS13 activity assay uses a portable readout device that is applicable for near-patient testing. Read in Blood VTH: ashpublications.org/bloodvth/article/3/3/100179/569268/A-…
-
Blood Journals Portfolio
@BloodPortfolio
"Implementation of thalassemia and hemoglobinopathy prevention and management programs in Thailand" read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/3/100122/569594… #thalassemia #thailand
-
Blood Journals Portfolio
@BloodPortfolio
Ziftomenib demonstrates potent activity against a subset of the drug-induced MEN1 mutations found in patients with acute myeloid leukemia. Read the study in Blood: ashpublications.org/blood/article/148/6/751/567278/Discov… #aml #ziftomenib #bloodjournal
-
Blood Journals Portfolio
@BloodPortfolio
High-throughput screen identified LCK-targeted molecular glues that use a unique G-loop degron for CRBN engagement. LCK MGDs overcome T-ALL resistance to inhibitors/inhibitor-based PROTACs pointing to strategies to target drug-resistant kinases. Read here: ashpublications.org/blood/article/148/6/739/567170/LCK-ta…
-
Blood Journals Portfolio
@BloodPortfolio
Posttransplant cyclophosphamide significantly reduced GVHD incidence but not TA-TMA incidence, which predated acute #gvhd in ∼50% of cases. Read the study in Blood Advances: ashpublications.org/bloodadvances/article/10/14/5076/5688…
-
Blood Journals Portfolio
@BloodPortfolio
miR-15b/16-2 represses BCL-2 and cyclin D3 expression and impairs tumor progression in human T-ALL, revealing its role as a tumor suppressor. Read here: ashpublications.org/blood/article/148/6/724/567630/A-tumo…
-
Blood Journals Portfolio
@BloodPortfolio
Patients on linvoseltamab generally had improved function, symptoms and general health status/quality of life over 2 years. Treatment responders improved on all scales, whereas changes generally trended toward worsening in nonresponders. Read here: ashpublications.org/bloodneoplasia/article/3/3/100225/567… #mm
-
Blood Journals Portfolio
@BloodPortfolio
ATP11C variants cause hemolytic anemia from infancy to late adulthood and can associate with hepatic iron overload. Skewed X-chromosome inactivation and functional assays clarify ATP11C variant pathogenicity and improve diagnosis of hemolytic anemia. ashpublications.org/bloodadvances/article/10/14/4912/5679…
-
Blood Journals Portfolio
@BloodPortfolio
Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study. Read the special report here: ashpublications.org/blood/article/148/6/657/568519/Consen… #all #specialreport #bloodjournal
-
Blood Journals Portfolio
@BloodPortfolio
RUNX1::RUNX1T1 alters the proteome of human HSPCs; mass spectrometry shows 257 proteins affected, including CEBPβ downregulation. CEBPβ expression is required for myeloid lineage choice and development. Read the study in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100259/569…
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
After more than 30 years of extraordinary leadership, Martha "Marty" Liggett, Esq., will retire as ASH Executive Director. The Society has named Matthew Gertzog, FASAE, MBA, as its next Chief Executive Officer, effective January 1, 2027. Learn more: www.hematology.org/news-and-media/press-releases/2026/ceo…
-
Blood Journals Portfolio
@BloodPortfolio
Nascent preplatelets are locally retained in the BM and coreside with ECM components after 5-FU treatment. B4GALT1 contributes to 5-FU–induced myeloablation recovery by maintaining MK integrity and platelet production. Read here: ashpublications.org/bloodadvances/article/10/14/5045/5687… #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
New episode of the Blood Podcast out now! Drs. Matthew Frank of @StanfordMed and Jieqing Zhu of @BloodCenterWI discuss their latest papers published in Blood. Listen to "HLH-like toxicities after CAR-T and Structure-Function Relationships of FNAIT" here:
bloodpodcast.transistor.fm/episodes/hlh-like-toxicities-a… -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Discovery and preclinical activity of ziftomenib, Single-day nonactivated IL-18 CAR T-cell therapy, RAASi and anemia in SCD, and more. Explore here: ashpublications.org/blood/issue/148/6
-
Blood Journals Portfolio reposted
Waggoner Lab
@LabWaggoner
B7-H3 expression affects outcomes in myeloma and is targetable with an NK cell engager @BloodPortfolio
ashpublications.org/bloodict/article/2/3/100069/569385/B7… @umn_dom -
Blood Journals Portfolio
@BloodPortfolio
This scoping review maps the earliest clinical signs of AL, ATTRwt, and ATTRv amyloidosis to improve early recognition and diagnosis. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/14/5097/5662…
-
Blood Journals Portfolio reposted
Hematopoiesis News
@Hema_News
MLL3 and MLL4 sustain hematopoietic stem cell multipotency by opposing a B-cell default state.
Researchers showed that MLL3 and MLL4 preserve #hematopoieticstemcell multipotency by preventing a default transition to a B-cell–like state.
🔖 ashpublications.org/blood/article/148/5/560/568353/MLL3-a… -
Blood Journals Portfolio
@BloodPortfolio
Find the research article "Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial" in Blood - ashpublications.org/blood/article/doi/10.1182/blood.20250…
Blood Cancers Today
@Blood_Cancers
Quizartinib improved survival in older patients with FLT3-mutated #aml when added to intensive chemotherapy but not for patients without the mutation, according to the UK NCRI AML18 trial published in @BloodPortfolio.
📰 www.bloodcancerstoday.com/post/quizartinib-extends-surviv… -
Blood Journals Portfolio
@BloodPortfolio
HMA-VEN is well tolerated in patients with AML/MDS who relapsed after alloHCT. HMA-VEN is effective for relapsed AML/MDS after alloHCT, even in patients who have failed prior VEN-based regimens. Read the study in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100257/569… #aml #mds #bloodneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
LOTR-Seq links mutations to cell states in MPN/AML revealing distinct transcriptional effects that affect clonal evolution. Disease progression from #mpn to #aml is characterized by a loss of genetic & transcriptional diversity in the HSPC compartment. ashpublications.org/bloodadvances/article/10/14/5016/5682…
-
Blood Journals Portfolio
@BloodPortfolio
Successful cytoreduction before CD19-directed CAR T-cell therapy improves LFS in high DB B-ALL. Read the full study in Blood ICT: ashpublications.org/bloodict/article/2/3/100066/568975/Cy… #b-ALL #bloodict
-
Blood Journals Portfolio reposted
Talha Badar
@TalhaBadarMD
Exciting to see the #delphinus results showing daratumumab + chemotherapy achieved an 83% overall response rate, enabled 75% of children with R/R T-ALL to proceed to allo-HSCT, and resulted in 24-month OS of 41%.
As co-chair of ECOG-ACRIN EA9213, I’m excited to see whether daratumumab can eradicate MRD in T-ALL, with the goal to improve depth of remission/ preventing relapse. #t_cell_all #leusm
doi.org/10.1182/blood.2024024493 @BloodPortfolio -
Blood Journals Portfolio
@BloodPortfolio
Molecular profiling of LyP reveals markers associated with cytotoxic hyperactivation, vascular dysfunction, and antiangiogenesis. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/14/5163/5681…
-
Blood Journals Portfolio
@BloodPortfolio
We're continuing the celebration of Blood's 80th anniversary with the most impactful articles from its history. Today we're highlighting "Evidence for stem cells in the peripheral blood of mice" published in 1962. Check out the paper here: ashpublications.org/blood/article/19/6/702/37536/Evidence…
Blood Journals Portfolio
@BloodPortfolio
Before the use of cytokines to mobilize hematopoietic stem & progenitor cells into peripheral blood, it was debated if steady-state peripheral blood had stem-cells. Authors used a mouse model, transplanting FI mouse peripheral blood leukocytes into irradiated parental-strain mice
Blood Journals Portfolio
@BloodPortfolio
Unique genetic markers in the repopulated mice showed that stem cells capable of repopulating the lymphoid, myeloid, and erythroid lineages were circulating in the peripheral blood, thus opening the window for use of peripheral blood stem & progenitor cells for transplantation.
-
Blood Journals Portfolio
@BloodPortfolio
ASCT is feasible and effective in resource-constrained settings. Depth of response at transplant and melphalan dosing are key modifiable determinants of survival in this population. Read the study in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/3/100121/569483… #asct #mm #multiplemyeloma
-
Blood Journals Portfolio
@BloodPortfolio
Neonatal platelets differentiate monocytes to myeloid-derived suppressor cells. Prostaglandin E2 is a mediator of neonatal platelet–driven myeloid-derived suppressor cell differentiation. Read the study in Blood: ashpublications.org/blood/article/148/5/610/567752/Neonat…
-
Blood Journals Portfolio
@BloodPortfolio
The high-risk subgroup had poorer survival, a higher transformation risk, and longer treatment time, surpassing other molecular models. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/14/4943/5687… #smzl #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Qualitative data from Brazil show hemophilia disrupts education, work, and leisure among generations who lacked early access to prophylaxis. Read the study in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/3/100118/569273… #hemophilia #brazil
-
Blood Journals Portfolio
@BloodPortfolio
Autologous CD19 CAR T-cell therapy can be safely administered and exhibits biological activity in autoimmune patients without lymphodepletion. Read the study, that was featured on our latest Blood Podcast episode, here: ashpublications.org/blood/article/148/5/574/568726/CD19-C…
-
Blood Journals Portfolio
@BloodPortfolio
Optimization of stem cell collection, vector design, and transduction conditions improved gene marking and therapeutic hemoglobin expression. Read the study in Blood Advances: ashpublications.org/bloodadvances/article/10/14/4991/5678… #scd #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
"International expert opinion on challenges and perspectives in sickle cell disease and equitable access to care: place of automated red cell exchanges" read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/3/100117/569302… #scd
-
Blood Journals Portfolio
@BloodPortfolio
MLL3 and MLL4 act redundantly in HSCs to sustain transcription factor and enhancer networks that support multipotency. Simultaneous loss of MLL3 and MLL4 drives hematopoietic progenitors into a uniform B-cell–like default state. Read the study in Blood: ashpublications.org/blood/article/148/5/560/568353/MLL3-a…
-
Blood Journals Portfolio
@BloodPortfolio
Modest gene correction (33.3% marrow chimerism) sustains adequate Hb, supporting reduced-intensity conditioning in α-thalassemia. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/14/5153/5687…
-
Blood Journals Portfolio
@BloodPortfolio
One-year cumulative incidence of occult cancer detection after unprovoked #vte was 6.3%. Extensive screening increased cancer detection, without a statistically significant survival difference; routine screening is not warranted. Read in Blood Global: ashpublications.org/bloodglobal/article/2/3/100070/566447…
-
Blood Journals Portfolio
@BloodPortfolio
CXCR4 inhibition improves clinical outcomes in patients with #aml with high CXCR4 expression. Read the study in Blood: ashpublications.org/blood/article/148/5/545/567755/Inhibi…
-
Blood Journals Portfolio
@BloodPortfolio
Find the study, "Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL" here: ashpublications.org/blood/article/doi/10.1182/blood.20250…
Northwestern Feinberg School of Medicine
@NUFeinbergMed
A leading-edge #immunotherapy may extend survival for patients with one of the most aggressive forms of blood #cancer, per @BloodPortfolio. news.feinberg.northwestern.edu/2026/07/14/immunotherapy-s…
-
Blood Journals Portfolio
@BloodPortfolio
Obesity and age, but not BSA, increase risk for AAT in ALL. AAT during induction did not adversely influence disease response. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/14/4923/5681… #all #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Epigenetic toggling between multipotency and differentiation, Nanotube trafficking fuels myeloma bone loss, Promises and potential pitfalls of in vivo CAR gene therapy, and more. Explore here: ashpublications.org/blood/issue/148/5
-
Blood Journals Portfolio
@BloodPortfolio
NEW! American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/14/5113/5662… #clinicalguidelines #bloodadvances #alamyloidosis
-
Blood Journals Portfolio
@BloodPortfolio
Check out today's new episode of the Blood Podcast! Blood editor Dr. Laura Michaelis interviews Drs. Pierre-Yves Dumas and Samik Basu on their latest articles published in Blood. They discuss #aml and #cd19 CAR T-cell therapy: bloodpodcast.transistor.fm/episodes/5f815691-e94c-46e4-88…
-
Blood Journals Portfolio reposted
Jorge Cortes MD
@jorgecortesmd
There is a national blood shortage due to low donations. I did my part today. Hoping many others will too. @uabmedicine @ONealCancerUAB @RedCross @icmlf @ASH_hematology @BloodPortfolio
-
Blood Journals Portfolio reposted
Nicolas Duployez
@NicolasDuployez
Our paper, “Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy”, is now published in @BloodPortfolio 🤩
Many thanks to all co-authors and collaborators!
Free access (until Sept. 18): authors.elsevier.com/a/1nWx41UYwurJ1 -
Blood Journals Portfolio reposted
Zhuoer (Zoey) Xie, MD, MSCR
@ZhuoerXie
🚨Sharing key insights from our latest study @BloodPortfolio advancing CCUS-focused clinical trials!
✨Clinical&Genomic Convergence of HR CCUS & LR MDS
1/N: This work offers vital benchmarks & roadmaps for patients, regulators, and industry sponsors.🩸
doi.org/10.1182/blood.2026033085 -
Blood Journals Portfolio
@BloodPortfolio
Relapsed/refractory #mzl is associated with widespread upregulation of PD-1 on immune subsets and dysfunctional T and NK cells. Read the study in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100260/569…
-
Blood Journals Portfolio reposted
Dr. Uma Borate: Professor
@beatalleukemia
Out in @BloodPortfolio ! OPTI-AML,Ph 2 randomized study of Aza+28D (AV28) vs 14D(AV14) Ven for first 2 cycles in AML pts >=60 yrs. This study generated a LOT of discussion so here are all the relevant details about this first prospective Ven dose optimization study ! 🧵
ashpublications.org/blood/article/doi/10.1182/blood.20260… -
Blood Journals Portfolio
@BloodPortfolio
Thrombosis in pediatric patients with #aml is associated with longer hospital stays, greater costs, and greater in-hospital mortality. Approaches to anticoagulation vary greatly across institutions in terms of use and anticoagulant choice. Read here: ashpublications.org/bloodvth/article/3/3/100178/569267/Cu…
-
Blood Journals Portfolio
@BloodPortfolio
BRAFV600E iPSCs produce microglia that are inflammatory & dysfunctional with neurohistiocytosis-specific gene alterations. BRAFV600E myeloid progenitors hyperproliferate and drive LCH-ND neuropathology with complex CNS lesions and motor deficits in mice: ashpublications.org/blood/article/148/4/433/567490/Pathog…
-
Blood Journals Portfolio
@BloodPortfolio
It's National Hemochromatosis Awareness Month and we're recognizing the condition and those affected through research. Read our pick, a Blood study from 2025, discussing how Iron overload in HFE-related #hemochromatosis impairs Vδ2+ γδ T-cell homeostasis: ashpublications.org/blood/article/146/2/219/536431/Iron-o…
-
Blood Journals Portfolio
@BloodPortfolio
Mouse models faithfully reproduce many alterations in systemic iron trafficking and hepcidin regulation observed in human iron disorders. Read the study in Blood RCI: ashpublications.org/bloodrci/article/2/3/100098/569373/Mo…
-
Blood Journals Portfolio
@BloodPortfolio
IgDlow B cells selectively promote endogenous Treg expansion through a GITRL-dependent mechanism. Increasing GITRL expression on B cells expands endogenous Tregs and attenuates inflammatory disease after bone marrow transplantation. Read in Blood ICT: ashpublications.org/bloodict/article/2/3/100065/568733/Gl…
-
Blood Journals Portfolio
@BloodPortfolio
Endogenous RBC life span was longer in patients who received an exchange transfusion compared with a top-up transfusion. Read the study in Blood RCI: ashpublications.org/bloodrci/article/2/3/100096/568829/Re… #scd #rbc #bloodrci
-
Blood Journals Portfolio
@BloodPortfolio
Today we're taking a look back at one of Blood's most impactful articles in honor of its 80th anniversary. "Successful Allogenic Bone Marrow Transplantation in Man: Chimerism, Induced Specific Tolerance and Possible Anti-Leukemic Effects" published in 1965 ashpublications.org/blood/article/25/2/179/38089/Successf…
Blood Journals Portfolio
@BloodPortfolio
Georges Mathe, a French pioneer, was the first to describe graft-versus-host disease #gvhd in humans and to understand the potential of the graft-versus-leukemia #gvl effect to treat human leukemia.
Blood Journals Portfolio
@BloodPortfolio
He described a 32-year-old man with relapsed/refractory ALL who received a myeloablative transplant using a mixed bone marrow collection from 6 donors (mother, father, and 4 siblings). Remarkably, his GVHD was controlled and he remained in remission at 12 months.
-
Blood Journals Portfolio
@BloodPortfolio
Lower baseline Hb level strongly correlates with increased acute and chronic complications in SCA. Read the Blood Global Hematology study here: ashpublications.org/bloodglobal/article/2/3/100116/569274… #sca
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
This Thursday, join the ASH Journal Club webinar to explore how integrated omics data, mouse models, and CRISPR screening are advancing research in NPM1-mutant AML.
Enroll now: academy.hematology.org/course/info.php?id=1767
#hematology -
Blood Journals Portfolio
@BloodPortfolio
PTP4A2 promotes the pathogenesis of #aml through inhibiting LIC apoptosis and senescence. PTP4A2 interacts with p53 and dephosphorylates it at serine 392, thereby inhibiting p53 activity in LICs. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/13/4468/5677…
-
Blood Journals Portfolio
@BloodPortfolio
"The impact of pyruvate kinase deficiency on cognition" check out the research letter in Blood RCI: ashpublications.org/bloodrci/article/2/3/100094/568621/Th… #pkd #bloodrci #researchletter
-
Blood Journals Portfolio
@BloodPortfolio
Dual targeting of lysosomal function and STAT signaling by pimozide overcomes TME-mediated drug resistance in CLL. Combination of pimozide and venetoclax gives synergistic apoptotic responses in relapsed #cll cells. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/13/4595/5681…
-
Blood Journals Portfolio
@BloodPortfolio
The current 1998 CDC guideline uses a serum ferritin cutoff of ≤15 μg/L for #id for children ≥6 months. Ferritin curve analyses in children 5-14 found a higher ID threshold of <24 μg/L for physiological onset based on Hb and ZPP. Read in Blood RCI: ashpublications.org/bloodrci/article/2/3/100093/568384/Ph…
-
Blood Journals Portfolio
@BloodPortfolio
"Challenges in venous thromboembolism prophylaxis: a narrative review of East and Southeast Asian perspectives." Read the study in Blood Global Hematology ➡️ ashpublications.org/bloodglobal/article/2/3/100114/569109… #vte
-
Blood Journals Portfolio
@BloodPortfolio
Genetic markers suitable for ctDNA-based MRD tracking were detectable in 98% of patients with PMBL. Combined PET negativity and undetectable MRD after 4 cycles of immunochemotherapy identifies patients with excellent prognosis. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/13/4455/5677…
-
Blood Journals Portfolio
@BloodPortfolio
Excess heme drives ferroptosis in sickle erythroblasts by disrupting glutamine-glutamate metabolism causing glutathione depletion. Heme-induced mitochondrial dysfunction promotes l-2-hydroxyglutarate accumulation, histone hypermethylation & GLS suppression ashpublications.org/bloodrci/article/2/3/100091/568329/He…
-
Blood Journals Portfolio
@BloodPortfolio
CML disease events (loss of MMR/CCR) occurred in 4% of the pregnancies, all of which were reversible upon postpartum TKI resumption. Read the full study in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/3/100110/568814… #cml
-
Blood Journals Portfolio
@BloodPortfolio
TCRVβ2-targeting antibody-drug conjugates kills malignant cells. Anti-TCRVβ2 ADC–induced malignant cell death is significantly greater compared to unconjugated antibody treatment. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/13/4508/5680…
-
Blood Journals Portfolio
@BloodPortfolio
New Blood Podcast episode: Initial CHORUS data on #hht and ASH HematOmics Program. Drs. @HannyAlSamkari of @MassGenBrigham and Xin Zhou of @StJudeResearch discuss their latest papers in Blood ➡️bloodpodcast.transistor.fm/episodes/148-4
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring ASH HematOmics Program, Clinical spectrum of hereditary hemorrhagic telangiectasia, RNF217 modulates iron metabolism, and more. Explore here: ashpublications.org/blood/issue/148/4
-
Blood Journals Portfolio
@BloodPortfolio
Gln inhibition promoted HSPC quiescent state and multilineage engraftment, and AA enhanced megakaryocytic differentiation. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/13/4798/5681…
-
Blood Journals Portfolio
@BloodPortfolio
TELL-Seq coupled to long-read sequencing of long PCR amplicons encompassing the pseudoautosomal region resolved ambiguous Xga short-read NGS typing. Read the full study in Blood RCI: ashpublications.org/bloodrci/article/2/3/100088/568331/A-…
-
Blood Journals Portfolio
@BloodPortfolio
Major barriers and facilitators for transitioning youth with #scd were identified in 2 Brazilian referral centers. Successful transition requires better patient education & structured communication between pediatric & adult care teams. Read in Blood Global ashpublications.org/bloodglobal/article/2/3/100113/569110…
-
Blood Journals Portfolio
@BloodPortfolio
It's #cordbloodawarenessmonth! Explore this study in Blood Advances "Low 5-year health care burden after umbilical cord blood transplantation". Recipients of #ucb had the lowest 5-year healthcare burden of the graft types using a density composite score ashpublications.org/bloodadvances/article/5/3/853/475145/…
-
Blood Journals Portfolio
@BloodPortfolio
Relapse risk in single-system skeletal LCH is determined by disease extent rather than skeletal lesion location. Diabetes insipidus is uncommon overall but occurs most frequently in patients with CNS-risk lesions. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/13/4776/5682…
-
Blood Journals Portfolio
@BloodPortfolio
MT for patients with cancer with lower extremity #dvt was clinically successful, with 96% (24/25) rapid and durable symptom relief. Pathologic analysis revealed tumor thrombus in 32% (7/22) of evaluable patients. Read the study in Blood VTH: ashpublications.org/bloodvth/article/3/3/100172/568343/Ve…
-
Blood Journals Portfolio
@BloodPortfolio
Axi-cel is cost-effective across treatment sequences in R/R diffuse LBCL, generating higher LYs and QALYs than alternative sequences. Misallocation of CAR T substantially reduces survival, highlighting the importance of timely access to axi-cel. Read here: ashpublications.org/bloodglobal/article/2/3/100109/568815…
-
Blood Journals Portfolio
@BloodPortfolio
I-STRONG is an integrative, multicomponent treatment program that may reduce chronic sickle cell pain. Community engagement strategies increased the feasibility and acceptability of I-STRONG through population-specific adaptations. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/13/4617/5679…
-
Blood Journals Portfolio reposted
Naveen Pemmaraju, MD
@doctorpemm
👉#transform-1 Phase 3 study: Efficacy and safety of #navitoclax plus ruxolitinib in patients with untreated myelofibrosis ashpublications.org/blood/article/doi/10.1182/blood.20250… | #mpnsm #bclxl @BloodPortfolio
-
Blood Journals Portfolio
@BloodPortfolio
We're looking back at some of the most impactful articles from Blood's history. This first one is titled "One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation" published in 1977:
ashpublications.org/blood/article/49/4/511/160646/One-hun…
Blood Journals Portfolio
@BloodPortfolio
This is a milestone paper from a Seattle group that included the Nobel Prize winner E. Donnall Thomas. At the time, this was by far the largest series of bone marrow transplants for acute leukemia ever reported from a single institution.
-
Blood Journals Portfolio
@BloodPortfolio
TMEM187 plays a crucial role in regulating erythroid differentiation, maturation, and senescence. TMEM187 competes with GRAB for binding to RAB11, leveraging TfR1 recycling to the cell membrane. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
In stage IIIb AL amyloidosis, the prognostic impact of GLS was diminished by effective treatment with daratumumab. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/13/4612/5678…
-
Blood Journals Portfolio
@BloodPortfolio
Anti–HPA-1a antibodies can inhibit αIIbβ3 and αvβ3 integrin activation. Inhibition of β3 integrin activation correlates with disease severity in FNAIT. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
Key symptoms, including fatigue, improved; 83% had stable or improved bone marrow fibrosis, and 56% had a reduction in driver mutations. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/13/4585/5680…
-
Blood Journals Portfolio
@BloodPortfolio
Iron biomarkers changed across #pregnancy regardless of dosing regimen, consistent with pregnancy-related physiological adaptations. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/13/4573/5679…
-
Blood Journals Portfolio
@BloodPortfolio
Earn CME credit! Blinatumomab consolidation improves MRD clearance, and disease-free and overall survival in adults with HR Ph− B-ALL. Check out the CME-accredited Blood article of the month: ashpublications.org/blood/article/doi/10.1182/blood.20260…
-
Blood Journals Portfolio
@BloodPortfolio
Special Report: Consensus recommendations for malignant histiocytic neoplasms (histiocytic, Langerhans, and interdigitating dendritic cell sarcomas). Read in Blood ➡️ ashpublications.org/blood/article/doi/10.1182/blood.20260…
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
What can proteomics reveal about new treatment strategies for NPM1-mutant AML?
Join the next ASH Journal Club to explore how integrated omics data, mouse models, and CRISPR screening are uncovering new therapeutic vulnerabilities.
Enroll today: academy.hematology.org/course/info.php?id=1767
#hematology -
Blood Journals Portfolio
@BloodPortfolio
Real-world PFS after CAR T-cell therapy for R/R LBCL in Japan has improved in the recent era despite expanded treatment indications. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/13/4427/5679… #bloodavances #japan #lbcl
-
Blood Journals Portfolio
@BloodPortfolio
Bitopertin is safe and well tolerated in DBA syndrome. Despite biological activity, bitopertin does not yield transfusion independence in steroid-relapsed/refractory DBA. Read in Blood RCI: ashpublications.org/bloodrci/article/2/3/100090/568349/Re… #dba #bloodrci
-
Blood Journals Portfolio reposted
CU Anschutz Lymphoma Program
@CULymphoma
Our @CULymphoma lead Dr. @mana1981 wrote a commentary @BloodPortfolio on a recent study of real-world liso-cel outcomes. #lymsm ashpublications.org/blood/article/148/3/269/569644/Crossi…
-
Blood Journals Portfolio reposted
Jorge Cortes MD
@jorgecortesmd
Check the just published consensus recommendations for malignant histiocytic neoplasms led by @GauravGoyalMD from @ONealCancerUAB @uabmedicine published in @BloodPortfolio. Great work. doi.org/10.1182/blood.2026033049
-
Blood Journals Portfolio
@BloodPortfolio
New Blood Podcast episode out now! Blood editor Dr. James Griffin interviews Drs. Haris Sohail of @CAMCHemOncIAM and Lucas Kühne on their latest articles published in volume 147 issue 21 of Blood:
bloodpodcast.transistor.fm/episodes/iv-iron-during-acute-… -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring OutFOXing a FENDRR bender in T-ALL, Crossing the trial-practice chasm in CAR-T for relapsed LBCL, Oxidized PDI promotes thrombus formation, and more. Explore here: ashpublications.org/blood/issue/148/3
-
Blood Journals Portfolio
@BloodPortfolio
In acute iTTP, platelet count drop and NET surge reappear 2 weeks into treatment without caplacizumab, but both are prevented with it. Read the study in Blood VTH: ashpublications.org/bloodvth/article/3/3/100175/568344/NE… #ittp #bloodvth
-
Blood Journals Portfolio
@BloodPortfolio
LRF represses γ-globin expression in a reversible manner in the absence of BCL11A. LRF-NuRD complex formation and composition remain largely unaffected by the presence or absence of BCL11A. Read in Blood RCI: ashpublications.org/bloodrci/article/2/3/100087/568040/Re…
-
Blood Journals Portfolio reposted
Manel Esteller
@ManelEsteller
Happy to see in the current issue of @BloodAdvances @BloodPortfolio @ASH_hematology the DNA #methylation-based classification of #hematolymphoid neoplasms led by David Capper @ChariteBerlin and @Kenneth_Aldape @NIH @theNCI where we have contributed. The study includes >1,600 patient samples! Enjoy.
ashpublications.org/bloodadvances/article/10/13/4842/5679… -
Blood Journals Portfolio reposted
London Medical Communication
@LondonMedComm
Rogers et al. introduce L-TOF, a new metric to quantify blood oxygen delivery.
Stored red blood cells may require higher doses than fresh blood for equivalent oxygen delivery, offering a new way to assess transfusion quality.
@BloodPortfolio
#londonmedcomm
pubmed.ncbi.nlm.nih.gov/42453356/ -
Blood Journals Portfolio
@BloodPortfolio
"Immune-mediated acute thrombocytopenia within 30 minutes of first obinutuzumab infusion" explore the research letter in Blood VTH: ashpublications.org/bloodvth/article/3/3/100174/568342/Im…
-
Blood Journals Portfolio
@BloodPortfolio
Blood Advances has just published two new sets of #clinicalguidelines about management of #all. @ASH_hematology 2026 guidelines for management of relapsed/refractory ALL in adolescents and young adults and frontline management of ALL in adolescents and young adults.
Blood Journals Portfolio
@BloodPortfolio
Find them and Blood Advances' other clinical guidelines here: ashpublications.org/bloodadvances/collection/42540/Clinic…
-
Blood Journals Portfolio
@BloodPortfolio
HbS polymerization inhibitors remain a treatment option for adults with SCD. The market withdrawal highlights the urgent need for continued research, regulatory support, and access to safe and effective treatments. Read in Blood RCI: ashpublications.org/bloodrci/article/2/3/100083/567805/Sa… #scd #bloodrci
-
Blood Journals Portfolio
@BloodPortfolio
PD analyses of several procoagulant and fibrinolytic parameters indicate OKL-1111 as potentially efficacious drug for anticoagulant reversal. Read the study in Blood VTH: ashpublications.org/bloodvth/article/3/3/100176/568732/A-… #bloodvth
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Advances out now featuring Navigating clinical decision-making for IEC-enterocolitis, Reaching consensus in relapsed/refractory ALL in AYAs, CAR-NK cell therapy for hematological malignancies, and more. Explore here: ashpublications.org/bloodadvances/issue/10/13
-
Blood Journals Portfolio
@BloodPortfolio
Newly developed AI-based assay might serve as an objective marker of disease severity and drug efficacy. The effects of voxelotor on erythrocyte sickling may provide an explanation for increased hemolysis after abrupt cessation of the drug. Read here: ashpublications.org/bloodrci/article/2/3/100082/567806/Ar… #ai
-
Blood Journals Portfolio
@BloodPortfolio
SS RBCs abnormally engage neutrophil Siglec-9 and induce Siglec-9 shedding, ineffectively inhibiting neutrophil activation. Soluble Siglec-9 may be a marker of mortality risk in SCD. Read in Blood RCI: ashpublications.org/bloodrci/article/2/3/100074/567470/Si… #scd #bloodrci
-
Blood Journals Portfolio
@BloodPortfolio
"Ten-day decitabine vs “3+7” in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21" read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100246/568… #aml #bloodneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
Circulating CD38-expressing CD8 T cells segregate ER from prolonged remission with >80% area under the curve in a risk-stratification model. Read the study in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100221/567… #multiplemyeloma #mm #bloodneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
The current MM CAR-T delivery model is unsustainable for much of the United States, necessitating urgent reforms to ensure equitable access. Read the study in Blood ICT: ashpublications.org/bloodict/article/2/3/100064/568512/Di… #multiplemyeloma #mm #bloodict
-
Blood Journals Portfolio
@BloodPortfolio
"BCMA-targeted T-cell engager therapy induces sustained remission in immune thrombocytopenia" read the study in Blood ICT: ashpublications.org/bloodict/article/2/3/100062/568514/BC…
-
Blood Journals Portfolio
@BloodPortfolio
An integrative framework reclassified PIEZO1 variants, revealing domain-specific pathogenic clustering. Patient analyses identified 3 phenotypic clusters, linking PIEZO1 variant domains to disease severity and presentation. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
LAST CHANCE! ASH-SAP is on sale through July 15. With 49 chapters, many newly rendered illustrations, and 254 multiple-choice questions, ASH-SAP is designed for self-directed learning and review. Get your copy before the price goes back up! ashpublications.org/books
-
Blood Journals Portfolio
@BloodPortfolio
Immune checkpoint blockade was associated with reduced tumor burden in PD-L1–expressing IVLBCL PDX models. Read the full study in Blood ICT: ashpublications.org/bloodict/article/2/3/100063/568513/Im…
-
Blood Journals Portfolio
@BloodPortfolio
"Unfinished business in chronic lymphocytic leukemia: translational and clinical priorities for a cure" read the special report in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #cll #specialreport #bloodjournal
-
Blood Journals Portfolio
@BloodPortfolio
New episode of the Blood Podcast out now! Blood Editor Dr. Laura Michaelis interviews Drs. Kirsty Hillier of @nyulangone and Marco Ruella of @PennMedicine on their latest papers published in Blood:
bloodpodcast.transistor.fm/episodes/147-16 -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring MDM4-related bone marrow failure, Pavurutamab in relapsed myeloma, Phenotype-driven analysis of PIEZO1 variants, and more. Explore here: ashpublications.org/blood/issue/148/2
-
Blood Journals Portfolio
@BloodPortfolio
SWAY highlights unequal #scd burden and treatment access across global regions, with SSA facing unique challenges. High VOC frequency in SSA despite younger age and limited treatment access underscore urgent care gaps. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/3/100092/567588…
-
Blood Journals Portfolio reposted
Naveen Pemmaraju, MD
@doctorpemm
👉👉👉Delighted to share our brand new paper 📝 just out in @BloodPortfolio ➡️major paper for our #bpdcn field ✅TAG/AZA/VEN clinical trial results for patients with #bpdcn | led by @lane_andy Dr Anthony Stein & @doctorpemm | #cd123 #bpdcn | #endcancer
ashpublications.org/blood/article/doi/10.1182/blood.20260… -
Blood Journals Portfolio
@BloodPortfolio
Find the research letter titled "Anti-fibrinolytic strategies improve liver regeneration in mice and reduce post-hepatectomy liver failure in patients" in Blood here: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
Full-dose VEN showed comparable effectiveness to azole-adjusted regimens in unfit patients with AML. Survival for unfit patients with #aml differed between public and private care in Brazil, reflecting LMIC disparities. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/3/100097/567802…
-
Blood Journals Portfolio
@BloodPortfolio
Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant ➡️ ashpublications.org/blood/article/doi/10.1182/blood.20250… #specialreport #blood #hcl
-
Blood Journals Portfolio
@BloodPortfolio
Among patients treated with IV iron, FCM was associated with a higher fracture risk than FDI. FCM accumulates in osteocytes and further impairs bone formation, which is reduced in IDA. Read the study, which was featured on our latest podcast episode, here: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
PRD and early relapse are associated with poor survival even in the CAR T era and are independent adverse factors across treatment lines. Read the full study in Blood ICT: ashpublications.org/bloodict/article/2/3/100060/568372/Ou… #prd #cart #cd19 #bloodict
-
Blood Journals Portfolio
@BloodPortfolio
Rituximab and methotrexate–based chemotherapy was associated with highest response rates and prolonged progression-free survival in ID-PCNSL. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
Accelerated single-agent glofitamab SUD was feasible in high-risk R/R DLBCL; 81% reached target dose in <21 days. Read the full study in Blood ICT: ashpublications.org/bloodict/article/2/3/100058/568186/Ac… #r/RDLBCL #bloodict
-
Blood Journals Portfolio
@BloodPortfolio
Noninvasive in vivo blood imaging in humans reveals sickle cells initiate vaso-occlusion via endothelial interactions. In vivo hemorheological indices capture changes in blood flow related to #scd and transfusion response. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/12/4215/5669…
-
Blood Journals Portfolio
@BloodPortfolio
Targeting of DLK1 with an antibody-drug conjugate eradicates leukemia cells and prolongs survival in ML-DS patient-derived xenograft models. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/12/4120/5676…
-
Blood Journals Portfolio
@BloodPortfolio
Taper and discontinuation of IS after allogeneic HCT are frequently complicated by GVHD development. Baseline clinical factors and immune cell measures may be associated with taper and discontinuation success. Read in Blood ICT: ashpublications.org/bloodict/article/2/3/100057/568033/Pr… #gvhd #bloodict #hct
-
Blood Journals Portfolio
@BloodPortfolio
AKI is common among children with SCD and is often present on admission. Hospital-associated AKI is not associated with NSAID exposure alone, suggesting patient-level factors contribute to AKI risk. Read the full study in Blood RCI: ashpublications.org/bloodrci/article/2/3/100085/568038/Ho… #aki #scd #bloodrci
-
Blood Journals Portfolio
@BloodPortfolio
The LySeqST targeted sequencing panel can be used for accurate genomic classification of DLBCL tumors. Application to a population-based cohort reveals subtype proportions and outcomes that will support clinical trial design. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/12/4208/5677… #dlbcl
-
Blood Journals Portfolio
@BloodPortfolio
Nine participants on emicizumab prophylaxis treated 33 bleeding events with initial doses of eptacog beta ranging from 56.8 to 245.1 μg/kg. Read the full study in Blood VTH: ashpublications.org/bloodvth/article/3/3/100169/567838/Sa… #bloodvth #hemophilia
-
Blood Journals Portfolio
@BloodPortfolio
CPI in salvage chemotherapy and TLI with ASCT yields 96.4% RFS at 3 years in relapsed/refractory Hodgkin lymphoma. Although not statistically significant, TLI and CPIs may increase ES risk, highlighting early detection and steroids. Read in Blood ICT: ashpublications.org/bloodict/article/2/2/100052/567786/Ou…
-
Blood Journals Portfolio
@BloodPortfolio
The addition of intrathecal cytarabine in induction does not mitigate the adverse prognostic impact of CNS2 status in children with B-ALL. Read the study in Blood Advances: ashpublications.org/bloodadvances/article/10/12/4184/5677… #cns2 #b-ALL
-
Blood Journals Portfolio
@BloodPortfolio
Highlighting papers that were among the most cited articles from 2024 that contributed to Blood Advances' 2025 Impact Factor! Read them now: a review article on BTK inhibitors in #cll, a drug advances paper on #hemophilia B, and a clinical trial on #aml.
Post not available here, view on X
Blood Journals Portfolio
@BloodPortfolio
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax: doi.org/10.1182/bloodadvances.2023011757
Blood Journals Portfolio
@BloodPortfolio
Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec: doi.org/10.1182/bloodadvances.2023010511
-
Blood Journals Portfolio
@BloodPortfolio
New episode of the Blood Podcast out now! Blood Editor Dr. James Griffin interviews Drs. Heinz Zoller of @MedUniInnsbruck and Raul Ribeiro of @StJudeResearch on their latest papers published in Blood:
bloodpodcast.transistor.fm/episodes/aa8f8174-4033-40e1-92… -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now! Featuring Ferric carboxymaltose and fracture risk, Genomic profiling of secondary myelofibrosis, Immunodeficiency-associated primary CNS lymphomas, and more. Explore here: ashpublications.org/blood/issue/148/1
-
Blood Journals Portfolio
@BloodPortfolio
JNJ-64619178 increases mitochondrial apoptotic priming and synergizes with venetoclax to induce apoptosis in B-NHL cells. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100249/568…
-
Blood Journals Portfolio
@BloodPortfolio
HLA-ESP-1C single-chain trimer protects gene-edited (MHC-I/II/TCR/CD54/CD58 deficient) human allogeneic CAR T cells from lysis by NK cells. UCART19 (gene-edited, HLA-ESP-1C) cells control Raji lymphoma in NSG mice engrafted with allogeneic NK cells. ashpublications.org/bloodadvances/article/10/12/4266/5676…
-
Blood Journals Portfolio
@BloodPortfolio
In NPM1-mutated AML, comutations in epigenetic modifier genes can dictate unique lineage trajectories in subsequent clones. Read the brief report in Blood: ashpublications.org/blood/article/147/26/3209/567631/Geno… #aml
-
Blood Journals Portfolio
@BloodPortfolio
The oral formulation of ixazomib is accepted and well tolerated by children with R/R ALL. Ixazomib, in addition to standard relapsed chemotherapy, is tolerable and has a promising early efficacy signal in R/R ALL. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100247/568…
-
Blood Journals Portfolio
@BloodPortfolio
We're thrilled to welcome a new Associate Editor to Blood today! Dr. Omar Abdel-Wahab is the Evnin Family Chair of Molecular Pharmacology at @MSKCancerCenter, where he also serves as Chair of the Molecular Pharmacology Program in the Sloan Kettering Institute. #neweditor
-
Blood Journals Portfolio
@BloodPortfolio
Distinct T-cell subsets were present at diagnosis in the bone marrow of pediatric patients with B-ALL or AML. A rare hemoglobin-expressing T-cell subset was present in B-ALL bone marrow that was linked to better outcomes. Read the study in Blood Advances: ashpublications.org/bloodadvances/article/10/12/4199/5677…
-
Blood Journals Portfolio reposted
Naveen Pemmaraju, MD
@doctorpemm
👉👉👉Proud to share our international randomized frontline Myelofibrosis Ph3 #transform-1 final results | #navitoclax + RUXO | #mpnsm just out in @BloodPortfolio today! 🙏 📝 🚨
@doctorpemm @AdamMead_Oxford @jjkiladjian @sk_tantravahi
ashpublications.org/blood/article/doi/10.1182/blood.20250… -
Blood Journals Portfolio reposted
Sangeetha Venugopal MD,MS
@drsangeetmd
🧬single-cell multiomics in NPM1-mut AML ➡️relapse often preserves the founding scaffold,while FLT3/RAS co-mut drive clonal & distinct cell states #aml #hematology #leukemia @BloodPortfolio @lindemilesphd ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
If you're looking for some impactful Blood articles, we've got you covered. The following Blood papers were among the most-cited in 2024 and contributed to our increased impact factor in 2025:
Post not available here, view on X
Blood Journals Portfolio
@BloodPortfolio
This clinical trial for R/R LBCL titled "Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001" - ashpublications.org/blood/article/143/5/404/498484/Two-ye…
Blood Journals Portfolio
@BloodPortfolio
Finally, this paper on JAK2-mutant clonal hematopoiesis and VTE titled "JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism" - ashpublications.org/blood/article/144/20/2149/517042/JAK2…
-
Blood Journals Portfolio
@BloodPortfolio
CD49d regulates BCR functionality in CLL, linking integrins to cytoskeletal dynamics and antigen responsiveness. Read in Blood: ashpublications.org/blood/article/147/26/3179/566986/CD49… #cll
-
Blood Journals Portfolio
@BloodPortfolio
Secondary TCLs after CAR T-cell therapy are enriched for genomic alterations in CH–associated genes, particularly TET2 and DNMT3A. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100244/568…
-
Blood Journals Portfolio
@BloodPortfolio
Delivery of the inpatient SICP by advanced practitioners and hematology/oncology fellows was feasible. The number of advance directives completed within 1 year after the SICP visit increased. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/12/4412/5676… #sicp #hematology #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
TTE outcomes are worse in DR CLL vs DE and DE-only CLL, indicating reduced response durability after cBTKi/BCL2i failure. Read the study in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100237/567… #bloodneoplasia #cll
-
Blood Journals Portfolio
@BloodPortfolio
Patients with SBPmm are at high risk for early progression to MM. Multifocal lytic bone lesions are the most common myeloma-defining event at progression to MM. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/12/4286/5679… #multiplemyeloma #mm #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Baseline marrow inflammation and senescence limit immune activation after epigenetic and immune checkpoint therapy. Durable survival is marked by interferon-driven immune reinvigoration and depletion of suppressive myeloid cells. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100243/568…
-
Blood Journals Portfolio
@BloodPortfolio
Most children with SCD receiving nonmyeloablative HLA-identical sibling transplant achieve cure with low toxicity. Secondary graft failure is a problem with this nonmyeloablative transplant approach. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/12/4160/5676… #scd #hct #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Cardiovascular events are common and associated with increased mortality in MDS. Cardiovascular risk assessment should be integrated into routine MDS management. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/3/100102/568020… #mds #cvd
-
Blood Journals Portfolio
@BloodPortfolio
Quizartinib maintenance therapy provided a clear clinical benefit vs placebo in patients who did not undergo allo-HCT. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/12/4144/5676… #aml
-
Blood Journals Portfolio
@BloodPortfolio
IgG1 and IgA2 antibodies against CD38 or CD20 were effective in recruiting macrophages for ADCP, but only IgA2 triggered ADCC by PMN. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100242/568… #b-ALL #adcp
-
Blood Journals Portfolio
@BloodPortfolio
INHERENT built one of the largest multiethnic cohorts for both SCD and thalassemia across 16 centers in 8 countries from 4 continents. Read the study in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/3/100098/567803… #scd #thalassemia
-
Blood Journals Portfolio
@BloodPortfolio
AZD0120 is a CAR T-cell product that targets both B-cell maturation antigen and CD19 and is manufactured using the novel FasTCAR platform. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/12/4134/5675… #ndmm
-
Blood Journals Portfolio reposted
Stephen Oh
@mpndoc
Super thrilled to share our latest effort "Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms" now online in Blood! 🤩
@ASH_hematology @BloodPortfolio
@WashUHematology @WashUDeptMed
ashpublications.org/blood/article/doi/10.1182/blood.20250… -
Blood Journals Portfolio
@BloodPortfolio
Patients with chemotherapy-sensitive DLBCL experience prolonged survival after ASCT. CR before transplant is associated with better survival; intensification of salvage treatment might lead to superior outcomes. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100240/568… #asct #dlbcl
-
Blood Journals Portfolio
@BloodPortfolio
"Invasive fungal infections after Bruton tyrosine kinase inhibitor treatment: a systematic review and meta-analysis" Read in Blood Advances: ashpublications.org/bloodadvances/article/10/12/4171/5676…
-
Blood Journals Portfolio
@BloodPortfolio
New episode of the Blood Podcast out now! Blood editor Dr. Laurie Sehn interviews Drs. Everett Meyer and Olivier Hermine on their latest articles published in volume 147 issue 11 of Blood. Listen here: bloodpodcast.transistor.fm/episodes/147-11
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Freeze-dried platelets for traumatic brain injury, Clonal evolution of NPM1-mutated AML, Iron overload rewires HSC metabolism, and more. Explore here: ashpublications.org/blood/issue/147/26
-
Blood Journals Portfolio
@BloodPortfolio
HTLV-1 carriers at high risk of ATL have low frequencies of circulating HTLV-1–specific CD8+ T cells, suggesting immune dysregulation. Read the full article in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100235/568… #bloodneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
Targeted screening identified high-risk couples early and enabled informed decisions to reduce the burden of severe hemoglobinopathies. Read the full article in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/3/100103/568325…
-
Blood Journals Portfolio
@BloodPortfolio
In the RW setting, talquetamab for multiple myeloma is often initiated with inpatient SUD, then every 2 weeks dosing. By 6 months, nearly one-third of RW talquetamab recipients transition to every 4 weeks or less frequent dosing. Read in Blood ICT: ashpublications.org/bloodict/article/2/2/100045/567454/Do…
-
Blood Journals Portfolio
@BloodPortfolio
Venetoclax and R-GDP can be safely combined. High efficacy is observed at the recommended phase 2 dose. Read the full article in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100233/567… #asct #lbcl
-
Blood Journals Portfolio
@BloodPortfolio
NEW in Blood Advances: @ASH_hematology / @isth 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism. Explore here ➡️ ashpublications.org/bloodadvances/article/10/12/4303/5673… #bloodadvances #clinicalguidelines #vte
-
Blood Journals Portfolio
@BloodPortfolio
CAR T-cell expansion was noted even in patients with no detectable disease, and higher CAR T-cell expansion had lower likelihood of relapse. Read in Blood ICT: ashpublications.org/bloodict/article/2/2/100059/568187/Br… #b-ALL #cart #bloodict
-
Blood Journals Portfolio
@BloodPortfolio
Read the Blood study "Erythroid-produced intact FGF23 is a paracrine inhibitor of erythropoiesis" here:
ashpublications.org/blood/article/doi/10.1182/blood.20250…
Northwestern Feinberg School of Medicine
@NUFeinbergMed
Northwestern scientists have discovered that the hormone #fgf23 reduces red #blood cell production, potentially contributing to #anemia in people with chronic #kidneydisease, per @BloodPortfolio. news.feinberg.northwestern.edu/2026/06/09/hormone-impacts…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Advances out now featuring Eligibility versus appropriateness in allogeneic HCT, Targeting erythroid cell–derived asparagine inhibits alloimmunization in sickle cell disease, Remission with residuals, but no cure and more. Explore here: ashpublications.org/bloodadvances/issue/10/12
-
Blood Journals Portfolio
@BloodPortfolio
Congratulations to Dr. Andrew Roberts, Editor-in-Chief of Blood, for being awarded the Helen M. Ranney Clinical and Translational Science Medal and Dr. Stella Chou, Blood Editorial Board Member, for earning the William Dameshek Prize.
ASH
@ASH_hematology
ASH is proud to honor 11 distinguished hematologists with its most prestigious awards and named lectures, recognizing transformative contributions that have advanced research, patient care, and education in blood diseases.
🔗www.hematology.org/news-and-media/press-releases/2026/202…
#hematology #ashawards -
Blood Journals Portfolio
@BloodPortfolio
PDX model validation supports high-throughput drug screening in cell lines as a viable strategy to identify synergistic therapies. Venetoclax, ponatinib, and trametinib combinations exhibited robust synergy in vitro and in vivo. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100230/567…
-
Blood Journals Portfolio
@BloodPortfolio
Full-dose VEN showed comparable effectiveness to azole-adjusted regimens in unfit patients with AML. Survival for unfit patients with AML differed between public and private care in Brazil, reflecting LMIC disparities. Read here: ashpublications.org/bloodglobal/article/2/3/100097/567802… #aml #brazil
-
Blood Journals Portfolio
@BloodPortfolio
"Iron-refractory iron deficiency anemia" read the full review article in Blood RCI: ashpublications.org/bloodrci/article/2/2/100080/567713/Ir… #irida #bloodrci
-
Blood Journals Portfolio
@BloodPortfolio
CRISPR editing exon 5 of PPIA retains expression of CypA but with an altered C-terminus, disrupting cyclosporine and voclosporin binding. Read in Blood ICT: ashpublications.org/bloodict/article/2/2/100054/567873/Pr… #bloodict
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood RCI out now featuring Red blood cells as sensors of stress in ultramarathons, Emerging concepts in sickle cell disease acute chest syndrome, Iron-refractory iron deficiency anemia and more. Explore here: ashpublications.org/bloodrci/issue/2/2
-
Blood Journals Portfolio
@BloodPortfolio
"Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial" read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100248/568… #dlbcl #bloodneoplasia
-
Blood Journals Portfolio reposted
Hematopoiesis News
@Hema_News
Researchers led by Lili Ren and Dr. Rui Su at @cityofhope identify the METTL1/m7G pathway as a key driver of #leukemia stem cell maintenance and show that pharmacological inhibition of METTL1 suppresses acute myeloid leukemia progression. 🩸#aml
Learn more via @BloodPortfolio:
📝 ashpublications.org/blood/article/147/25/3069/567169/Targ… -
Blood Journals Portfolio reposted
ASH
@ASH_hematology
This Tuesday, join the Journal Club webinar to explore the explore the cellular pathways involved in hemoglobin uptake and processing in SCD and potential therapeutic implications. academy.hematology.org/course/info.php?id=1765
#conquerscd @BloodPortfolio -
Blood Journals Portfolio
@BloodPortfolio
In mice, daprodustat increases RBC production, reduces sickling, and increases iron availability for erythropoiesis. Read the full article in Blood RCI: ashpublications.org/bloodrci/article/2/2/100077/567489/Da… #scd #bloodrci
-
Blood Journals Portfolio
@BloodPortfolio
"Olutasidenib as maintenance therapy after treatment response in acute myeloid leukemia with persistent IDH1 mutation" read the full article in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100226/567… #aml #bloodneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
STEPP is feasible and acceptable for patients undergoing HSCT. STEPP shows improvements in psychological distress and QOL, warranting further evaluation in a larger trial. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/11/3987/5676…
-
Blood Journals Portfolio
@BloodPortfolio
Blocking FXI with gruticibart stopped early clot formation on the mechanical valve surface. Gruticibart kept valve function normal throughout the study, with no bleeding or embolic events observed. Read in Blood VTH: ashpublications.org/bloodvth/article/3/3/100168/567718/Fa… #bloodvth
-
Blood Journals Portfolio
@BloodPortfolio
Although AndA sequesters TFPIα, rendering it unable to bind and inhibit FXa directly, some TFPIα function remains in plasma. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/11/4028/5676…
-
Blood Journals Portfolio
@BloodPortfolio
ELN 2024 stratifies patients with less-intensive AML, and its prognostic accuracy may improve if cytogenetic data are incorporated. Read the full article in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100238/568… #aml #bloodneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
The high-sustained FVIII therapy efanesoctocog alfa resulted in 3 to 5.5 times lower consumption and may save $38 947 to $81 000 per surgery. Read the full study in Blood VTH: ashpublications.org/bloodvth/article/3/3/100166/567494/Co… #hemophilia #bloodvth
-
Blood Journals Portfolio
@BloodPortfolio
Axi-cel and tisa-cel both demonstrated efficacy in patients with R/R FL in real-world settings, although PFS was inferior to that observed in clinical trials. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/11/3757/5668…
-
Blood Journals Portfolio
@BloodPortfolio
Inhibition of histone lysine–specific demethylases by JIB-04 induces ferroptosis-like phenotype in AML due to increased oxidative stress. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100236/567… #aml #bloodneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
It's World Sickle Cell Day, a day to raise awareness of #scd and the ongoing need for research that improves outcomes for patients worldwide. Explore our curated collection of SCD articles in Blood Global Hematology to discover the latest global research: ashpublications.org/bloodglobal/collection/43091/Sickle-C…
-
Blood Journals Portfolio
@BloodPortfolio
RPVO is observed in ∼30% patients with unprovoked PE and is associated with long-term complications such as recurrent PE and chronic thromboembolic pulmonary hypertension. Read the full article in Blood VTH: ashpublications.org/bloodvth/article/3/3/100164/567498/Im…
-
Blood Journals Portfolio
@BloodPortfolio
New episode of the Blood Podcast out now: Treating AML Before and After Relapse. Blood editor Dr. Laura Michaelis interviews Drs. Nigel Russell and Uwe Platzbecker on their articles published in volume 147 issue 10 of Blood. Listen here:
bloodpodcast.transistor.fm/episodes/147-10 -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now! Featuring Immune-mediated side effects of cancer immunotherapies, The prevalence and clinical significance of clonal monocytosis, and more. Explore here: ashpublications.org/blood/issue/147/25
-
Blood Journals Portfolio
@BloodPortfolio
Tabelecleucel demonstrates efficacy and safety in the real-world setting. Tools for response prediction, immune reconstitution surveillance, and consolidation strategies may be useful to enhance response stability. Read here: ashpublications.org/bloodadvances/article/doi/10.1182/blo…
-
Blood Journals Portfolio
@BloodPortfolio
Plasma VEN concentration in patients with AML is potentially helpful in predicting prolonged #neutropenia. A low WBC count and impaired renal function heighten the risk of elevated VEN, causing prolonged neutropenia. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100234/567… #aml
-
Blood Journals Portfolio
@BloodPortfolio
We're proud to share that Blood has a JIF of 23.9 and continues its position as the most-cited journal in hematology, with 168,805 total citations in 2025. Blood Advances' JIF is 7.7. With 26,750 citations in 2025, it's among the top ten most cited hematology journals. #jcr2026
-
Blood Journals Portfolio
@BloodPortfolio
LiP-Seq analysis of persistent MCL cells revealed upregulated IFITM2, which confers relative protection from CAR-T killing in vitro. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/11/3845/5672… #mcl #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Patients with oligomonocytic CMML have unique features overlapping MDS and dysplastic CMML and are enriched with SF3B1 mutation. Read the full article in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/3/100224/567… #cmml #bloodneoplasia
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
Want to help highlight the next wave of hematology research? Organize a virtual or in-person ASH Poster Walk at the 68th ASH Annual Meeting and Exposition and showcase emerging science on a global stage.
Apply today: www.hematology.org/meetings/annual-meeting/abstracts/post…
#hematology #hemeonc -
Blood Journals Portfolio reposted
Hematopoiesis News
@Hema_News
A new study from @IUMedSchool led by Drs. Reuben Kapur and Santhosh Pasupuleti suggests that existing, accessible drugs could be repurposed to treat juvenile myelomonocytic #leukemia by targeting a key inflammatory pathway.
🔖 ashpublications.org/blood/article/doi/10.1182/blood.20250… -
Blood Journals Portfolio
@BloodPortfolio
LNP mRNA delivery of VEc to endothelium restores vascular homeostasis in 3 models of hyperpermeability. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/11/3820/5671…
-
Blood Journals Portfolio
@BloodPortfolio
CureSCi CDE recommendations build upon current consensus and allow for outcome comparison across SCD gene therapy studies. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/11/3960/5675… #worldscdday #scd #sicklecelldisease #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
UBA1-mutated monocytes are susceptible to RIPK1-dependent cell death and display impaired NF-κB–mediated cytokine responses to TLR agonists. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #vexas
-
Blood Journals Portfolio
@BloodPortfolio
Newborns with both SCA and vertically transmitted HIV in Uganda can be identified using screening techniques. Children born with both SCA and HIV have poor clinical outcomes and high mortality compared with those with either condition alone. Read here: ashpublications.org/bloodglobal/article/2/2/100093/567712…
-
Blood Journals Portfolio
@BloodPortfolio
T-cell responses did not differ between patients vaccinated earlier vs later after cellular therapy within the time frames studied. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/11/3945/5675…
-
Blood Journals Portfolio
@BloodPortfolio
It's World Blood Donor Day! In observance, we're sharing this article from Blood RCI, on how donor genetic traits affect red blood cell transfusion effectiveness: ashpublications.org/bloodrci/article/1/3/100030/547477/In… #worldblooddonorday #bloodrci
-
Blood Journals Portfolio
@BloodPortfolio
Patients with ITP can be classified into 3 groups according to the complement activation profile of platelets. Complement activation may be associated with PA-IgM, increased platelet turnover, and treatment burden. Read in Blood: ashpublications.org/blood/article/147/24/2958/567491/Comp…
-
Blood Journals Portfolio
@BloodPortfolio
Long-term phase 1/2 data demonstrate high response rates and sustained PFS with acalabrutinib in both TN and R/R CLL. Acalabrutinib was well tolerated; adverse event rates decreased over time with no new safety signals with long-term follow-up. Read here: ashpublications.org/bloodadvances/article/10/11/3931/5675…
-
Blood Journals Portfolio
@BloodPortfolio
Recipient NK cells and T cells increase during graft rejection, suggesting these recipient cells are the primary drivers of rejection. Read the full article in Blood ICT: ashpublications.org/bloodict/article/2/2/100046/567453/Pl… #hsct #bloodict
-
Blood Journals Portfolio
@BloodPortfolio
Ropeg showed clinically relevant activities and manageable safety in patients with early MF. After 104 weeks, ropeg resulted in reductions in VAF of JAK2V617F and CALR mutants in 67.6% and 40% of patients, respectively. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/11/3920/5673…
-
Blood Journals Portfolio
@BloodPortfolio
To the authors' knowledge, this is the largest analysis of acquired AA in Latin America, demonstrating outcomes comparable to those previously reported. Read the full study in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/2/100094/567771…
-
Blood Journals Portfolio
@BloodPortfolio
Severe GVHD can be effectively controlled by adoptive transfer of regulatory T cells preceded by lymphodepletion. In refractory GVHD, regulatory T-cell transfer can provide a safe alternative to induce long-term disease control. Read in Blood ICT: ashpublications.org/bloodict/article/2/2/100039/566630/Ad… #gvhd
-
Blood Journals Portfolio
@BloodPortfolio
MYB loss in acute lymphoblastic leukemia cells downregulates key oncogenes, with the loss of enhancer-promoter contacts. Read the plenary paper in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
New Blood Podcast episode out now! Blood editor Dr. Phillipe Armand interviews Drs. Manali Kamdar of @CUDenver and Nancy Bartlett of @WashU on their review article about relapsed/refractory large B-cell lymphoma:
bloodpodcast.transistor.fm/episodes/from-breakthrough-to-… -
Blood Journals Portfolio
@BloodPortfolio
The all-oral, MRD-driven, time-limited regimen duvelisib plus venetoclax is active in R/R CLL and RT, including in high-risk patients. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/11/3811/5674…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Ven-aza and the bone marrow niche, Complement activation in ITP, CD7 CAR T cells for relapsed/refractory AML, and more. Explore here: ashpublications.org/blood/issue/147/24
-
Blood Journals Portfolio reposted
Federico Gaiti
@fgaiti
Thanks to Diane Krause and the editors for the opportunity, and to the other authors (@AlejoFraticelli @shalinhnaik) in the clonal tracking series: doi.org/10.1182/blood.2026034019
We also recorded a podcast together—well worth a listen!
bloodpodcast.transistor.fm/episodes/review-series-on-clon… -
Blood Journals Portfolio
@BloodPortfolio
"Prognostic nutritional index and geriatric nutritional risk index in lisocabtagene maraleucel for B-cell lymphoma" Read the full article in Blood ICT: ashpublications.org/bloodict/article/2/2/100051/567652/Pr… #bcl #bloodict
-
Blood Journals Portfolio
@BloodPortfolio
Don't miss the meet and greets with our editors at #eha2026!
-
Blood Journals Portfolio
@BloodPortfolio
PET mTMTV showed prognostic impact in NDMM. Baseline PET was complementary to R-ISS to stratify prognosis. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/11/3787/5674…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Global Hematology out now! Featuring Developing nations’ guide to Hodgkin lymphoma, The challenge of treating African children with hydroxyurea, Sickle cell disease: then and now, and more. Explore here: ashpublications.org/bloodglobal/issue/2/2
-
Blood Journals Portfolio
@BloodPortfolio
Memory features in primary T cells show associations with CAR T-cell expansion that are not observed in postmanufacturing phenotypes. Read in Blood ICT: ashpublications.org/bloodict/article/2/2/100049/567651/Li… #lbcl #bloodict
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
How does extracellular sickle hemoglobin contribute to liver damage?
Join this month's Journal Club to explore the cellular pathways involved and potential therapeutic implications. academy.hematology.org/course/info.php?id=1765
#hematology #conquerscd @BloodPortfolio -
Blood Journals Portfolio
@BloodPortfolio
Congratulations to our Deputy Editor of Blood, Dr. Jorge Di Paola, on his new role as Executive Vice President and Chief Scientific Officer at @Versiti starting in October! Learn more: versiti.org/stories-and-impact/press-releases/2026/jorge-…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Advances out now featuring Real-world experience with tabelecleucel, Management of relapsed/refractory AL amyloidosis, and more. Explore here: ashpublications.org/bloodadvances/issue/10/11
-
Blood Journals Portfolio
@BloodPortfolio
BCMA CAR T cells are effective in MM, but patients relapse because of TGF-β–driven immunosuppression in the bone marrow microenvironment. Read in Blood ICT: ashpublications.org/bloodict/article/2/2/100048/567482/Cl… #mm #multiplemyeloma #bloodict
-
Blood Journals Portfolio
@BloodPortfolio
Current testing practices for #ida reveal missed opportunities for diagnosis and management in cirrhosis. Ferritin & MCV remain useful for IDA diagnosis in cirrhosis, but current thresholds are unable to exclude Hb response to oral iron. Read in Blood RCI: ashpublications.org/bloodrci/article/2/2/100070/567287/Pa…
-
Blood Journals Portfolio
@BloodPortfolio
Benefits and perils of generic drugs for hematologic neoplasms and their use in low- and middle-income countries: a narrative review. Read the full article in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/2/100095/567770…
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
ASH is heading to #eha26!
Visit Booth A4.05 to explore resources and meet the Blood Journals editors. 🩸
@BloodPortfolio #hemesky -
Blood Journals Portfolio
@BloodPortfolio
BCL2 overexpression in T cells is related to a lower risk of GVHD. BCL2 inhibitors should be used with caution after allogeneic hematopoietic stem cell transplantation. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/10/3572/5675… #gvhd #bcl2 #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Respondents endorsed a national plan for scale-up, including regional clinic selection based on demonstrated readiness. Read in BGH: ashpublications.org/bloodglobal/article/2/2/100091/567600… #hydroxyurea #uganda #bloodglobal
-
Blood Journals Portfolio
@BloodPortfolio
KO rats develop severe and spontaneous thrombocytopenia and organ injury recapitulating the features of #ttp. Pregnancy and postpartum do not worsen thrombocytopenia in TTP, but fetal-placental ADAMTS13 is crucial for perinatal survival. ashpublications.org/bloodadvances/article/10/10/3615/5675…
-
Blood Journals Portfolio
@BloodPortfolio
The use of systemic steroids for grade I acute GVHD was associated with more steroid-resistant GVHD and increased risk of infectious NRM. Read in Blood ICT: ashpublications.org/bloodict/article/2/2/100044/567372/Sy… #gvhd #bloodict
-
Blood Journals Portfolio
@BloodPortfolio
Interrogation of patients with the same HBB genotype reveals severity driven by dysregulated autophagy, chaperones, and ferroptosis pathways. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/10/3690/5663… #tdt #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Molecular diagnosis of hemophilia in the era of advanced genomic technology: current status and future in Africa. Read in Blood Global Hematology ➡️ ashpublications.org/bloodglobal/article/2/2/100089/567548… #africa #hemophilia #technology #bloodglobal
-
Blood Journals Portfolio reposted
Cell Therapy News
@celltherapynews
Despite promise in mouse models, new work led by Dr. Chris Peterson at @fredhutch found that #hiv-specific #cartcell activity across multiple immunocompetent macaque models is minimal. 🐒
Read the @BloodPortfolio study: ashpublications.org/blood/article/147/22/2621/566800/Anti… -
Blood Journals Portfolio
@BloodPortfolio
RT is the cornerstone of ENKTL, significantly improving survival in this disease. A Mexican cohort reveals unique clinical and outcome differences compared with Asian and global reports. Read in BGH: ashpublications.org/bloodglobal/article/2/2/100090/567549…
-
Blood Journals Portfolio
@BloodPortfolio
Combined PAR1 and PAR4 stimulation boosts platelet contractility by 50% beyond adhesion signaling and far beyond P2Y or GPVI stimulation. High thrombin concentrations are required to overcome the inhibition of clot contraction by antiplatelet drugs. ashpublications.org/bloodadvances/article/10/10/3442/5666…
-
Blood Journals Portfolio
@BloodPortfolio
GC-specific expression of a CREBBP KAT missense mutation leads to GC hyperplasia, memory B-cell expansion, and clonal lymphoproliferation. Read the plenary paper in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
New #reviewseries episode of the Blood Podcast is now live! Dr. Diane Krause interviews contributing authors @fgaiti @shalinhnaik @AlejoFraticelli from the Review Series on Clonal tracking in Hematopoiesis: bloodpodcast.transistor.fm/episodes/review-series-on-clon…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Predictive markers of glofitamab resistance, CREBBP mutations and lymphomagensis, Arterial thrombosis in hypofibrinogenemia and more. Explore here: ashpublications.org/blood/issue/147/23
-
Blood Journals Portfolio
@BloodPortfolio
Superior manufacturing outcomes are associated with better CAR T expansion in vivo, deeper responses, and longer progression-free survival. Read in Blood ICT: ashpublications.org/bloodict/article/2/2/100036/566310/Pr…
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
Will you be at #eha26? Be sure to stop by the ASH Booth (A4.05)!
Meet the ASH team, explore resources, and meet the Blood Journals editors. See you there! 🩸
@BloodPortfolio #hemesky -
Blood Journals Portfolio
@BloodPortfolio
MAPKis achieve rapid efficacy in active R-LCH, but less frequently and later when manifestations are chronic. Despite long-term follow-up, no validated exit strategy for discontinuation of MAPKis was found, as ND is a frequent and late complication. ashpublications.org/bloodadvances/article/doi/10.1182/blo…
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
New research published in Blood found that stem cell transplantation was the most cost-effective treatment option for adults living with sickle cell disease compared with gene therapy & standard of care. Read more 🔗 www.hematology.org/news-and-media/press-releases/2026/ste…
#hematology #conquerscd @bloodjournals -
Blood Journals Portfolio
@BloodPortfolio
Platelet activation predictions from carotid models match ex vivo data, supporting personalized stroke and thrombosis risk assessment. Read the full article in Blood VTH: ashpublications.org/bloodvth/article/3/2/100158/567188/Co… #platelets #thrombosis #bloodvth
-
Blood Journals Portfolio
@BloodPortfolio
A real-world cohort of patients with secondary #erythrocytosis had higher rates of #thrombosis compared with treated PV. Secondary erythrocytosis was associated with a higher prevalence of smoking, obesity, and diabetes mellitus. Read in Blood RCI: ashpublications.org/bloodrci/article/2/2/100071/567282/Re…
-
Blood Journals Portfolio
@BloodPortfolio
MDS/AML with MDR mutations display overall different mutation profiles and improved prognosis, when compared to corresponding AML subtype. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/10/3347/5669… #aml #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Sepsis-triggered proteolysis of A2 reduces cell surface fibrinolytic activity. A2 proteolysis is associated with microvasculopathic organ dysfunction in humans. Read in Blood VTH: ashpublications.org/bloodvth/article/3/2/100161/567294/Se…
-
Blood Journals Portfolio reposted
Jorge Cortes MD
@jorgecortesmd
Colleagues from India presenting great work in TFR and in renal dysfunction with TKI during #asco26. Looking forward to seeing the manuscript submitted to @BloodGlobalHema. @icmlf @uabmedicine @ONealCancerUAB
-
Blood Journals Portfolio reposted
Yale Cancer Center
@YaleCancer
Stem cell transplantation is the most cost-effective option for long-term care of #sicklecelldisease in adults compared to gene therapy and standard of care treatment, according to new research from @GeorgeGoshuaMD published in @BloodPortfolio.
➡️ashpublications.org/blood/article/doi/10.1182/blood.20250…
@SmilowCancer @ASH_hematology -
Blood Journals Portfolio
@BloodPortfolio
Integrative genomic profiling improves diagnostic resolution and risk stratification of B-ALL using WHO-HAEM5 and ICC classifications. Updated classifications reveal distinct subtypes and highlight limitations that require refinement of B-ALL taxonomy. ashpublications.org/bloodadvances/article/10/10/3640/5674…
-
Blood Journals Portfolio
@BloodPortfolio
"Dimethyl sulfoxide acutely induces shear-dependent thrombosis in flow assays via red blood cell–dependent mechanisms" Read the full article in Blood VTH: ashpublications.org/bloodvth/article/3/2/100149/566628/Di… #bloodvth
-
Blood Journals Portfolio
@BloodPortfolio
"Isovolemic hemodilution red cell exchange and blood use in children and young adults with sickle cell disease" Read in Blood RCI: ashpublications.org/bloodrci/article/2/2/100064/567072/Is… #scd #sicklecelldisease #bloodrci
-
Blood Journals Portfolio
@BloodPortfolio
Dynamic on-treatment cfEBV-DNA is significantly associated with prognosis in patients with early-stage #nktcl. cfEBV-DNA response phenotype serves as a prognostic biomarker and may inform risk-adapted treatment strategies in early-stage NKTCL. Read in BA: ashpublications.org/bloodadvances/article/10/10/3457/5671…
-
Blood Journals Portfolio
@BloodPortfolio
High ALC after cilta-cel treatment is associated with high risk of mortality and atypical neurologic events. Patients with elevated ALC who received 3 days of dexamethasone prophylaxis tended to have fewer neurologic events and lower mortality. Read in BA: ashpublications.org/bloodadvances/article/10/10/3629/5674…
-
Blood Journals Portfolio
@BloodPortfolio
Camonsertib directly induces cell death, accumulation of ROS, labile iron, and lipid peroxidation in erythroblasts in vitro. Ferrostatin-1 reverses ferritinophagy and ferroptosis in camonsertib-treated erythroblasts. Read in Blood RCI: ashpublications.org/bloodrci/article/2/2/100075/567468/Fe…
-
Blood Journals Portfolio
@BloodPortfolio
Patients at high risk as identified by these models may benefit from targeted antimicrobial prophylaxis rather than a universal approach. Read the full article in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/2/100087/567367… #multiplemyeloma #ndmm #bloodglobal #hematology
-
Blood Journals Portfolio
@BloodPortfolio
An intergenic region upstream of HBG2 termed the FCD binds transfactors and undergoes DNA looping during erythropoiesis. FCD-KO produced partial reversal of HBG silencing, supporting a silencer role in HbF expression. Read in Blood RCI: ashpublications.org/bloodrci/article/2/2/100046/565897/An…
-
Blood Journals Portfolio
@BloodPortfolio
CD19-CAR is effective in treating B-ALL in patients with EMD or CNS disease, particularly in the setting of low BM disease burden. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/10/3467/5666… #b-ALL #emd #cns
-
Blood Journals Portfolio
@BloodPortfolio
Sickle Confirm offers highly reliable detection of sickle cell disease in routine clinical conditions. Its low cost and field-adapted design make it practical, despite the need for basic equipment such as a centrifuge. Read in Blood Global: ashpublications.org/bloodglobal/article/2/2/100096/567804… #scd
-
Blood Journals Portfolio reposted
Daniel Lipka
@dblipka1
Check out this tweetorial about our recent paper in @BloodPortfolio:
doi.org/10.1182/blood.2025031268
🩸🩸🩸
@ASH_hematology
Translational Cancer Epigenomics
@TransCanEpi
🧵 NEW PAPER in @BloodJournal!
Why do IDH1 mutations almost exclusively drive myeloid #leukemia, while IDH2 mutations occur in both myeloid AND lymphoid cancers? #aml #epigenetics
Despite sharing the same biochemical mechanism, they are NOT equivalent. Here's what we found 👇 -
Blood Journals Portfolio reposted
Muzaffar Qazilbash
@Transplant_Doc
How I treat HLH-like toxicities after immune effector cell therapy #bmtsm @BloodPortfolio ashpublications.org/blood/article-abstract/doi/10.1182/bl…
-
Blood Journals Portfolio
@BloodPortfolio
Genetic testing is an important tool in the management of VAs, but not all patients receive it. Higher odds of PA were associated with skin findings and male sex, whereas lower odds were associated with higher Area Deprivation Index at 1 center. Read here: ashpublications.org/bloodvth/article/3/2/100165/567495/Fa…
-
Blood Journals Portfolio
@BloodPortfolio
Hematology-oncology–trained SCD physicians experience significantly more burnout than their non–SCD counterparts. Less recreational time and less job pride are mediators of burnout among SCD physicians. #burnout #scd #mham ashpublications.org/bloodadvances/article/10/10/3653/5670…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring CD117-targeted HCT preconditioning in AML and MDS, CSNK1E as a key to unlocking drug persistence in DLBCL, Novel functions of WPB proteins seem to cluster with VWF and more. Explore here: ashpublications.org/blood/issue/147/22
-
Blood Journals Portfolio
@BloodPortfolio
New episode of the Blood Podcast out now! Dr. James Griffin interviews Drs. Johnny Mahlangu and @JMRocco5 on their latest articles published in Blood. They discuss Marstacimab Therapy for Hemophilia A/B and HLH biomarkers. Listen now:
bloodpodcast.transistor.fm/episodes/147-9 -
Blood Journals Portfolio
@BloodPortfolio
Avapritinib elicited a high rate of deep and durable responses (73% ORR); median OS was 62 months after 4 years follow-up. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/10/3676/5663… #mastocytosis #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
VLX-1005 demonstrates potential as an effective treatment for HIT by preventing platelet activation without increasing bleeding risk. Read in Blood VTH: ashpublications.org/bloodvth/article/3/2/100146/566910/VL…
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
Heading to #asco26? So is ASH! Stop by booth #15032 to learn about #hematology funding opportunities, training programs, leadership pathways, mentorship, career resources, and more. Plus, a meet-and-greet with @jorgecortesmd, Editor in Chief of Blood Global Hematology.
#hemeonc -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood VTH out now! Featuring: Screening chemical libraries for the development of oral treatments for bleeding disorders, Social vulnerability, access to care, and outcomes in hemophilia, and more. Explore here ashpublications.org/bloodvth/issue/3/2 #bloodvth
-
Blood Journals Portfolio
@BloodPortfolio
A single infusion of fidanacogene elaparvovec exhibited a favorable safety profile, robust efficacy, and improved PROs for up to 6 years. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/10/3517/5668… #hemophiliab #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Advances out now featuring CD19 CAR T cells for B-ALL with EMD, Six-year FIX-padua gene therapy in hemophilia B, Popping FVIII concentrates into an updated classification and more. Explore here: ashpublications.org/bloodadvances/issue/10/10 #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Similar ICH rates were observed for patients treated with DOACs and LMWH. No major ICH were observed in patients receiving DOACs. Read in Blood VTH: ashpublications.org/bloodvth/article/3/2/100140/566130/In…
-
Blood Journals Portfolio
@BloodPortfolio
Methylation loss and increased expression of EBV BGLF4 was associated with favorable response to the GARD regimen in aggressive EBV-CNSL. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/2/100200/566…
-
Blood Journals Portfolio reposted
Muzaffar Qazilbash
@Transplant_Doc
Administration of IV iron therapy during acute infections was associated with improved 14- and 90-day survival #hematology @BloodPortfolio @CAMCHemOncIAM ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
Crystalglobulinemia is associated with a procoagulant platelet phenotype and high shear stress-like endothelial alterations. Markers of platelet and endothelial function reflect monoclonal protein burden. Read in Blood VTH: ashpublications.org/bloodvth/article/3/2/100134/557445/On…
-
Blood Journals Portfolio
@BloodPortfolio
Therapeutic inhibition of ferroportin restricts iron availability, RBC sickling, and hemolysis. Vamifeport treatment attenuates cardiopulmonary dysfunction in a sickle cell mouse model of precapillary pulmonary hypertension. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/9/3229/56602… #scd
-
Blood Journals Portfolio
@BloodPortfolio
"Safety of MMR vaccination for patients with myeloma receiving daratumumab after autologous stem cell transplantation" read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/2/100220/567…
-
Blood Journals Portfolio
@BloodPortfolio
vEM coupled with machine learning–based image analysis provides a detailed analysis of hemostatic plug structure. Contextual variables in distinct vascular environments influence coagulation and platelet activation. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/9/3143/56658…
-
Blood Journals Portfolio
@BloodPortfolio
A new C3 humanized rat was developed by crossing a human C3 transgenic rat with a C3 knockout rat. This new C3 humanized rat serves as a model to test various human C3-targeted therapies. Read in Blood VTH: ashpublications.org/bloodvth/article/3/2/100138/566129/A-…
-
Blood Journals Portfolio
@BloodPortfolio
5-Aza plus HDAC3i has a synergistic antilymphoma effect in vitro and in vivo. HDAC3i shows higher efficacy than pan-HDACi. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/2/100214/566… #dlbcl #bloodneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
Immunofluorescent microscopy demonstrates the presence of circulating megakaryocytes in patients with giant platelets and thrombocytopenia. Read in Blood VTH: ashpublications.org/bloodvth/article/3/2/100153/566736/As…
-
Blood Journals Portfolio
@BloodPortfolio
HF downregulates hepcidin expression in hepatocytes by interfering with HSPG biosynthesis and lowers hepcidin in mouse models of iron overload and inflammation, showing promise as a treatment for hepcidin-driven anemias. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/9/3020/56656…
-
Blood Journals Portfolio
@BloodPortfolio
Selective GPER agonist G-1 induces growth arrest and apoptosis in malignant T cells while largely sparing normal lymphocytes. G-1 effectively limits CTCL tumor progression in vivo, highlighting GPER signaling as a promising therapeutic approach. Read here: ashpublications.org/bloodneoplasia/article/3/2/100213/566…
-
Blood Journals Portfolio
@BloodPortfolio
Single‑donor human whole blood and blood fraction models of blood vessels were established for early phase drug safety assessments. Read in Blood VTH: ashpublications.org/bloodvth/article/3/2/100143/566452/De…
-
Blood Journals Portfolio
@BloodPortfolio
A new antibody to αIIbβ3 reciprocally inhibits PDI binding to platelets and partially inhibits ligand binding and platelet aggregation. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/9/3172/56692…
-
Blood Journals Portfolio
@BloodPortfolio
Rux (30 mg twice daily) plus Ven (400 mg once daily) was safe and well tolerated for patients with R/R AML on a phase 1 trial. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/2/100205/566…
-
Blood Journals Portfolio
@BloodPortfolio
"Atypical single PML::RARA fusion in acute promyelocytic leukemia: mechanisms and clinical implications" read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/2/100208/566…
-
Blood Journals Portfolio
@BloodPortfolio
The maximum tolerated dose and recommended phase 2 dose of belamaf in combination with KRd was 1.9 mg/kg. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/9/2925/56667… #mm #multiplemyeloma #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
A high-throughput screening of 2300 chemical compounds identified adapalene as a procoagulant in severe HA plasma. The mechanism of action of adapalene involves FXII activation. Read in Blood VTH: ashpublications.org/bloodvth/article/3/2/100139/566128/Sc…
-
Blood Journals Portfolio
@BloodPortfolio
Plasma levels of platelet and coagulation proteins in plasma are associated with increased bleeding severity. A subset of platelet proteins was also linked to time to major bleeding events in hemato-oncological patients. Read in Blood VTH: ashpublications.org/bloodvth/article/3/2/100144/566453/He…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Neoplasia out now! Featuring Predictors of sensitivity to immune therapies in classic Hodgkin lymphoma, Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia, and more. Explore here: ashpublications.org/bloodneoplasia/issue/3/2
-
Blood Journals Portfolio
@BloodPortfolio
Three distinct evolutionary patterns of tumor subclones are associated with variable ibrutinib responses and are predicted by the WIP score. Read in Blood: ashpublications.org/blood/article/147/20/2298/566572/Evol…
-
Blood Journals Portfolio
@BloodPortfolio
Patients with XP-C with isolated global genome NER defects show higher somatic mutation rates than patients with other XP groups that lack both NER pathways. A cancer-like mutational burden and signature are already present in normal XP-C PBMCs. Read here: ashpublications.org/bloodneoplasia/article/3/2/100209/566…
-
Blood Journals Portfolio
@BloodPortfolio
For patients with AML treated with LIT, ELN 2024 and Beat AML 2024 best identify a favorable group. Allogeneic stem cell transplant improves survival, but patients classified as adverse risk by any system still have poor outcomes. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/2/100212/566…
-
Blood Journals Portfolio
@BloodPortfolio
Exposure of highly activated platelet surfaces to intravascular factors peaks after bleeding cessation. Modulating exposure of highly activated platelet surfaces to circulating coagulation factors is a potential target for limiting thrombosis. Read here: ashpublications.org/bloodvth/article/3/2/100154/566750/Mu…
-
Blood Journals Portfolio
@BloodPortfolio
Frontline eltrombopag plus IST is cost-effective compared with IST alone for adults with severe aplastic anemia. Incremental net monetary benefit per patient treated with frontline eltrombopag is ∼$64 000. Read in Blood RCI: ashpublications.org/bloodrci/article/2/2/100076/567469/Co… #aplasticanemia
-
Blood Journals Portfolio reposted
Sanam Loghavi, MD صنم لغوی 🔬🧬
@sanamloghavi
Sometimes a $50 IHC is just as good as single cell sequencing 😉 🔬
In @BloodPortfolio today we show concurrent CLL + AML with p53 IHC identifying which clone carries the TP53 mutation. Direct Dx and Tx implications.
See details here:
ashpublications.org/blood/article/147/20/2415/568370/Next… -
Blood Journals Portfolio
@BloodPortfolio
HLA matching did not affect late transplantation outcomes after PT-Cy–based GVHD prophylaxis. Older donor age and female-to-male donor-recipient sex mismatch were associated with increased late NRM. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/2/100199/566…
-
Blood Journals Portfolio
@BloodPortfolio
Small-molecule hepcidin mimetics were found to engage in canonical FPN-hepcidin binding interface. Oral SchB was found to restore systemic iron homeostasis in vivo. Read in Blood RCI: ashpublications.org/bloodrci/article/2/2/100069/567174/Id…
-
Blood Journals Portfolio
@BloodPortfolio
HFE C282Y homozygous individuals have reduced blood clonogenic activity and increased incidence of myelodysplastic syndrome. Read in Blood RCI: ashpublications.org/bloodrci/article/2/2/100061/566620/Lo…
-
Blood Journals Portfolio
@BloodPortfolio
"Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial" read the full article in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/2/100216/567…
-
Blood Journals Portfolio
@BloodPortfolio
Dietary iron absorption from biofortified potatoes is higher in high-altitude residents than in matched sea-level counterparts. Read the study in Blood RCI: ashpublications.org/bloodrci/article/2/2/100056/566323/Hi…
-
Blood Journals Portfolio
@BloodPortfolio
"Predictors of sensitivity to immune therapies in classic Hodgkin lymphoma" read the review article in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/2/100207/566…
-
Blood Journals Portfolio reposted
Jayant Gadrey
@JayantYGadrey6
Beyond thrilled to share our (w/ @HannahUckelmann & @BrunettiLab) Spotlight article in @BloodPortfolio !!🤩NPM1-mutant AML is the most common subset of AML worldwide. For ~20 years since defining this subset, researchers wondered: how does a mainly cytoplasmic protein drive leukemia causing gene expression programs? What does this mean for treating these patients? We NOW have answers!
@Armstrong_dfci @Goodell_Lab
@rosslevinemd @Daver_Leukemia @jayastuMD @LeukDocJZ @beatalleukemia @DrGauravNarula @nvpatkar @AML_Hub @oncodaily @OncoAlert
ashpublications.org/blood/article-abstract/doi/10.1182/bl… -
Blood Journals Portfolio reposted
URochester Medicine Department of Medicine
@URMed_DeptMed
#urochesterresearch led by @CraigMorrell5 shows that neonatal platelets indirectly limit T-cell responses in the postnatal period, which may contribute to adverse outcomes of platelet transfusions in neonates.
More in @BloodPortfolio > doi.org/10.1182/blood.2025028734 -
Blood Journals Portfolio
@BloodPortfolio
New episode of The Blood Podcast! Dr. Laurie Sehn interviews Drs. @racampbell04 of @washumedicine @WashUHematology and Reuben Kapur of @IUMedSchool on their latest papers published in Blood. Learn more about IBD, Malaria, and immune signaling:
bloodpodcast.transistor.fm/episodes/147-20 -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring WM evolution during ibrutinib therapy, Bidirectional relationship for CHIP and IBD, Targeting DHODH in B-ALL and more. Explore here: ashpublications.org/blood/issue/147/20
#bloodjournal #newissue -
Blood Journals Portfolio
@BloodPortfolio
Viscoelastic testing of whole blood identifies delayed clot formation and altered fibrinolysis. ROTEM parameters discriminate patients with BDUC vs healthy controls well but do not predict bleeding severity or bleeding risk. Read in Blood VTH: ashpublications.org/bloodvth/article/3/2/100151/566737/Ab…
-
Blood Journals Portfolio
@BloodPortfolio
Rh and K-matched red cell units from racially similar donors minimized foreign antigen exposure to 1.6 per transfusion for patients with SCD. Read in Blood RCI: ashpublications.org/bloodrci/article/2/2/100059/566448/Re… #scd #bloodrci
-
Blood Journals Portfolio
@BloodPortfolio
APAC interacts with complement C1q and FH, targeting them onto APAC ligands on injured cells. APAC enhances complement activation on cells at the C3 level, without associated proinflammatory C5b-9 activation. Read in Blood VTH: ashpublications.org/bloodvth/article/3/2/100150/566626/In…
-
Blood Journals Portfolio
@BloodPortfolio
Impaired effector-to-memory transition increases terminally differentiated CAR T cells and reduces in vivo persistence. Read the full article in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/2/100203/566… #mm #multiplemyeloma
-
Blood Journals Portfolio
@BloodPortfolio
Are you going to be at ASCO this year? If so, stop by the ASH Booth for a meet and greet with the Editor-in-Chief of Blood Global Hematology, @jorgecortesmd of @ONealCancerUAB. Sunday, May 31st at 1 PM. See you there! #asco26
-
Blood Journals Portfolio
@BloodPortfolio
PACS is a chronic thromboinflammatory disorder driven by persistent endothelial injury, immune dysregulation and coagulation imbalance. The 1-year persistence of coagulation abnormalities supports future surveillance strategies in patients with PACS. ashpublications.org/bloodvth/article/3/2/100147/566624/En…
-
Blood Journals Portfolio
@BloodPortfolio
SCD RBCs with mitochondria exhibit high calcium, increased sickling, reduced life span, obstruction in microfluidic channels, and reduced Hb. Ex vivo calcium chelation reduces RBC sickling in pediatric patients with SCD. Read in Blood RCI: ashpublications.org/bloodrci/article/2/2/100058/566322/Hi… #scd
-
Blood Journals Portfolio
@BloodPortfolio
Two multidisciplinary guideline panels prioritized 34 outcomes for 32 research questions related to ALL in AYAs. The prioritized outcomes can inform future primary studies, systematic reviews, and guidelines. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/2/100222/567…
-
Blood Journals Portfolio
@BloodPortfolio
🎙️ Check out our latest episode of the Blood Podcast! Blood editor Dr. Laura Michaelis interviews Dr. Alexis Thompson on her latest research surrounding β-thalassemia. Listen here: bloodpodcast.transistor.fm/episodes/long-term-efficacy-an…
-
Blood Journals Portfolio
@BloodPortfolio
RBCs can effect vasoconstriction via adrenergic receptor–mediated COX activation leading to TxA2 synthesis and release. Read the study in Blood RCI: ashpublications.org/bloodrci/article/2/2/100057/566324/No…
-
Blood Journals Portfolio reposted
Yazan Abou-Ismail, MD - د. يزن أبواسماعيل
@DoctorYazanA
Available now @ASH_hematology @BloodPortfolio 🩸 Grateful to all collaborators across 5 US institutions and incredibly proud of all my mentees on this study, especially Ashley who first took it on in 2021 when she was a medical student, and @docrishabhsingh who carried it to the finish line of peer-reviewed publication— full circle since we first met at #isth2025 in Bangkok where he picked it up, now a rising star in thrombosis and hemostasis!
This is the largest multicenter study to date of the widely used and valuable PLASMIC score for diagnosing #ttp, where we uncover limitations in its diagnostic performance and highlight ongoing opportunities for refinement.
My 34th peer-reviewed journal publication and second study as the senior author 👴🏻
ashpublications.org/bloodvth/article/3/2/100163/567496/A-… -
Blood Journals Portfolio reposted
Tina Termini
@CterminiPhD
Excited to share recent work from our lab in @BloodPortfolio #bloodadvances! We studied the impact of CD45-targeted radioimmunotherapy (RIT) on the bone marrow vascular niche. Turns out the vasculature is majorly disrupted by hematopoietic targeted RIT☢️🩸
shorturl.at/qzWIB -
Blood Journals Portfolio
@BloodPortfolio
Compared with 7+3, CPX-351 improves OS in patients with AML-MR gene mutations who meet the enrollment criteria of the pivotal trial. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/8/2854/56638… #aml #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Female-derived PEVs from resting platelets offer superior endothelial barrier protection vs male-derived and stored-platelet PEVs. Read in Blood VTH: ashpublications.org/bloodvth/article/3/2/100148/566625/Do…
-
Blood Journals Portfolio
@BloodPortfolio
ASAH1 expression is associated with venetoclax resistance, and AC inhibition sensitizes AML to venetoclax. Cotargeting AC and BCL-2 induces a cytotoxic ISR, NOXA upregulation, and mitochondrial dysfunction. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/2/100196/566…
-
Blood Journals Portfolio
@BloodPortfolio
Risk progression after HMA worsens post-alloHSCT outcomes, whereas risk improvement does not confer a survival benefit. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/8/2817/56624…
-
Blood Journals Portfolio
@BloodPortfolio
AVA was effective in treating primary ITP in a diverse cohort, regardless of prior thrombopoietin receptor agonist use or disease duration. Read in Blood VTH: ashpublications.org/bloodvth/article/3/2/100142/566405/Re…
-
Blood Journals Portfolio
@BloodPortfolio
In the National MDS Study, the annual rates of progression, defined clinically, were 15% among LR-MDS and 7% among precursor states. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/8/2743/56656…
-
Blood Journals Portfolio
@BloodPortfolio
The IMS-IMWG consensus genomic criteria defined 31% of NDMM cases as HR. Patients at HR had inferior survival with daratumumab-based quadruplet induction, even when achieving MRD negativity. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/8/2616/56663… #ndmm #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Hb-based transfusion dosing overlooks patient, donor, and preparation differences in actual O2 delivery potency. L-TOF predicts and compares O2 delivery potency across blood products, providing a transfusion quality metric. Read in Blood RCI: ashpublications.org/bloodrci/article/2/2/100054/565973/De…
-
Blood Journals Portfolio
@BloodPortfolio
Transplantation from a matched unrelated donor resulted in superior outcomes compared with sibling donors in pediatric ALK-positive ALCL. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/8/2767/56640… #alcl #hsct #tbi
-
Blood Journals Portfolio
@BloodPortfolio
"Nucleic acid tests for scalable testing of blood donations for Oropouche virus in affluent and resource-limited settings." Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/2/100081/567120…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Gene therapy for transfusion-dependent thalassemia, Long telomeres and risk of lymphoma, Role of transferrin receptors in hepcidin induction, and more. Explore here: ashpublications.org/blood/issue/147/19
-
Blood Journals Portfolio reposted
Emma M. Groarke
@emmamgroarke
Super excited to share our How-I-Treat our today in @BloodPortfolio where we show how we integrate somatic mutations and other alterations 🧬 into the diagnosis and clinical care of #bmfsm patients. @fergutierrezro1 @bhavishap29 @NIH ashpublications.org/blood/article-abstract/doi/10.1182/bl…
-
Blood Journals Portfolio
@BloodPortfolio
Patients with #lbcl had a sustained increased risk of developing nonischemic HF after chemotherapy. After HF, LBCL history was associated with a higher all-cause but not cardiovascular mortality than comparators. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/8/2754/56642…
-
Blood Journals Portfolio
@BloodPortfolio
SCT-associated molecular differences appear as early as the first week of life. SCT in newborns is linked to early changes in liver, kidney, and blood-related biology. Read in Blood RCI: ashpublications.org/bloodrci/article/2/2/100051/566005/Ne… #sct #bloodrci
-
Blood Journals Portfolio
@BloodPortfolio
Hypertension is associated with shorter survival following both CLL diagnosis and treatment for patients with CLL aged <75 years. The increased mortality is primarily driven by infections and cardiocerebrovascular causes of death. Read in BA: ashpublications.org/bloodadvances/article/10/8/2729/56630… #cll
-
Blood Journals Portfolio
@BloodPortfolio
If you've been following along as we highlight the past Editors-in-Chief of Blood, in honor of its 80th anniversary, we hope you enjoy this feature of our current EiC Dr. Andrew Roberts: www.linkedin.com/feed/update/urn:li:activity:745782510894…
-
Blood Journals Portfolio
@BloodPortfolio
"Twenty-five years of tyrosine kinase inhibitors for chronic myeloid leukemia in Brazil." Read the full study in Blood Global Hematology: ashpublications.org/bloodglobal/article/doi/10.1016/j.bgl… #cml #brazil
-
Blood Journals Portfolio
@BloodPortfolio
Genome-wide association studies identified regulatory elements controlling erythropoietin gene expression. Anemia-associated polymorphisms affect known and novel EPO hypoxia response elements. Read in Blood RCI: ashpublications.org/bloodrci/article/2/2/100066/567020/Si…
-
Blood Journals Portfolio
@BloodPortfolio
HRS cell transcriptome is distinct from HL cell lines and tonsil CD30+ cells and reveals a program of cellular senescence. Treatment with B-cell lymphoma 2 inhibitor increases sensitivity to apoptosis in primary HL HRS cells in vitro. Read in BA: ashpublications.org/bloodadvances/article/10/8/2711/56601… #hrs
-
Blood Journals Portfolio
@BloodPortfolio
Cobicistat allowed an eightfold reduction in venetoclax while optimizing exposure, demonstrating a cost-effective strategy for AML treatment. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/2/100218/567… #aml #bloodneoplasia
-
Blood Journals Portfolio reposted
Samer Al Hadidi, MD,MS,FACP
@HadidiSamer
Pleased to share our recent publication @BloodPortfolio @ASH_hematology @utswcancer @ldandersonjr @HadidiSamer @UAMSMyeloma
#mmsm #bmtsm
Actual patients cases with difficult to treat entity and nice smear figures with suggested treatment algorithms and a look into the future
How I Treat Plasma Cell Leukemia
➡️ ashpublications.org/blood/article/doi/10.1182/blood.20250… -
Blood Journals Portfolio
@BloodPortfolio
Mean Hb increase after HU initiation was 0.3 to 0.4 g/dL, and only ∼25% of patients had an Hb increase of ≥1 g/dL. Read the study in Blood RCI: ashpublications.org/bloodrci/article/2/2/100048/565974/Fa… #scd #sicklecelldisease #bloodrci
-
Blood Journals Portfolio
@BloodPortfolio
Zanubrutinib demonstrated significantly longer PFS vs acalabrutinib-venetoclax (HR = 0.45, P = .0197) in treatment-naïve fit patients with CLL. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/8/2599/56624… #cll #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Treatment initiation in #mzl is driven by clinical urgency, balancing efficacy, toxicity, and cost considerations. Financial barriers significantly limit optimal care of MZL in Southeast and East Asia. Read in Blood Global: ashpublications.org/bloodglobal/article/2/2/100082/567071…
-
Blood Journals Portfolio
@BloodPortfolio
They found robust CCR4 expression in >60% of T-ALL cases, multiple high-risk genomic subtypes, and microenvironmental T-regulatory cells. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/8/2676/56656…
-
Blood Journals Portfolio
@BloodPortfolio
NEW Clinical practice guidelines for the diagnosis and management of Hodgkin lymphoma in countries with restricted resources from Blood Global Hematology! Explore here: ashpublications.org/bloodglobal/article/2/2/100080/567119…
-
Blood Journals Portfolio
@BloodPortfolio
Platelets from donors with obesity or prior SARS-CoV-2 infection were associated with higher platelet increments and reduced RBC transfusion. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/8/2582/56613…
-
Blood Journals Portfolio
@BloodPortfolio
IgG subclasses have differential activity in clearing transfused platelets. Although multiple IgG subclasses may be present in the antisera, a single IgG subclass can be required for platelet clearance. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/8/2592/56638…
-
Blood Journals Portfolio
@BloodPortfolio
FRD overwhelmingly dominates blood supply in Kano, Nigeria, and female blood donors are grossly underrepresented. Blood donation services should be regionally centralized to maintain minimal quality standards. Read in Blood Global: ashpublications.org/bloodglobal/article/2/2/100075/566885…
-
Blood Journals Portfolio
@BloodPortfolio
Nonpermissive BM stroma hinders B-cell recovery after HSCT and rituximab therapy in 1 of 2 twins with X-linked lymphoproliferative disease. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/8/2786/56604… #hsct #bonemarrow #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
The probiotic was safe but showed poor gut colonization, indicating that higher doses or alternative strains may be needed. Read the full study in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/2/100073/566618…
-
Blood Journals Portfolio
@BloodPortfolio
New episode of the Blood Podcast! Blood editor Dr. James Griffin interviews Drs. Francesco Forconi (@Forconi_Lab) and Bin Guo on their latest research. Listen now:
bloodpodcast.transistor.fm/episodes/2d1d69fa-134d-4499-b3… -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring DC-SIGN function in follicular lymphoma, Immune biomarkers of infection risk in MM, Targeting donor DCs to prevent gut GVHD and more. Explore here: ashpublications.org/blood/issue/147/18
-
Blood Journals Portfolio
@BloodPortfolio
An intergenic region upstream of HBG2 termed the FCD binds transfactors and undergoes DNA looping during erythropoiesis. FCD-KO produced partial reversal of HBG silencing, supporting a silencer role in HbF expression. Read in Blood RCI: ashpublications.org/bloodrci/article/2/2/100046/565897/An…
-
Blood Journals Portfolio
@BloodPortfolio
Findings include that some protocols appear more sterilizing than others and the impact of assisted reproduction is substantial. Read the study in Blood Advances: ashpublications.org/bloodadvances/article/10/8/2634/56630… #pregnancy #fertility #hct
-
Blood Journals Portfolio
@BloodPortfolio
High (94%) concordance of SCD diagnosis between physician-attested and manual data abstraction supports data quality for future DH studies. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/8/2608/56616… #scd #sicklecelldisease #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Tanzanian patients with #cml are younger, presenting with a high disease burden that confers molecular resistance to the first-line imatinib. Read in Blood Global: ashpublications.org/bloodglobal/article/2/2/100083/567200…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Advances out now featuring Finding the genes that fit CPX-351, Investigative reporting on factor VIII whereabouts, Pregnancy after hematopoietic stem cell transplant: an international multicenter study and more. Explore here ➡️ ashpublications.org/bloodadvances/issue/10/8
-
Blood Journals Portfolio
@BloodPortfolio
Made by @ASH_hematology in collaboration with @StJudeResearch and Munich Leukemia Lab, ASHOP hosts genomic, transcriptomic, clinical, and demographic data from 5,960 patients with hematologic malignancies. Read more in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
Missense mutations P258L/Y259C were identified as the predominant Chinese-specific germ line DDX41 variants. Read the full study in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/2/100071/566619…
-
Blood Journals Portfolio reposted
Minoru Kanaya, 金谷穣
@MinoruKanaya
I am delighted to announce that my paper on Venetoclax blood concentrations in Japanese AML patients has been published in Blood Neoplasia.@BloodPortfolio ashpublications.org/bloodneoplasia/article/doi/10.1016/j.…
-
Blood Journals Portfolio reposted
Hematopoiesis News
@Hema_News
Scientists show that donor-derived anti-CD33 CAR T therapy is safe and shows early efficacy in relapsed AML after transplant.
Learn more at @BloodPortfolio:
🔖 ashpublications.org/blood/article-abstract/147/17/1914/56… -
Blood Journals Portfolio
@BloodPortfolio
Median age at #cml diagnosis in Mexico is 43 years, almost 2 decades earlier than that in high-income countries. Read in Blood Global: ashpublications.org/bloodglobal/article/2/2/100069/566446…
-
Blood Journals Portfolio
@BloodPortfolio
AML PDXs capture patients’ AML diversity, facilitate druggable targets identification and unlock new therapeutic frontiers in pAML. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/7/2153/56623… #aml
-
Blood Journals Portfolio
@BloodPortfolio
A structured, home-based exercise intervention in MPN was feasible, well accepted, and showed initial benefits on disease-related markers. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/7/2142/56589…
-
Blood Journals Portfolio
@BloodPortfolio
"The DKMS Access to Transplantation program: addressing barriers to HSCT." Read the full article in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/2/100067/566276… #hsct
-
Blood Journals Portfolio
@BloodPortfolio
POD24 serves as an early surrogate end point by reliably identifying patients with unfavorable subsequent survival. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/7/2322/56588…
-
Blood Journals Portfolio
@BloodPortfolio
High serum FFA predicts inferior outcome across PTCL subtypes, linking to JAK-STAT activation and immunosuppressive microenvironment. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/7/2125/56616… #ptcl
-
Blood Journals Portfolio
@BloodPortfolio
We're excited to announce our new Associate Editor for Blood VTH, Dr. Scott Cameron of @ClevelandClinic. Learn more and join us in congratulating him on this new role:
www.linkedin.com/feed/update/urn:li:activity:745317971252… -
Blood Journals Portfolio
@BloodPortfolio
"Tabelecleucel as a bridge to hematopoietic stem cell transplant in systemic chronic active Epstein-Barr virus disease". Read the full article in Blood ICT: ashpublications.org/bloodict/article/2/2/100043/567371/Ta…
-
Blood Journals Portfolio reposted
Hrishi Srinagesh
@HSrinagesh
It was a real pleasure to talk about our latest work from the ROCCA consortium! Please check out to learn more about how prior blinatumomab affects brexu-cel outcomes in adults with B-ALL in the real-world setting.
Blood Journals Portfolio
@BloodPortfolio
New Blood Podcast episode! Dr. Laurie Sehn interviews Drs. Shengwen Calvin Li of @UCIrvine and Hrishi K. Srinagesh of @Stanford on their latest articles published in Blood. From thrombocytopenia to B-ALL, listen to the conversation here:
bloodpodcast.transistor.fm/episodes/blood-podcast-episode-17 -
Blood Journals Portfolio
@BloodPortfolio
NK-X cells enhance aNK cell cytotoxicity and antileukemic activity. CIML NK cells from exercise donors delay leukemia progression in xenogeneic mice. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/doi/10.1182/blo…
-
Blood Journals Portfolio
@BloodPortfolio
New Blood Podcast episode! Dr. Laurie Sehn interviews Drs. Shengwen Calvin Li of @UCIrvine and Hrishi K. Srinagesh of @Stanford on their latest articles published in Blood. From thrombocytopenia to B-ALL, listen to the conversation here:
bloodpodcast.transistor.fm/episodes/blood-podcast-episode-17 -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Removal of anti-ABO B cells by bispecific antibody, Common variants influence AML risk and prognosis, a new #howitreat and more. Explore here: ashpublications.org/blood/issue/147/17
-
Blood Journals Portfolio reposted
A. Emre Eşkazan, MD 🩸🔬
@eskazanae
I sincerely congratulate Drs Özer Çerme and Yılmaz from our hematology division for writing this nice commentary accompanying a recently published paper on Hodgkin lymphoma in the Blood Global Hematology 🤓🥰🤗👏👏
@ASH_hematology @BloodPortfolio
👉 ashpublications.org/bloodglobal/article/2/2/100086/567926… -
Blood Journals Portfolio
@BloodPortfolio
Learn more about the 11th Editor-in-Chief of Blood, Dr. Bob Löwenberg!
www.linkedin.com/feed/update/urn:li:activity:745272713978… -
Blood Journals Portfolio reposted
CU Anschutz Lymphoma Program
@CULymphoma
Our @CULymphoma lead Dr. @mana1981 was just published @BloodPortfolio as part of a phase II trial of mosun/pola in relapsed/refractory mantle cell lymphoma. #lymsm #tcellrx
ashpublications.org/blood/article/doi/10.1182/blood.20250… -
Blood Journals Portfolio
@BloodPortfolio
Age, sex, IgG, IgA, IgM, platelet and lymphocyte counts, known secondary cause, and positive direct antiglobulin tests predicted chronic ITP. Read the full study in Blood: ashpublications.org/blood/article/147/16/1863/566403/Pred… #itp
-
Blood Journals Portfolio
@BloodPortfolio
CD45-targeted RIT more effectively suppresses the hematopoietic system than nontargeted radiation delivery. The BM vascular niche is differentially reprogrammed by CD45-targeted RIT compared to nontargeted radiation. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/7/2452/56656…
-
Blood Journals Portfolio
@BloodPortfolio
CD2 is a viable target for CAR T-cell immunotherapy for T-cell malignancies, but CD2 deletion in CAR T cells can lead to dysfunction. Read in Blood: ashpublications.org/blood/article/147/16/1842/565858/Harn…
-
Blood Journals Portfolio
@BloodPortfolio
Find the research in Blood: ashpublications.org/blood/article/147/10/1048/548218/CPX-… #aml
Hematology Advisor
@HematologyAdv
In recognition of #amlworldawarenessday, the NCRI AML18 trial reports DAGO2 induction is superior to CPX-351 for older patients without adverse-risk cytogenetics. 🩺 With @BloodPortfolio.
Read the review: www.hematologyadvisor.com/news/acute-leukemia-aml-dago2-s…
#amlsm #knowaml #leukemia -
Blood Journals Portfolio
@BloodPortfolio
Osteocytes produce ERFE, a hormone that regulates red cell production. ERFE produced by osteocytes in vivo contributes to suppressing liver hepcidin production. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/7/2408/56632…
-
Blood Journals Portfolio
@BloodPortfolio
The number of lines of systemic therapy, along with markers of disease burden and inflammation, are associated with ALC at leukapheresis. Read the full article in Blood ICT: ashpublications.org/bloodict/article/2/2/100042/566985/Id…
-
Blood Journals Portfolio
@BloodPortfolio
Compared with historical care, CAR-T improves hospitalization and infection rates, as well as 3-year survival. These data highlight the lack of other effective salvage options for patients with R/R-LBCL. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/7/2304/56604…
-
Blood Journals Portfolio
@BloodPortfolio
Well done! Check out their paper on a novel signaling pathway for platelet adhesion here: ashpublications.org/blood/article/doi/10.1182/blood.20250…
UNC Biochemistry and Biophysics
@UNC_BCBP
🩸 New paper in Blood from the Bergmeier Lab! David Paul and David Rocco (co–first authors) identify a new signaling pathway critical for platelet adhesion under arterial shear—advancing insights into platelet function and cardiovascular disease. @BloodPortfolio
-
Blood Journals Portfolio
@BloodPortfolio
Physiological bone remodeling shapes the nonuniform inflammatory landscape of bone marrow macrophages that regulates Tet2+/− clonal burden. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20240…
-
Blood Journals Portfolio
@BloodPortfolio
Pirtobrutinib appears to offer clinical benefit in R/R MZL, with ORR of 55.6% and median DOR of 17.8 months. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/7/2441/56604… #mzl
-
Blood Journals Portfolio
@BloodPortfolio
Receipt of thiotepa-ASCT was the prognostic variable most favorably associated with survival in a landmark 6-month multivariable analysis. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #lbcl
-
Blood Journals Portfolio
@BloodPortfolio
Long-term responses up to 5 years were accompanied by expression of CD27 and CD127 along with increased expansion of CAR+ TCM cells. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/7/2395/56594…
-
Blood Journals Portfolio
@BloodPortfolio
New Blood #howitreat on breakthrough thrombosis in patients with cancer. Explore here: ashpublications.org/blood/article/doi/10.1182/blood.20250… #thrombosis
-
Blood Journals Portfolio
@BloodPortfolio
"Infections following CAR T-cell therapies in children, adolescents, and young adults: a systematic review and meta-analysis" Read the full article in Blood ICT: ashpublications.org/bloodict/article/2/2/100040/566666/In…
-
Blood Journals Portfolio
@BloodPortfolio
It’s World Hemophilia Day! A recent study in Blood VTH examined social vulnerability, access to care, and outcomes for #hemophilia patients in the United States. Explore the findings: ashpublications.org/bloodvth/article/3/2/100145/566627/So… @wfhemophilia #whd2026 #worldhemophiliaday #bloodvth
-
Blood Journals Portfolio
@BloodPortfolio
RIC BMT with 400 cGy provides durable engraftment, low GVHD toxicity, and may preserve fertility. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/7/2202/56620… #scd
-
Blood Journals Portfolio reposted
Hematopoiesis News
@Hema_News
Scientists showed that allogeneic #hematopoietic stem cell transplant is a viable curative strategy for ERCC6L2 disease when performed before transformation to an aggressive malignancy.
Learn more at @BloodPortfolio:
🔖 ashpublications.org/bloodadvances/article/10/7/2525/56638… -
Blood Journals Portfolio
@BloodPortfolio
🎙️New episode alert! Dr. Edward Cliff of @PeterMacCC discusses his latest Blood paper covering CAR T-cell therapies and the mismatch between innovation & implementation across high-income and selected-upper-middle-income countries for products. Listen now: bloodpodcast.transistor.fm/episodes/eeee
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Anti-CD2 CAR T-cells for T-cell neoplasms, Inflammatory landscape in clonal hematopoiesis, GRK5 variant linked to thrombotic disease, and more. Explore here: ashpublications.org/blood/issue/147/16
-
Blood Journals Portfolio
@BloodPortfolio
Combined PTCy/SIR/VIC-1911 was safe and feasible as GVHD prophylaxis in a phase 1 study. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/7/2190/56626… #gvhd #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
We're excited to feature the 10th Editor-in-Chief of Blood, Dr. Cynthia Dunbar, who is also the @ASH_hematology 2026 President-elect. Learn more about her and her career:
www.linkedin.com/feed/update/urn:li:activity:745027039690… -
Blood Journals Portfolio reposted
ASH
@ASH_hematology
What’s the difference between nascent and mature reticulocytes and why does it matter? Join this month’s Journal Club to explore new biomechanics + proteomics insights, discuss anemia in SCD and P. vivax, and engage live with authors. hematology.zoom.us/webinar/register/WN_MKnlIk3fSxas0Jvd0y…
@BloodPortfolio -
Blood Journals Portfolio
@BloodPortfolio
"How to determine the optimal duration of anticoagulation for VTE: an evidence-based decision-analytical approach" read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/7/2314/56613… #vte #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
New issue of #bloodadvances out now featuring Monovalent antibody treatment of von Willebrand disease, Osteocyte-derived erythroferrone regulates liver hepcidin during stress erythropoiesis, and more. Explore here: ashpublications.org/bloodadvances/issue/10/7
-
Blood Journals Portfolio
@BloodPortfolio
Important #pressrelease today regarding new research of #scd in Sub-Saharan Africa. If you'd like to read the full study in Blood Global Hematology, click here: ashpublications.org/bloodglobal/article/doi/10.1016/j.bgl…
ASH
@ASH_hematology
Sickle cell disease is the most common inherited blood disorder worldwide, but experiences vary by region. SWAY data show individuals in sub-Saharan Africa are less likely to know their variant or use standard treatments.
Learn more in the press release: www.hematology.org/news-and-media/press-releases/2026/scd… -
Blood Journals Portfolio
@BloodPortfolio
aGVHD causes loss of gastric stem cells, G-cells, and PCs, leading to increased gastric pH. Read the full article in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
Heatstroke causes MODS and death through necroptosis-dependent disseminated intravascular coagulation. Read the full article in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
NEW #howitreat series: How I approach clinical ethics consultation in hematology. Read in Blood ➡️ ashpublications.org/blood/article/147/15/1693/566368/How-…
-
Blood Journals Portfolio
@BloodPortfolio
"Charting human developmental hematopoiesis in vitro to open new routes for regenerative medicine" read the full article in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20240…
-
Blood Journals Portfolio
@BloodPortfolio
Ercc6l2 deficiency leads to replication stress, p53 pathway activation, and decreased Runx1 and Gata1 expression resulting in BMF. Read the plenary paper in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #plenarypaper #bloodjournal #p53
-
Blood Journals Portfolio reposted
James Davis, PharmD, BCOP
@thisisJamesD
💡 🧠 Hot off the press in its entirety... Our multi-center study looking into the safety of MMR vaccination in patients with myeloma receiving daratumumab maintenance after ASCT! Out now in @BloodPortfolio #bloodneoplasia doi.org/10.1016/j.bneo.2026.100220
-
Blood Journals Portfolio
@BloodPortfolio
ASHOP hosts genomic, transcriptomic, clinical, and demographic data from 5,960 patients with hematologic malignancies. It enables integrated, interactive analysis of hematologic data with intuitive, user-friendly tools. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
St. Jude Research
@StJudeResearch
St. Jude collaborated with the @ASH_hematology and the @leukaemielabor to establish the ASH HematOmics Program (ASHOP), an open platform that unites multi-omics and clinical outcomes data from nearly 6,000 patients with blood cancers. www.stjude.org/media-resources/news-releases/2026-medicin…
-
Blood Journals Portfolio
@BloodPortfolio
The antileukemic drug forodesine was evaluated for generating antitumor DNTs under conditions of CD8+ T-cell lymphopenia. Read the full article in Blood ICT: ashpublications.org/bloodict/article/2/1/100031/565978/Ad…
-
Blood Journals Portfolio reposted
Boettcher Lab
@TheBoettcherLab
Bonus 2/2: Thanks to #dr. James D. Griffin for featuring our work on the @BloodPortfolio podcast. bloodpodcast.transistor.fm/episodes/consequences-of-p53-l…
-
Blood Journals Portfolio reposted
Kate Sears
@OpenMedKate
What happened this week in #acutemyeloidleukemia:
1⃣ Guidelines update for older adults and pediatrics
Newly published guidance for newly diagnosed older-adult AML in Blood Advances and international consensus recommendations for pediatric AML in Blood support near-term pathway changes in diagnosis and management across age strata, as detailed in clinical guidelines for treating newly diagnosed acute myeloid leukemia in older adults and consensus recommendations from an international expert panel.
ashpublications.org/bloodadvances/article/10/6/1897/54845… -
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Targeted therapy in early-stage classical Hodgkin lymphoma, How I approach clinical ethics consultation in hematology, Gastrin for the treatment of acute graft-versus-host disease of the stomach, and more. Explore here: ashpublications.org/blood/issue/147/15
-
Blood Journals Portfolio
@BloodPortfolio
New episode of the Blood Podcast is out now! Dr. James Griffin interviews Drs. Steffen Boettcher and Robert Zeiser on their latest research published in Blood on the topics of p53 loss and aGVHD. Listen here: bloodpodcast.transistor.fm/episodes/consequences-of-p53-l…
-
Blood Journals Portfolio
@BloodPortfolio
MODA boosts antitumor activity of bispecific T-cell engagers and conventional monoclonal antibodies in preclinical models. Read the full article in Blood ICT: ashpublications.org/bloodict/article/2/1/100034/566309/Mo…
-
Blood Journals Portfolio reposted
Waggoner Lab
@LabWaggoner
HLA-E single-chain trimer shields gene-edited allogeneic CAR T Cells from NK cell attack @BloodPortfolio @Penn
ashpublications.org/bloodadvances/article/doi/10.1182/blo… -
Blood Journals Portfolio
@BloodPortfolio
In continued celebration of Blood's 80th anniversary, we're excited to highlight the 9th Editor-in-Chief of Blood, Dr. Sanford Shattil:
www.linkedin.com/feed/update/urn:li:activity:744767068663… -
Blood Journals Portfolio
@BloodPortfolio
Explore the @ASH_hematology @isth 2026 guidelines for Anticoagulant Prophylaxis of Pediatric Patients at Risk of Venous Thromboembolism in Blood Advances: ashpublications.org/bloodadvances/article/doi/10.1182/blo…
ASH
@ASH_hematology
ASH and @isth have released new guidelines on anticoagulant prophylaxis for pediatric patients at risk of VTE, providing evidence-based recommendations to improve care.
Learn more in the press release: www.hematology.org/news-and-media/press-releases/2026/ash…
#hematology #vte #ashguidelines -
Blood Journals Portfolio
@BloodPortfolio
SP140 inhibition overcomes epigenetic barriers, enabling robust generation of serially transplantable HSCs from hPSCs. Read the full article in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies." Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #epsteinbarr #bloodjournal #ebv
-
Blood Journals Portfolio
@BloodPortfolio
CAR-T therapy shows comparable survival outcomes in older and younger patients with #lbcl. In younger patients, axi-cel and liso-cel improve PFS vs tisa-cel; in older patients, axi-cel increases nonrelapse mortality vs tisa-cel. Read in Blood ICT: ashpublications.org/bloodict/article/2/1/100037/566307/Ol…
-
Blood Journals Portfolio
@BloodPortfolio
"Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel." Read the special report in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20240… #aml #bloodjournal #specialreport
-
Blood Journals Portfolio
@BloodPortfolio
TLR8 GOF is an X-linked dominant disease that should be considered in both male and female patients with cytopenia and immune dysregulation. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/6/1967/55721…
-
Blood Journals Portfolio
@BloodPortfolio
Rate of grade 3+ CRS was lower than in the pivotal trial and rate of grade 3+ neurotoxicity (ICANS) was similar. Prior allogeneic #hct was the only factor that demonstrably reduced the odds of developing grade 3+ CRS. Read in Blood ICT: ashpublications.org/bloodict/article/2/1/100028/557442/Re…
-
Blood Journals Portfolio
@BloodPortfolio
The molecular subtypes of Korean DLBCL differ from those observed in Western populations. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/6/1929/56604…
-
Blood Journals Portfolio
@BloodPortfolio
The identified immune marker panel enables the development of an individualized approach to preventing and treating aGVHD in pediatric HCT. Read the full article in Blood ICT: ashpublications.org/bloodict/article/2/1/100035/566308/Id…
-
Blood Journals Portfolio
@BloodPortfolio
In the G20, among 7 commercial CAR T products with 18 FDA-approved indications, <48% (122/252) of these indications are publicly reimbursed. Read the plenary paper in Blood: ashpublications.org/blood/article/147/14/1521/566028/Glob… #bloodjournal #cart #plenarypaper
-
Blood Journals Portfolio
@BloodPortfolio
CAR-T yields deep early responses in PCL with manageable toxicity. Presence of circulating plasma cells predict early post–CAR-T progression. Read the full article in Blood ICT: ashpublications.org/bloodict/article/2/1/100033/566082/CA… #pcl
-
Blood Journals Portfolio
@BloodPortfolio
Ectopic expression of FD in the mouse liver surprisingly depleted FB and abolished AP complement activity. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/6/2024/56604…
-
Blood Journals Portfolio
@BloodPortfolio
Findings support including B-leader status in haploidentical donor selection in Latin America. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100048/548136… #latinamerica #hsct #gvhd
-
Blood Journals Portfolio
@BloodPortfolio
Radiotherapy is highly effective in patients with POEMS syndrome and solitary plasmacytoma. Read the full article in Blood Advances: ashpublications.org/bloodadvances/article/10/6/2074/56620…
-
Blood Journals Portfolio
@BloodPortfolio
γMSC trafficking to #gvhd tissues relies on integrin α4β1–MAdCAM-1 adhesion and CCR5-driven chemotaxis toward inflammatory chemokines. Read the full article in Blood ICT: ashpublications.org/bloodict/article/2/1/100017/548165/In…
-
Blood Journals Portfolio reposted
Eddie Cliff
@Eddie_Cliff
In this week's issue of @BloodPortfolio, our study of global access to CAR T, led by Alex Ge.
Thanks to Blood editors for making it a plenary paper!
Free access link: authors.elsevier.com/a/1mt5a1UYwuoeB
Thanks @kjmeetswrld for the thoughtful commentary
ashpublications.org/blood/article/147/14/1509/567410/Acce… -
Blood Journals Portfolio reposted
Nicole Arellano
@nsarellano9
Really enjoyed writing this commentary for a new @BloodPortfolio publication on dual-epitope targeting of mutant CALR from @chloecanscience! Check it out now: ashpublications.org/blood/article-abstract/doi/10.1182/bl… @TheElfLab
-
Blood Journals Portfolio reposted
Emilio M
@EmilioM74
Excited to share the final version of our article published in Blood Neoplasia! @BloodPortfolio
Big thanks to the whole team #cepimmy and also to @FondationARC for supporting this research
You can read the paper here: doi.org/10.1016/j.bneo…
#dlbcl #epigenetictherapy -
Blood Journals Portfolio
@BloodPortfolio
New #reviewseries episode of the Blood Podcast out now! Blood Associate Editor Dr. Jason Gotlib interviews Drs. Stefan Constantinescu, Ann Mullally, and Marina Kremyanskaya on their articles relating to myeloproliferative neoplasms and exciting advances: bloodpodcast.transistor.fm/episodes/review-series-on-mpns
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now featuring Global access to CAR T, BelaRd in ASCT-ineligible patients with NDMM, Human HSC generation from pluripotent stem cells, and more. Explore here: ashpublications.org/blood/issue/147/14
-
Blood Journals Portfolio
@BloodPortfolio
We're pleased to share our recently published clinical guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/6/1897/54845… #aml #clinicalguidelines #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
A lateral flow device testing urine for CA1 enables rapid detection of hemolysis in resource-limited settings. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100058/557437…
-
Blood Journals Portfolio
@BloodPortfolio
Hydroxyurea use in patients with #scd reduced acute care use but did not decrease total health care costs. Total health costs were likely higher due to persistent chronic care management, decreased adherence, and later initiation of hydroxyurea. ashpublications.org/bloodglobal/article/2/1/100040/547950…
-
Blood Journals Portfolio reposted
Talha Badar
@TalhaBadarMD
Guidelines on management of #all in AYA doi.org/10.1182/bloodadvances.2021006469
@AyaOncologist 👏👏
One slide summary 👇🏽 -
Blood Journals Portfolio
@BloodPortfolio
Continuing our features of the past editors-in-chief of Blood, we're excited to highlight the 8th EIC, Dr. Kenneth Kaushansky:
www.linkedin.com/feed/update/urn:li:activity:744514130774… -
Blood Journals Portfolio
@BloodPortfolio
Children with SCD have a higher prevalence of CH vs matched controls. Hydroxyurea therapy did not increase CH prevalence. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #ch #scd
-
Blood Journals Portfolio
@BloodPortfolio
Very exciting #pressrelease on the new @ASH_hematology 2026 Guidelines for the Diagnosis and Management of Severe Acquired Aplastic Anemia. Find them in Blood Advances: ashpublications.org/bloodadvances/article/doi/10.1182/blo… #clinicalguidelines #bloodadvances #aplasticanemia
ASH
@ASH_hematology
ASH has released new clinical practice guidelines on the diagnosis & management of severe acquired aplastic anemia. These recommendations provide practical guidance to help clinicians diagnose earlier & treat more effectively. Learn more: www.hematology.org/news-and-media/press-releases/2026/ash…
-
Blood Journals Portfolio
@BloodPortfolio
Read the study "racial and clinical determinants of response in 2304 large B-cell lymphomas treated with CD19 CAR T in clinical trials" in Blood Advances: ashpublications.org/bloodadvances/article/10/5/1497/54810…
Targeted Onc
@TargetedOnc
New analysis in @BloodPortfolio confirms that race does not significantly impact CD19 CAR T-cell therapy efficacy or safety in B-cell lymphomas.
#oncology #lymphoma #cartcell #healthequity #meded
www.targetedonc.com/view/cd19-car-t-efficacy-is-consisten… -
Blood Journals Portfolio reposted
Hematopoiesis News
@Hema_News
A distinct #leukemia subtype with a surprising weakness!
Researchers from @UOsaka_en uncover a distinct NUTM1-rearranged leukemia subtype with stem-like features and notable vulnerability to chemotherapy. @BloodPortfolio
📕 ashpublications.org/blood/article/147/13/1395/557529/Comp… -
Blood Journals Portfolio
@BloodPortfolio
Various CAR designs were evaluated for allogeneic CAR-NKT cells in treating solid tumors to identify optimal antitumor efficacy. Read the full article in Blood ICT: ashpublications.org/bloodict/article/2/1/100025/557344/En…
-
Blood Journals Portfolio
@BloodPortfolio
Older patients with AML treated with intensive chemotherapy in Brazil experience a high early death rate and low overall survival. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100057/557438… #aml #brazil
-
Blood Journals Portfolio
@BloodPortfolio
Asciminib showed increasingly superior efficacy and favorable safety/tolerability vs all IS-TKIs, consistent with the primary analysis. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #cml
-
Blood Journals Portfolio
@BloodPortfolio
Varnim-cel in a fractionated infusion protocol (10%, 30%, and 60%) yielded durable responses and a favorable safety profile. Read the full article in Blood ICT: ashpublications.org/bloodict/article/2/1/100024/557343/Va…
-
Blood Journals Portfolio
@BloodPortfolio
Using a physiological-based approach, we find a ferritin threshold of 33 μg/L in both men and postmenopausal women, and 25 μg/L for premenopausal non-pregnant women for ID. Read in Blood RCI: ashpublications.org/bloodrci/article/2/1/100029/547478/Ph…
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
Happy National Doctors’ Day to all the physicians making a difference.
And a special thank you to hematologists for the work you do, the progress you drive, and the lives you impact every single day.
#nationaldoctorsday @ConquerSCD @BloodPortfolio @ASHCollab -
Blood Journals Portfolio
@BloodPortfolio
Outcomes of NPM1-mutated AML in Brazil are influenced by limited access to novel therapies and low transplantation rates. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100055/557316… #aml #brazil
-
Blood Journals Portfolio
@BloodPortfolio
"Evolution of multiple myeloma from a genomic perspective." Check out the review article in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20240… #mm #multiplemyeloma #bloodjournal
-
Blood Journals Portfolio
@BloodPortfolio
Outpatient low-dose VenAza combined with itraconazole reduced early mortality and hospitalizations while maintaining treatment efficacy. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100045/548068… #aml
-
Blood Journals Portfolio
@BloodPortfolio
Ketogenic diet improves colitis in CGD mice by reducing NLRP3 inflammasome activity, restoring immune balance, and altering the microbiome. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #cgd
-
Blood Journals Portfolio
@BloodPortfolio
Nivolumab monotherapy following CAR-T therapy failure in MM or NHL rarely leads to clinical responses. However, for a minority of patients with myeloma, nivolumab leads to remarkably durable responses likely driven by endogenous T cells. Read in Blood ICT: ashpublications.org/bloodict/article/2/1/100022/548235/Ni…
-
Blood Journals Portfolio
@BloodPortfolio
RBCs and their exosomes from old donors disrupt metabolic signaling, promote heme accumulation, and modulate neurobiological processes. Read in Blood RCI: ashpublications.org/bloodrci/article/2/1/100044/557317/Ag…
-
Blood Journals Portfolio
@BloodPortfolio
LDA influenced the predictive value of Doppler indices and may reduce placental dysfunction severity. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100062/566098… #scd #sicklecelldisease #pregnancy
-
Blood Journals Portfolio
@BloodPortfolio
DNA methylation matters: methylation of the γ-globin (HBG) gene promoters is required for postnatal silencing of HbF. Read the full article in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
HBM levels are elevated in some patients with alpha thalassemia likely because of compensation and could serve as a diagnostic biomarker. Read in Blood RCI: ashpublications.org/bloodrci/article/2/1/100043/557318/He…
-
Blood Journals Portfolio
@BloodPortfolio
Strong interest in AI, data analysis, and collaboration shows shift toward shared learning and innovation in hemoglobinopathy care. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100060/557521… #ai #bloodglobal
-
Blood Journals Portfolio reposted
Richard Godby
@RichGodby
Foundations of Systems-Based Hematology @BloodPortfolio
ashpublications.org/bloodadvances/article/10/6/2038/55700… -
Blood Journals Portfolio reposted
Daichi Inoue
@DaichiInoue5
Excited to share our latest work in @BloodPortfolio "Plenary Paper"! We present a comprehensive molecular and functional map of NUTM1-rearranged (NUTM1-r) leukemia. Why does this subtype show such favorable outcomes compared to KMT2A-r?
ashpublications.org/blood/article/doi/10.1182/blood.20240… -
Blood Journals Portfolio
@BloodPortfolio
Statin exposure during treatment with CD19-directed CAR-T for relapsed or refractory LBCL is associated with improved responses and survival. Read the full article in Blood ICT: ashpublications.org/bloodict/article/2/1/100021/548214/St…
-
Blood Journals Portfolio
@BloodPortfolio
New Blood Podcast episode featuring Drs. Alexander Bick and @jorgecortesmd, current EIC of Blood Global Hematology, interviewed by Blood editor Dr. Laura Michaelis. Learn more about their latest research on CH in children with #scd and Asciminib for #cml: bloodpodcast.transistor.fm/episodes/ch-in-children-with-s…
-
Blood Journals Portfolio
@BloodPortfolio
NUTM1 rearrangement in infant leukemia leads to unique transcriptomic and epigenetic landscapes, defining a distinct #leukemia subtype. Read the plenary paper in today's new issue of Blood: ashpublications.org/blood/article/doi/10.1182/blood.20240… #bloodjournal #plenarypaper
-
Blood Journals Portfolio
@BloodPortfolio
Normative modeling revealed males with SCD had reduced brain volumes vs controls, while females maintained normal volumes. Read the full article in Blood RCI: ashpublications.org/bloodrci/article/2/1/100036/547969/Se… #scd #sicklecelldisease
-
Blood Journals Portfolio reposted
Kiavasch Farid
@KFHemeOnc
Finally out in Blood Advances🎉 Our experience with Tabelecleucel in EBV+ lymphoproliferative diseases in DACH - check it out: ashpublications.org/bloodadvances/article/doi/10.1182/blo… 📷
Grateful for the collaboration 🙏
@BloodPortfolio @BloodAdvances -
Blood Journals Portfolio
@BloodPortfolio
Check out the study in Blood Advances: ashpublications.org/bloodadvances/article/10/4/1381/54845…
WCM Lymphoma
@WCMLymphoma
Dr. Jia Ruan led research evaluating triplet combination therapy for previously untreated mantle cell #lymphoma (MCL). She spoke with @OncLive about the key takeaways: www.onclive.com/view/acalabrutinib-based-triplets-yield-u… (cc: @BloodPortfolio)
-
Blood Journals Portfolio
@BloodPortfolio
Of 55 patients with indolent lymphoma enrolled 2013-2021 in Malawi, only 11 survived to December 2022; median overall survival was 15 months. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100050/548227… #indolentlymphoma #lymphoma #mawali
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood ICT out now featuring Varnimcabtagene autoleucel in relapsed or refractory B-cell malignancies, CAR T-cell therapy outcomes in plasma cell leukemia, and more. Explore here: ashpublications.org/bloodict/issue/2/1
-
Blood Journals Portfolio
@BloodPortfolio
CH affects most patients with CLL and is associated with neutropenia and RT. BAX- and U2AF1-mutated clones expand under venetoclax exposure but decline after fixed-duration treatment, indicating transient selection. Read in Blood: ashpublications.org/blood/article/147/12/1323/557450/The-… #ch #cll
-
Blood Journals Portfolio
@BloodPortfolio
Age >55 years was significantly associated with an increased prevalence of MGs, supporting age-targeted screening strategies. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100061/566097… #uruguay #bloodglobal
-
Blood Journals Portfolio
@BloodPortfolio
This new study in Blood Advances is the perfect way to continue celebrating Women's History Month and Bleeding Disorders Awareness Month! Read "The interplay of von Willebrand disease and women’s reproductive health" in BA: ashpublications.org/bloodadvances/article/doi/10.1182/blo… #vonwillebranddisease #bdam #whm
-
Blood Journals Portfolio
@BloodPortfolio
We're excited to announce the 2026 Blood Journals' Editorial Fellows! Learn more about them: www.linkedin.com/feed/update/urn:li:activity:744049490414…
-
Blood Journals Portfolio
@BloodPortfolio
Earlier infusion time of CAR T-cell therapy was independently associated with improved PFS in large B-cell lymphoma. Read in Blood: ashpublications.org/blood/article/147/12/1315/557451/Time…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Advances out now! Featuring Advancing systems-based hematology, A new era for heavy menstrual bleeding, The interplay of von Willebrand disease and women’s reproductive health, and more. Explore here: ashpublications.org/bloodadvances/issue/10/6 #bloodadvances
-
Blood Journals Portfolio reposted
Eduardo Rodríguez Arbolí
@ArboliEduardo
Late outcomes after posttransplant cyclophosphamide–based GVHD prophylaxis in patients with AML: an ALWP-EBMT study @BloodPortfolio @Bloodneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
A mouse model of transfusion provides a relevant platform to identify new biomarkers for antidoping purposes. Quantifying SME is a promising biomarker to detect ABT in athletes. Read in Blood RCI: ashpublications.org/bloodrci/article/2/1/100040/548176/Mo…
-
Blood Journals Portfolio
@BloodPortfolio
An important study in observance of #dvt Awareness Month! It concluded that Dasatinib, ponatinib, and nilotinib damage ECs in different ways, all of which can contribute to #arterialthrombosis. Read the full article in Blood VTH: ashpublications.org/bloodvth/article/3/1/100127/548232/Di… #bloodvth
-
Blood Journals Portfolio
@BloodPortfolio
Global MM incidence in AYA increased 60% (1990-2021), with males experiencing 43% higher rates and widening health inequalities. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100063/566099… #multiplemyeloma
-
Blood Journals Portfolio
@BloodPortfolio
Check out the full study, "Self-reinforcing IL-1b signaling accelerates the development and recurrence of TCF3::HLF-positive B-ALL" in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
Tokyo University of Science (TUS)
@TUS_PR_en
TUS researchers have discovered an inflammatory feedback mechanism in an aggressive type of pediatric leukemia that causes bone loss, as reported in @BloodPortfolio.
-
Blood Journals Portfolio reposted
HemOnc Today
@HemOncToday
6️⃣0️⃣% of physicians who treat #sicklecelldisease report #burnout, per data in @BloodAdvances.
Systemic health care system factors, not individual internal factors, likely are the cause, researchers concluded. vist.ly/4vts4 -
Blood Journals Portfolio
@BloodPortfolio
"Hemoglobin A2 levels in Indian patients with sickle cell disease reveal heterozygosity" Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100059/557436… #scd #sicklecelldisease
-
Blood Journals Portfolio
@BloodPortfolio
Patients with low-risk disease can successfully be treated without novel therapeutics and with limited RT in just 8 weeks. Check out this month's CME-accredited article in Blood: ashpublications.org/blood/article/147/12/1289/565989/Dose… #chemotherapy #bloodjournal #hodgkinlymphoma
-
Blood Journals Portfolio
@BloodPortfolio
"The role of hemoglobin F in sickle cell disease complications: a descriptive secondary analysis" Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100114/547656/Th… #scd #sicklecelldisease #hemoglobinf
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
This Bleeding Disorders Awareness Month, ASH recognizes everyone impacted by bleeding disorders and the clinicians and researchers working toward better care. Continued research is essential to improving outcomes and expanding treatment options.
#bleedingdisordersawarenessmonth -
Blood Journals Portfolio
@BloodPortfolio
Shout out to the 2025 Hematology Education Book!
𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM
@nihardesai89
Excellent review in @ASH_hematology education book by my @pmcancercentre colleague and friend, @Ruah_Mahmoud 🙌🏽
Here is the estimated incidence of thrombosis in heme malignancies 👇🏽
#medtwitter -
Blood Journals Portfolio
@BloodPortfolio
The beneficial effect of hypoxic storage on red cell function can be monitored using FlowScore, a flow cytometric surrogate of cell shape. Read the full article in Blood RCI: ashpublications.org/bloodrci/article/2/1/100038/548138/St…
-
Blood Journals Portfolio
@BloodPortfolio
Elevated VWF with normal ADAMTS13 levels observed in VOC and ischemic stroke in pediatric #scd, accompanied with inflammation and #hemolysis. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100124/547956/El… #pediatricscd
-
Blood Journals Portfolio
@BloodPortfolio
Distinct gene–phenotype correlations and treatment outcomes were identified among 1077 patients with DBA, despite considerable overlap. Read in Blood RCI: ashpublications.org/bloodrci/article/2/1/100053/565972/Ex… #dba #bloodrci
-
Blood Journals Portfolio
@BloodPortfolio
The 100-day #vte incidence rate by manual chart review and our institutional NLP was 10.3% and 8.8%, respectively. The sensitivity, specificity, PPV, and NPV of the NLP were ≥85% when considering all VTE events. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100122/547955/Au…
-
Blood Journals Portfolio
@BloodPortfolio
A multicenter retrospective study from Argentina shows the clinical management and limitations of CNS prophylaxis in patients with DLBCL. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100047/548067… #argentina #dlbcl
-
Blood Journals Portfolio
@BloodPortfolio
Readily available risk factors, some of which could be considered modifiable, are associated with anticoagulant-related bleeding in cancer. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100116/547657/Ri…
-
Blood Journals Portfolio
@BloodPortfolio
"Integrated genetic analyses identified T-cell neoplasms other than adult T-cell leukemia/lymphoma in HTLV-1 carriers" Read in Blood Advances: ashpublications.org/bloodadvances/article/10/5/1670/55744…
-
Blood Journals Portfolio
@BloodPortfolio
Tailored infectious screening, including endemic pathogens, is critical in CAR-T candidates in endemic areas. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100046/548066… #cartcell #bloodglobal
-
Blood Journals Portfolio
@BloodPortfolio
New episode of Blood Podcast out now! Emerging Mechanisms: Neutrophils and ICI from Immune thrombocytopenia. Have a listen: bloodpodcast.transistor.fm/episodes/emerging-mechanisms-n… #bloodjournal #bloodpodcast
-
Blood Journals Portfolio
@BloodPortfolio
Disruption of pathogenic VWF alleles in the ECFCs from heterozygous patients with VWD leads to a healthy VWF phenotype in vitro. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/5/1429/55739…
-
Blood Journals Portfolio
@BloodPortfolio
In continued observance of Bleeding Disorders Awareness Month, we're highlighting an important article from Blood Advances on the treatment of von Willebrand Disease. ashpublications.org/bloodadvances/article/10/3/794/548108…
#vonwillebranddisease #bdam #bloodadvances -
Blood Journals Portfolio reposted
Khushali Jhaveri
@JhaveriKhushali
In lymphoma, progress feels rapid.
Yet only ~6% of drugs entering phase I reach approval —> most lost before phase III 💊
As a junior faculty member, that’s a sobering reality.
Important paper in Blood Advances — ashpublications.org/bloodadvances/article/10/5/1713/54811…
#lymsm #hemonc -
Blood Journals Portfolio
@BloodPortfolio
Thrombotic patients with COVID-19 show enhanced neutrophil activation and suppressed lymphocytes, revealing immune dysregulations. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100137/565861/Ex… #covid19
-
Blood Journals Portfolio
@BloodPortfolio
Hematologic malignancies in the #saarc region pose a growing burden, with incidence and mortality varying across countries. Read in Blood Global: ashpublications.org/bloodglobal/article/2/1/100036/547862… #hematologiccancers #bloodcancer
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood RCI out now! Featuring Long-distance trail running induces inflammation-associated protein, lipid, and purine oxidation in red blood cells, Sex-specific brain morphology differences in pediatric sickle cell disease, and more. Explore here:
-
Blood Journals Portfolio
@BloodPortfolio
TD curcumin gel can protect mitochondrial proteome and bioenergetic functions from oxidative stress in BERK-SS mouse heart. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100131/548492/A-…
-
Blood Journals Portfolio
@BloodPortfolio
We're pleased to share the ASH Consortium on Newborn Screening in Africa, recently published in Blood Advances. Through CONSA, ~175,000 infants in sub-Saharan Africa have been screened, documenting a high incidence of #scd and trait. Read here: ashpublications.org/bloodadvances/article/doi/10.1182/blo…
-
Blood Journals Portfolio
@BloodPortfolio
In honor of Blood's 80th anniversary, we're looking back at all the past Editors-in-Chief. Check out our feature on the sixth ever EIC, Dr. Arthur Nienhuis: www.linkedin.com/feed/update/urn:li:activity:744005826454…
-
Blood Journals Portfolio
@BloodPortfolio
One-time genotyping revealed necessary, hitherto unrecognized, restrictions in 20% of patients and led to the ease of red cell allocation in 29%. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100065/566123… #redcellgenotyping #thalassemia #bloodglobal
-
Blood Journals Portfolio
@BloodPortfolio
Megakaryocytes are reprogrammed during CKD progression, leading to the production of dysfunctional platelets. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/5/1444/55738…
-
Blood Journals Portfolio
@BloodPortfolio
Young age, male sex, and #thrombocytopenia are associated with nonspecific PFD in children. WBILA can be used to rule out #pfd in children. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100135/557331/Di…
-
Blood Journals Portfolio
@BloodPortfolio
Findings will advance the field and can form the basis of a framework that informs the optimal implementation of recommendations. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100056/565883… #mm #multiplemyeloma
-
Blood Journals Portfolio
@BloodPortfolio
Cytoplasmic cleaved #gsdmd in live activated macrophages and #dlbcl cells marks cognate interactions and predicts better patient survival. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/5/1756/55694… #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
An important study in observance of #dvt Awareness Month! "Targeting FXR in hepatocytes: a promising approach to enhance fibrinolysis and reduce DVT risk." Learn how FXR plays a novel role in regulating DVT, linking metabolism to thrombus formation: ashpublications.org/blood/article/146/20/2464/546905/Targ…
-
Blood Journals Portfolio
@BloodPortfolio
MT mutations are associated with the development of AIC. Rare variants in MT gene are associated with AIC and lower immunoglobulin G levels. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100109/547482/Mu…
-
Blood Journals Portfolio
@BloodPortfolio
Deleterious germ line mutations in IKAROS can cause immunodeficiency and leukemia; functional validation is critical to assign causality. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/5/1522/55727…
-
Blood Journals Portfolio
@BloodPortfolio
HPX gene transfer using a viral vector can increase HPX expression in an animal model of sickle cell disease, without causing toxicity. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100115/547864/Su… #scd #sicklecelldisease #anemia #sicklecellanemia
-
Blood Journals Portfolio
@BloodPortfolio
"A novel palmitoylethanolamide formulation improves hyperalgesia and red cell instability in murine sickle cell disease" Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100136/565860/A-… #bloodvth #scd #sicklecelldisease
-
Blood Journals Portfolio
@BloodPortfolio
Cascade screening efficiently identifies #thalassemia carriers, but uptake remains low despite counseling. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/doi/10.1016/j.bgl…
-
Blood Journals Portfolio
@BloodPortfolio
TM-induced inhibition of ETP <20% (R-ETP/TM) is common in patients with unprovoked VTE. Identifiable risk factors for R-ETP/TM have insufficient predicting performances and require further investigations. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100117/547655/Hi… #vte #bloodvth
-
Blood Journals Portfolio
@BloodPortfolio
High kynurenine levels stimulate AHR-TF axis in microvasculature of patients with COVID-19, which is a pharmacologically targetable pathway. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100128/565862/Tr…
-
Blood Journals Portfolio reposted
Christopher Heery MD
@ChrisHeery
Congrats to @LMikkMD and team. Incredible scientific effort. It’s what we’ve come to expect from @theNCI clinical fellows! ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
Tracing the origin of sickle cell disease back to 50 000 years. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100041/547948… #scd #sicklecelldisease #sicklecell
-
Blood Journals Portfolio
@BloodPortfolio
First-line treatment with IV iron results in greater QALYs than oral iron across the reproductive lifetime. Treatment with IV iron dextran is cost-effective compared with treatment with IV iron sucrose, IV ferumoxytol, and oral ferrous sulfate. ashpublications.org/bloodadvances/article/10/5/1508/56589… #anemia
-
Blood Journals Portfolio reposted
Cell Therapy News
@celltherapynews
Led by @Penn scientists, this #openaccess study published in @BloodPortfolio explores the efficacy and specificity of CCR4-directed CARTs by characterizing #treg depletion in human malignant pleural effusions and tumor digests ex vivo. 🥼
🔓 ashpublications.org/bloodadvances/article/10/5/1646/55721… -
Blood Journals Portfolio
@BloodPortfolio
Exciting news for the hematology community! We’re proud to share that Blood Immunology & Cellular Therapy is now indexed in the Directory of Open Access Journals @DOAJplus 🥳 #bloodict #doaj #hematologyresearch
-
Blood Journals Portfolio
@BloodPortfolio
New episode of the Blood Podcast out now: bloodpodcast.transistor.fm/episodes/hepcidin-dmt1-interac… #mm #multiplemyeloma #bloodpodcast #bloodjournal
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now! Featuring Orca-T to prevent GVHD, Gene expression profiling in ALCL, VEXAS Syndrome-associated anemia, and more. Explore here: ashpublications.org/blood/issue/147/11
-
Blood Journals Portfolio
@BloodPortfolio
Overcoming these barriers requires innovation, investment, and local solutions. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100051/548229… #cartcell #bloodglobal
-
Blood Journals Portfolio
@BloodPortfolio
47% of sickle cell physicians strongly agreed that they felt a sense of pride in their job (distinct from fulfillment in one’s profession), compared to 65% of their colleagues. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/doi/10.1182/blo… #scd #bloodadvances #pressrelease
ASH
@ASH_hematology
New research in Blood Advances found that 60% of hematology-oncology physicians who treat SCD reported burnout. Learn more: www.hematology.org/news-and-media/press-releases/2026/hig…
@BloodPortfolio @vale_restrepo1 @SmilowCancer -
Blood Journals Portfolio
@BloodPortfolio
Check out the study in Blood Advances: ashpublications.org/bloodadvances/article/10/4/1348/55721…
Targeted Onc
@TargetedOnc
🔬 A validated analysis of nearly 22,000 patients receiving allogeneic hematopoietic cell transplant led to development of a risk calculator for acute graft-vs-host disease. #gvhd www.targetedonc.com/view/validated-risk-score-may-help-fo…
-
Blood Journals Portfolio
@BloodPortfolio
PPM1D mutations dominate t-CH/t-CCUS, show the shortest latency after genotoxic therapy, and are enriched in this subgroup. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/5/1746/56588…
-
Blood Journals Portfolio
@BloodPortfolio
In observance of Bleeding Disorders Awareness Month, we'll be sharing relevant articles throughout March. Our first pick highlights the Brazilian experience with a public policy, published in the latest issue of Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100052/548228… #bdam #brazil
-
Blood Journals Portfolio
@BloodPortfolio
CD22 CAR T cells demonstrated efficacy in relapsed/refractory B-cell acute lymphoblastic leukemia, regardless of disease burden. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/5/1700/55738…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Global Hematology out now! Featuring Gap in hematologic cancer burden analysis across South Asia, A growing global burden of multiple myeloma in young adults, CAR-T in resource-limited regions, and more. ashpublications.org/bloodglobal/issue/2/1
-
Blood Journals Portfolio
@BloodPortfolio
In honor of Blood's 80th anniversary, we're taking a look back at all the past Editors-in-Chief. Today, we're highlighting Dr. John Adamson, the fifth EIC of Blood. Learn more about him and his career:
www.linkedin.com/feed/update/urn:li:activity:743750424447… -
Blood Journals Portfolio
@BloodPortfolio
IFN-γ and IFN-β enhance δ-globin expression in erythroid cells, suggesting an approach to treating β-hemoglobinopathies. Inhibition of JAK/STAT signaling reduces both basal and IFN-γ–mediated δ-globin expression. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
Check out the study in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/1/100176/547…
Blood Cancers Today
@Blood_Cancers
Tisa-cel in combination with ibrutinib is a safe and feasible treatment for adult patients with relapsed or refractory large B-cell #lymphomas, according to a study published in @BloodPortfolio by @JulioChavezMD of @MoffittNews, and colleagues.
➡️ www.bloodcancerstoday.com/post/tisa-cel-plus-ibrutinib-a-… -
Blood Journals Portfolio
@BloodPortfolio
FVIII potentiates procoagulant platelet activity by thrombin-independent signaling involving integrin αIIbβ3 and glycoprotein VI. rFVIII products modified to extend the half-life show reduced binding to proaggregatory #platelets. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100132/557221/rF…
-
Blood Journals Portfolio
@BloodPortfolio
Did you know we have 8 newsletters? Whatever your specialty is within #hematology, we have the publication for you. Visit our subscription center, sign into your ASH account, and subscribe to some or all of our newsletters. That's brand new research, directly to your inbox! 📧
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Advances out now! Featuring Emerging from the shadows of congenital TTP, Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia, and more. Explore: ashpublications.org/bloodadvances/issue/10/5 #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
MRD-guided azacitidine therapy can effectively prevent or delay relapse in MDS/AML. Over half of initial responders stayed relapse-free for ≥2 years after treatment. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #mrd #mds #aml
-
Blood Journals Portfolio
@BloodPortfolio
miR-126 enhances BCL-2 signaling to sustain FAO/OXPHOS and mitofusion, promoting metabolic homeostasis and leukemogenic activity in AML LSCs. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #aml #bloodjournal
-
Blood Journals Portfolio
@BloodPortfolio
March is Deep Vein Thrombosis Awareness Month and we'll be sharing relevant articles in observance. Today's is "D-dimer after 3 months of anticoagulation therapy and outcomes in cancer-associated isolated distal deep vein thrombosis" from Blood VTH: ashpublications.org/bloodvth/article/2/2/100063/535729/D-… #dvt
-
Blood Journals Portfolio
@BloodPortfolio
Alpelisib shows benefit across a broad spectrum of VAs, including those without confirmed PIK3CA mutations or PROS diagnoses. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100133/548386/Al…
-
Blood Journals Portfolio
@BloodPortfolio
Happy #iwd! In honor of this and #womenshistorymonth, we're pleased to share ASH's maternal healthcare resources. This collection of articles, guidelines, and policy statements covers a wide array of hematological topics relating to maternal health: www.hematology.org/initiatives/excellence-and-inclusion/m…
-
Blood Journals Portfolio
@BloodPortfolio
PD-1 blockade given before ASCT is associated with superior post-ASCT outcomes in R/R cHL. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
"Inflammatory cytokines, inflammasomes, and neutrophil extracellular traps in primary immune thrombocytopenia pathogenesis" Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100129/548271/In…
-
Blood Journals Portfolio
@BloodPortfolio
Although GPRC5D is highly expressed on tumor PCs and less on normal PCs, BCMA is detectable throughout the B-cell lineage. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
A higher GTL ratio improves daratumumab response and prolongs progression-free survival in patients with MM. BM-derived granulocytes are involved in the therapeutic activity of daratumumab. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/1/100174/547… #multiplemyeloma #bonemarrow
-
Blood Journals Portfolio
@BloodPortfolio
TCR outperforms a CD22 CAR in targeting CD22low cells, which may also emerge in vivo after CD19 or CD22 CAR T-cell treatment. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
Dasatinib, ponatinib, and nilotinib damage ECs in different ways, all of which can contribute to arterial #thrombosis. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100127/548232/Di…
-
Blood Journals Portfolio reposted
Jorge Cortes MD
@jorgecortesmd
Congratulations to my new colleague Luciano Costa @End_myeloma from @uabmedicine @ONealCancerUAB on the approval of teclistamab combined with daratumumab for R/R myeloma based on MajesTEC-3 presented at @ASH_hematology 2025 @icmlf @BloodPortfolio www.fda.gov/drugs/resources-information-approved-drugs/fd…
-
Blood Journals Portfolio
@BloodPortfolio
Patients with relAML have distinct transcriptomes potentially regulated by a core group of transcriptional coregulators (LMO2-LDB1-TAL1). Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/1/100186/548…
-
Blood Journals Portfolio
@BloodPortfolio
For fit patients with AML aged >60 y without known adverse-risk cytogenetics, we randomized DA chemotherapy plus gemtuzumab against CPX-351. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #aml #bloodjournal
-
Blood Journals Portfolio
@BloodPortfolio
🎙️ New episode of Blood Podcast out now! PETAL Consortium Survival Prognosticators and How Inflammation Impacts Hematopoiesis. Have a listen: bloodpodcast.transistor.fm/episodes/petal-consortium-surv…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now! Featuring Tuning mitochondrial fate to disarm leukemic stem cells, Pretransplant promise for PD-1 in Hodgkin lymphoma, Hemophagocytic lymphohistiocytosis in adults, and more. Explore here: ashpublications.org/blood/issue/147/10 #bloodjournal
-
Blood Journals Portfolio
@BloodPortfolio
Reticulated #platelets increase after myocardial ischemia/reperfusion injury with enhanced activation and distinct transcriptional profile. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100125/547959/A-…
-
Blood Journals Portfolio
@BloodPortfolio
"From oversight to insight: the curious case of the endothelial insulin receptor" Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100123/547958/Fr… #insulin #insulinreceptor #insulinsensitivity
-
Blood Journals Portfolio
@BloodPortfolio
In honor of Blood's 80th anniversary, we're looking back at all the past Editors-in-Chief. Today we're highlighting the fourth ever EIC, Dr. Paul Marks. Learn more about him and his career from @Columbia to @MSKCancerCenter: www.linkedin.com/feed/update/urn:li:activity:743502839297…
-
Blood Journals Portfolio
@BloodPortfolio
APA is associated with LM gain with significant improvement in all physical tests. It's more efficient in case of shorter neutropenia or younger age. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/1/100183/548…
-
Blood Journals Portfolio
@BloodPortfolio
Editor-in-Chief of Blood, Dr. Andrew Roberts, speaking at #ndlr2026 for today's meet the editor session sponsored by @EHA_Hematology and @Hemasphere_EHA. Thanks to all who joined him in Adelaide. #bloodjournal
-
Blood Journals Portfolio
@BloodPortfolio
Ex vivo stored platelet-rich plasma undergoes profound changes once transfused into an in vivo environment regardless of temperature. Cold-stored platelets aggregate more at the site of injury, whereas room-temperature platelets cause more fibrin formation ashpublications.org/bloodvth/article/3/1/100120/547957/Tr…
-
Blood Journals Portfolio
@BloodPortfolio
The French STIM1 study significantly contributes to understanding treatment-free remission in CML, clarifying its long-term survival implications. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/1/100177/547… #cml
-
Blood Journals Portfolio
@BloodPortfolio
Check out our 2026 Guidelines on Diagnosis of Light Chain Amyloidosis in Blood Advances: ashpublications.org/bloodadvances/article/doi/10.1182/blo… #lightchainamyloidosis #bloodadvances #clinicalguidelines
Hematology Advisor
@HematologyAdv
A new guideline for the diagnosis of #lightchainamyloidosis was published by @BloodPortfolio.
www.hematologyadvisor.com/news/ash-clinical-practice-guid… -
Blood Journals Portfolio
@BloodPortfolio
Hemophilia A dogs treated with intraosseous infusions of platelet-specific FVIII LVs achieved partial phenotypic correction. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100119/547892/Tr…
-
Blood Journals Portfolio
@BloodPortfolio
Dapolsertib (MEN1703) is a dual kinase inhibitor of proviral integration site for PIM and FLT3 kinases. It has a manageable safety profile and activity in a phase 1/2 study in patients with AML. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/1/100178/547…
-
Blood Journals Portfolio reposted
Kate Cwynarski
@CwynKate
Advancing the classification of hematolymphoid neoplasms together: for patients, medicine, and science
@BloodPortfolio
American Society of Hematology ashpublications.org/blood/article/147/9/915/557589/Advanc… -
Blood Journals Portfolio
@BloodPortfolio
R788 treatment reduced splenomegaly in Townes sickle mice but suppressed hematopoiesis leading to #neutropenia and worsened #anemia. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100118/547821/Th… #bloodvth #sicklecell
-
Blood Journals Portfolio
@BloodPortfolio
Single-cell proteogenomic analysis of AML PDX models offers the potential to study clonal evolution in response to different therapies. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/1/100182/548…
-
Blood Journals Portfolio
@BloodPortfolio
ANKRD26 VUSs complicate risk assessment in hematologic malignancy and may extend beyond the known pathogenic hot spot. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100113/547585/Li…
-
Blood Journals Portfolio
@BloodPortfolio
Reclassifying patients treated from 2017 to 2022 according to ELN 2010 confirmed improved survival in IR patients without treatment bias. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/1/100181/548…
-
Blood Journals Portfolio
@BloodPortfolio
The combination of MEZI with BTZ increases cell death through disruption of the cell cycle. The combination of MEZI/BTZ/DEX demonstrates superior efficacy compared with POM/BTZ/DEX in the preclinical setting. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/1/100179/548…
-
Blood Journals Portfolio
@BloodPortfolio
Anticoagulation improved QOL, pain & D-dimer levels in patients with slow-flow vascular malformations. Minor bleeding events, particularly heavy menstrual bleeding, occurred in 24% of patients, highlighting the importance of monitoring. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100112/547584/Im…
-
Blood Journals Portfolio
@BloodPortfolio
🎙️ New episode of Blood Podcast out now! Review Series on the Structural Underpinnings of Hemostatic Plugs and Thrombotic Occulsions. Have a listen: bloodpodcast.transistor.fm/episodes/review-series-on-the-… #reviewseries #bloodjournal #bloodpodcast
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now! Featuring Platelet defects in Ehlers-Danlos syndrome, CD38+ monocytes fuel fibrosis in myeloproliferative neoplasm, p27Kip1 regulates γ-globin production, and more. Explore here: ashpublications.org/blood/issue/147/9
-
Blood Journals Portfolio
@BloodPortfolio
Mitochondrial ARG2 regulates arginine availability, nitric oxide levels, and fatty acid metabolism. It is a key regulator of hematopoietic and cardiovascular responses to acute and chronic hypoxia. Read in Blood VTH: ashpublications.org/bloodvth/article/3/1/100110/547583/Mi…
-
Blood Journals Portfolio
@BloodPortfolio
We're proud of this crew, featuring Blood Advances founding Editor-in-Chief and ASH President Dr. Negrin, past Blood EIC & ASH President elect Dr. Dunbar, and the Government Affairs Committee for advocating in support of hematology research today on Capitol Hill.
ASH
@ASH_hematology
The government affairs committee is at capitol hill today to #fight4hematology
-
Blood Journals Portfolio
@BloodPortfolio
We're so glad this Tatyana was able to find a cure. Check out the research, published in Blood Advances: ashpublications.org/bloodadvances/article/doi/10.1182/blo… #scd #sicklecelldisease #sicklecellanemia #bonemarrowtransplant #bloodadvances
TODAY
@TODAYshow
A different kind of bone marrow transplant changed Tatyana Thompson's life. www.today.com/health/disease/mom-sickle-cell-cure-half-ma…
-
Blood Journals Portfolio
@BloodPortfolio
CH may occur before the clinical diagnosis of AA by several years, particularly in those with SRSF2, TET2, ASXL1, and DNMT3A mutations. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/4/1293/54848…
-
Blood Journals Portfolio
@BloodPortfolio
Patients with previous exposure to ibrutinib had greater CAR T-cell expansion, CAR-toxicity, and effector-polarized CAR T cells. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/4/1023/55700…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood VTH out now! Featuring Impact of anticoagulation on quality of life in patients with slow-flow vascular malformations, From oversight to insight: the curious case of the endothelial insulin receptor, and more. Explore here ➡️ ashpublications.org/bloodvth/issue/3/1
-
Blood Journals Portfolio
@BloodPortfolio
CD8MMR integrates pretreatment tumor immunity into risk stratification for patients with DLBCL. Low CD8MMR is linked to poor survival and adds prognostic value beyond IPI and cell of origin in DLBCL. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/1/100180/548…
-
Blood Journals Portfolio
@BloodPortfolio
Today, we're celebrating 80 years of Blood by highlighting our third ever Editor-in-Chief. Dr. Ernst Jaffé was a hematologist who helped reveal the workings of a hereditary disorder that impairs red blood cells’ ability to transport oxygen. Learn more: www.linkedin.com/feed/update/urn:li:activity:743244071619…
-
Blood Journals Portfolio reposted
ScienceAlert
@ScienceAlert
Pushing to the limit.
www.sciencealert.com?p=193142 -
Blood Journals Portfolio
@BloodPortfolio
We're pleased to introduce a new Associate Editor for Blood! Dr. Ellis Neufeld is EVP, Clinical Director, Physician-in-Chief, and John and Lorine Thrasher Endowed Chair in Pediatric Medicine at @StJude @StJudeResearch Children's Hospital. Join us in welcoming him to the team.
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Advances! Featuring The TCXpress lane to T-cell receptor–engineered T cells, Platelet Rubicon drives thrombosis independent of autophagy, Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years, and more. ashpublications.org/bloodadvances/issue/10/4
-
Blood Journals Portfolio
@BloodPortfolio
Itacitinib improved constitutional symptoms in patients with T-PLL and resulted in encouraging response and survival outcomes with CAMPATH. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/1/100175/547…
-
Blood Journals Portfolio
@BloodPortfolio
Ibrutinib administration in combination with tisagenlecleucel was feasible and well tolerated by patients. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/1/100176/547…
-
Blood Journals Portfolio
@BloodPortfolio
Increased hemolysis is associated with thrombocytopenia and molecular signatures of programmed cell death in platelets during vivax malaria. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/3/575/547846…
-
Blood Journals Portfolio
@BloodPortfolio
Happening tomorrow! 👀 Save your spot below #journalclub
ASH
@ASH_hematology
On Tuesday, join the ASH Journal Club for insights on applying #ai to allogeneic transplantation donor selection.
Save your spot: academy.hematology.org/local/catalog/view/product.php?pro…{
@BloodPortfolio @RShouval @nmdp_org #medtwitter #ashtrainee -
Blood Journals Portfolio reposted
Waggoner Lab
@LabWaggoner
Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation @CincyResearch @BloodPortfolio
ashpublications.org/blood/article/doi/10.1182/blood.20250… -
Blood Journals Portfolio
@BloodPortfolio
SKIDA1 sustains MLL::ENL-expressing neonatal HSCs and multipotent progenitor cells and promotes B-cell lineage priming. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/1/100185/548…
-
Blood Journals Portfolio
@BloodPortfolio
Impairing lipid detoxification via inhibition of DGAT1-mediated lipid droplet formation synergizes with metformin treatment. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/3/733/548006… #metformin #bloodadvances #aml
-
Blood Journals Portfolio
@BloodPortfolio
Patient-derived iPSC models of KMT2A-rearranged AML reveal transcriptional rewiring of HSPCs driven by Polycomb-mediated silencing. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/1/100172/547… #aml #bloodneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
Targeting R-loop formation and the cGAS-STING axis attenuates leukemogenesis linked to SRSF2 mutations in zebrafish and human blood stem cells. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/3/710/556941…
-
Blood Journals Portfolio
@BloodPortfolio
The addition of GO to standard-of-care cytarabine, anthracycline, and midostaurin induction was well tolerated in ND FLT3–mutated AML. Read in Blood Neoplasia: ashpublications.org/bloodneoplasia/article/3/1/100171/547… #aml #bloodneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
PCDLBCL-LT polarizes macrophages toward an immunosuppressive phenotype and function through a pivotal IL-10 secretion. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/3/850/557100…
-
Blood Journals Portfolio
@BloodPortfolio
RBCs and their exosomes from old donors disrupt metabolic signaling, promote heme accumulation, and modulate neurobiological processes. Read in Blood RCI: ashpublications.org/bloodrci/article/2/1/100044/557317/Ag…
-
Blood Journals Portfolio
@BloodPortfolio
🎙️ New episode of Blood Podcast out now: VTE Risk Model in Children and a Novel Tri-specific T-cell-engager for MM. Have a listen bloodpodcast.transistor.fm/episodes/vte-risk-model-in-c
-
Blood Journals Portfolio
@BloodPortfolio
HBM levels are elevated in some patients with alpha thalassemia likely because of compensation and could serve as a diagnostic biomarker. Read in Blood RCI: ashpublications.org/bloodrci/article/2/1/100043/557318/He…
-
Blood Journals Portfolio
@BloodPortfolio
CCL22 mutations improve diagnostic accuracy in NK-LGLL. Updated criteria reduce the number of unclassified NK cell expansion. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/3/642/548034…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Neoplasia out now! Explore here: ashpublications.org/bloodneoplasia/issue/3/1 #bloodneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
Urinary CA1 excretion detects intravascular hemolysis across diverse conditions. A lateral flow device testing urine for CA1 enables rapid detection of hemolysis in resource-limited settings. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100058/557437…
-
Blood Journals Portfolio reposted
New Scientist
@newscientist
Running 170 kilometres over mountainous terrain caused people's red blood cells to accumulate more age-related damage than those of less ambitious athletes www.newscientist.com/article/2516226-ultramarathons-could…
-
Blood Journals Portfolio
@BloodPortfolio
A mouse model of transfusion provides a relevant platform to identify new biomarkers for antidoping purposes. Quantifying SME is a promising biomarker to detect ABT in athletes. Read in Blood RCI: ashpublications.org/bloodrci/article/2/1/100040/548176/Mo…
-
Blood Journals Portfolio
@BloodPortfolio
'Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing' read in Blood Advances: ashpublications.org/bloodadvances/article/10/3/821/548294…
-
Blood Journals Portfolio
@BloodPortfolio
Ultra-running accelerates RBC aging via inflammation, IL-6, kynurenine, oxidation, and copper. Check out this new study, that's already making waves, recently published in Blood RCI: ashpublications.org/bloodrci/article/doi/10.1016/j.brci.2…
ASH
@ASH_hematology
Can extreme endurance running change how red blood cells function? 🏃♀️🩸
New research published in Blood Red Cells & Iron suggests that ultra endurance races may damage red blood cells and reduce their flexibility.
Learn more: www.hematology.org/news-and-media/press-releases/2026/ult…
@BloodPortfolio @CUAnschutz -
Blood Journals Portfolio
@BloodPortfolio
Outcomes of NPM1-mutated AML in Brazil are influenced by limited access to novel therapies and low transplantation rates. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100055/557316…
-
Blood Journals Portfolio
@BloodPortfolio
We're excited to welcome Dr. Nelson Chao as a new Associate Editor of Blood! He started on January 1st and is already such a valuable addition. Learn more: www.linkedin.com/feed/update/urn:li:activity:742961519348…
-
Blood Journals Portfolio
@BloodPortfolio
The beneficial effect of hypoxic storage on red cell function can be monitored using FlowScore, a flow cytometric surrogate of cell shape. Read in Blood RCI: ashpublications.org/bloodrci/article/2/1/100038/548138/St…
-
Blood Journals Portfolio
@BloodPortfolio
Heterozygous LCP1 variants cause immunodeficiency characterized by neutropenia, monocytopenia, lymphopenia, and tetraploid hematopoiesis. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/3/627/547627…
-
Blood Journals Portfolio
@BloodPortfolio
Implementation of a public policy in inherited bleeding disorders in a less-resourced country: the Brazilian experience. Read in Blood Global Hematology ➡️ ashpublications.org/bloodglobal/article/2/1/100052/548228…
-
Blood Journals Portfolio
@BloodPortfolio
Normative modeling revealed males with SCD had reduced brain volumes vs controls, while females maintained normal volumes. Read in Blood RCI: ashpublications.org/bloodrci/article/2/1/100036/547969/Se… #scd #sicklecelldisease #bloodrci
-
Blood Journals Portfolio
@BloodPortfolio
Standardized ED pain protocols with INF improve time to first analgesia dose in pediatric patients with SCD pain. Protocol implementation was associated with a reduction in hospital pain admission rates. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/3/802/547925… #scd #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Findings support including B-leader status in haploidentical donor selection in Latin America. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100048/548136…
-
Blood Journals Portfolio
@BloodPortfolio
Free heme from hemolysis disrupts endothelial–astrocyte coupling, causing neuroaxonal damage and cognitive decline. Heme triggers pTau that reactivates astrocytes and mediates neurocognitive impairment in SCD. Read in Blood RCI: ashpublications.org/bloodrci/article/2/1/100041/548137/He… #scd
-
Blood Journals Portfolio
@BloodPortfolio
UBE2O downregulation reduces erythroid differentiation capability in human umbilical cord blood–derived erythroid progenitor 2 cell line. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/3/782/548029…
-
Blood Journals Portfolio
@BloodPortfolio
Older patients with AML treated with intensive chemotherapy in Brazil experience a high early death rate and low overall survival. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100057/557438… #aml
-
Blood Journals Portfolio
@BloodPortfolio
The addition of quizartinib to induction chemotherapy results in deeper remissions. FLT3-ITD MRD after induction treatment correlates with relapse and survival. Read in Blood Advances: ashpublications.org/bloodadvances/article/doi/10.1182/blo…
-
Blood Journals Portfolio
@BloodPortfolio
Various CAR designs were evaluated for allogeneic CAR-NKT cells in treating solid tumors to identify optimal antitumor efficacy. Read in Blood ICT: ashpublications.org/bloodict/article/2/1/100025/557344/En…
-
Blood Journals Portfolio
@BloodPortfolio
Outpatient low-dose VenAza combined with itraconazole reduced early mortality and hospitalizations while maintaining treatment efficacy. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100045/548068…
-
Blood Journals Portfolio
@BloodPortfolio
Want to amplify your research? Submit to the Blood Journals Portfolio—renowned across hematology for rapid publication, global reach, and trusted impact! 🩸 Learn more about submitting to our 7 journals: ashpublications.org/journals/pages/publish
-
Blood Journals Portfolio
@BloodPortfolio
Varnim-cel is a novel autologous CD19-directed CAR T-cell therapy with a murine A3B1 binder. Read in Blood ICT: ashpublications.org/bloodict/article/2/1/100024/557343/Va…
-
Blood Journals Portfolio
@BloodPortfolio
Using a physiological-based approach, we find a ferritin threshold of 33 μg/L in both men and postmenopausal women, and 25 μg/L for premenopausal non-pregnant women for ID. Read in Blood RCI: ashpublications.org/bloodrci/article/2/1/100029/547478/Ph…
-
Blood Journals Portfolio
@BloodPortfolio
Hydroxyurea use in patients with #scd reduced acute care use but did not decrease health care costs. Total health costs were likely higher due to persistent chronic care management, decreased adherence & later initiation of hydroxyurea. ashpublications.org/bloodglobal/article/2/1/100040/547950… #sicklecelldisease
-
Blood Journals Portfolio
@BloodPortfolio
Nivolumab monotherapy following CAR-T therapy failure in MM or NHL rarely leads to clinical responses. However, for a minority of patients with myeloma, nivolumab leads to remarkably durable responses likely driven by endogenous T cells. Read in Blood ICT: ashpublications.org/bloodict/article/2/1/100022/548235/Ni…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood out now! Featuring The ticking clock of relapse in T-cell lymphomas, MMF unlocks a new path to venetoclax sensitivity in AML, Inflammation perturbs hematopoiesis by remodeling specific compartments of the bone marrow niche and more. ashpublications.org/blood/issue/147/7
-
Blood Journals Portfolio
@BloodPortfolio
🎙️ New episode of Blood Podcast out now: CAR-iNKT cell immunotherapy and Jagged2/Notch regulation of HSC. Have a listen: bloodpodcast.transistor.fm/episodes/147-2-for-2-12
-
Blood Journals Portfolio
@BloodPortfolio
Anemia, indirect bilirubinemia, leukocytosis, and crizanlizumab use directly associate with low bone density in SCD. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/3/748/547927… #scd #sicklecelldisease #lowbonedensity #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Explore the ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Blood Advances: ashpublications.org/bloodadvances/article/doi/10.1182/blo…
ASH
@ASH_hematology
ASH has released new guidelines for frontline management of ALL in adolescents and young adults. The recommendations focus on pediatric-inspired regimens, asparaginase use, and transplant decisions in first remission. Learn more: www.hematology.org/news-and-media/press-releases/2026/ash…
#hematology #hemeonc -
Blood Journals Portfolio
@BloodPortfolio
This study aimed to elucidate variations in HbA2 levels and its correlations with hematological parameters. The data set revealed a notably high incidence (17%) of elevated HbA2, necessitating a deeper review. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100059/557436…
-
Blood Journals Portfolio
@BloodPortfolio
In honor of Blood's 80th anniversary, we're looking back at all of the journal's past Editors in Chief. Today we're kicking off with our Founding Editor, Dr. William Dameshek (served 1946-1969). Learn more about him in this special feature: www.linkedin.com/feed/update/urn:li:activity:742738653657…
-
Blood Journals Portfolio
@BloodPortfolio
Statin exposure during treatment with CD19-directed CAR-T for relapsed or refractory LBCL is associated with improved responses and survival. Read in Blood ICT: ashpublications.org/bloodict/article/2/1/100021/548214/St…
-
Blood Journals Portfolio
@BloodPortfolio
A multicenter retrospective study from Argentina shows the clinical management and limitations of CNS prophylaxis in patients with DLBCL. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100047/548067…
-
Blood Journals Portfolio
@BloodPortfolio
Rare human missense variants in TF impede the activation of blood coagulation. These variants disrupt either the TF interaction with FVIIa or TF exosite for macromolecular substrates. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
New issue of Blood Advances out now featuring: FLT3-ITD measurable residual disease from the QuANTUM-First trial, Low bone mineral density and pain impact in adults with SCD, Antibiotic risk score for acute graft-versus-host disease and more. ashpublications.org/bloodadvances/issue/10/3
-
Blood Journals Portfolio reposted
ASH
@ASH_hematology
#ai models can inform unrelated donor selection for allogeneic hematopoietic cell transplantation — but how should you use them, and what are the limitations?
Register to learn from the study authors: academy.hematology.org/local/catalog/view/product.php?pro… #hematology @BloodPortfolio @RShouval @nmdp_org -
Blood Journals Portfolio
@BloodPortfolio
γMSC trafficking to GVHD tissues relies on integrin α4β1–MAdCAM-1 adhesion and CCR5-driven chemotaxis toward inflammatory chemokines. Read in Blood ICT: ashpublications.org/bloodict/article/2/1/100017/548165/In…
-
Blood Journals Portfolio
@BloodPortfolio
Tailored infectious screening, including endemic pathogens, is critical in CAR-T candidates in endemic areas. Read in Blood Global Hematology: ashpublications.org/bloodglobal/article/2/1/100046/548066…
-
Blood Journals Portfolio
@BloodPortfolio
Adult erythroblasts have differential BAF complex subunit requirements for HBG expression. Loss of noncanonical BAF complex components in adult erythroblasts disrupts HBG and HBD gene expression. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
TP53 mutation rewires the histone gene regulatory network via the XPO7-NPAT pathway, creating a vulnerability in TP53-mutated AML cells. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #aml #bloodjournal
-
Blood Journals Portfolio
@BloodPortfolio
'Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profiling' read in Blood Advances: ashpublications.org/bloodadvances/article/10/2/379/547952…
-
Blood Journals Portfolio
@BloodPortfolio
Synchronous systemic/CNS LBCL is rare, yet frontline systemic and CNS-directed chemoimmunotherapy results in durable remission and survival. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/2/479/547995…
-
Blood Journals Portfolio
@BloodPortfolio
Autophagy disruption via PIKfyve inhibition upregulates MHC class I expression in MM, with implications in tumor immunity. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #multiplemyeloma #bloodjournal
-
Blood Journals Portfolio
@BloodPortfolio
'Ectopic expression of BEX genes in T-cell acute lymphoblastic leukemia' read in Blood Advances: ashpublications.org/bloodadvances/article/10/2/452/546725…
-
Blood Journals Portfolio
@BloodPortfolio
Modernizing eligibility for AML trials by using safety-based criteria can improve overall enrollment and population representation. Read in Blood: ashpublications.org/blood/article/doi/10.1182/blood.20250… #aml #bloodjournal
-
Blood Journals Portfolio
@BloodPortfolio
CLL-CNSi is a rare condition that can affect treatment-naive patients. Initial treatment with BTKi-based therapy is highly effective. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/2/428/547926…
-
Blood Journals Portfolio
@BloodPortfolio
Posttransplant cyclophosphamide in HLA-matched peripheral blood transplantation: what’s next? Read in Blood ➡️ ashpublications.org/blood/article/doi/10.1182/blood.20250…
-
Blood Journals Portfolio
@BloodPortfolio
This study investigates outcomes and treatments of aggressive LBCLs presenting failure after 3 months from CAR T-cell infusion. Read in Blood Advances: ashpublications.org/bloodadvances/article/10/2/392/547866…
-
Blood Journals Portfolio
@BloodPortfolio
AI reduces manual analysis time for the detection of MRD to 1 minute per case, on average. Read the full study in Blood Advances: ashpublications.org/bloodadvances/article/10/1/58/547303/… #ai #bloodadvances
-
Blood Journals Portfolio
@BloodPortfolio
Patients with germ line G6b-B mutations and primary MF with thrombocytopenia share similar clinical phenotypes. ashpublications.org/blood/article-abstract/146/13/1612/54… #clinicaltrialsandobservations #hematopoiesisandstemcells #plateletsandthrombopoiesis #myeloidneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
Voruciclib combined with venetoclax was well tolerated and achieved objective responses in patients with AML and prior venetoclax. ashpublications.org/bloodneoplasia/article/2/3/100108/537… #clinicaltrialsandobservations #myeloidneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
Breaking ribosomes to fight leukemia ashpublications.org/blood/article/146/10/1155/547029/Brea… #myeloidneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
Distinct molecular subtypes in Waldenström macroglobulinemia ashpublications.org/blood/article/146/10/1153/547027/Dist… #lymphoidneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
Targeting ferritinophagy to iron out Tet2-mutant cells ashpublications.org/blood/article/146/10/1146/547030/Targ… #hematopoiesisandstemcells
-
Blood Journals Portfolio
@BloodPortfolio
Visualizing amyloidosis: the role of radionuclide imaging in systemic amyloidosis ashpublications.org/blood/article/146/10/1157/546193/Visu… #bloodspotlight #lymphoidneoplasia
-
Blood Journals Portfolio
@BloodPortfolio
🔊“Ironing out” Tet2-mutant HSPCs; A CAR-T “license to kill” in T cell leukemia/lymphoma; insights on cHL genetics, through the lens of ctDNA 🎧share.transistor.fm/e/93fa5eac
-
Blood Journals Portfolio
@BloodPortfolio
New Blood issue out now featuring:
Age shapes the immunogenetic fingerprint of ALL ashpublications.org/blood/issue/146/5?preview=true -
Blood Journals Portfolio
@BloodPortfolio
Barrier disruption by coagulation FXIa
ashpublications.org/blood/article/144/17/1760/518195/Barr… #thrombosisandhemostasis -
Blood Journals Portfolio
@BloodPortfolio
Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma
ashpublications.org/blood/article/doi/10.1182/blood.20240… #clinicaltrialsandobservations #immunobiologyandimmunotherapy #lymphoidneoplasia -
Blood Journals Portfolio
@BloodPortfolio
Eligibility criteria and Enrollment of a Diverse Racial and Ethnic population in Multiple Myeloma Clinical Trials ashpublications.org/blood/article/doi/10.1182/blood.20220…
-
Blood Journals Portfolio
@BloodPortfolio
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis ashpublications.org/blood/article/138/3/273/475738/HLA-ha…
-
Blood Journals Portfolio
@BloodPortfolio
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in #cll after chemoimmunotherapy ashpublications.org/blood/article/134/22/1951/374988/Mini…
-
Blood Journals Portfolio
@BloodPortfolio
Blood Spotlight: Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma ashpublications.org/blood/article/134/19/1573/375003/Duve…
-
Blood Journals Portfolio
@BloodPortfolio
Inside Blood Commentary: Targeting CD20 takes the backseat in #cll www.bloodjournal.org/content/133/10/1003?sso-checked=true @OhioState
-
Blood Journals Portfolio
@BloodPortfolio
Inside Blood Commentary: DUO delivers for duvelisib www.bloodjournal.org/content/132/23/2422?sso-checked=true @DanaFarber
-
Blood Journals Portfolio
@BloodPortfolio
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory #cll/SLL www.bloodjournal.org/content/132/23/2446?sso-checked=true
-
Blood Journals Portfolio
@BloodPortfolio
Check out this week’s issue of Blood: www.bloodjournal.org/content/132/23 #hematology




















































































































































































































































































































































































































































































































































































































































































































































































































































































































